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Abstract  
 
Chronic cough is defined as a cough that lasts for greater than 8 weeks in duration and 
has been estimated to have a prevalence of 11-13% of the population. Limited research 
has been conducted exploring its impact on the wider community. In up to 42% of chronic 
cough cases, the cough persists despite medical management, these cases tend to be 
labelled as refractory chronic cough. Pharmacological treatments are limited often with 
undesirable side effects. Research into non-pharmacological treatments for refractory 
chronic cough has been limited. 
An internet based European survey explored the impact of chronic cough (January 2012 - 
April 2013). A systematic review investigated the effectiveness of non-pharmacological 
interventions for refractory chronic cough. A single blinded multi-centre randomised 
controlled trial (RCT) investigated the efficacy of a non-pharmacological intervention 
(Physiotherapy, Speech and Language Therapy Interventions, - PSALTI) on cough related 
quality of life (QoL), cough frequency, severity, sensitivity, vocal performance, anxiety and 
depression alongside a control intervention. 
In total 1120 responses were collected and analysed from the European survey. Findings 
identified that cough impacted upon QoL, mood and ability to undertake activities and 
limited/ no effectiveness of medication; also a wish for more patient information to be 
available.  
PSALTI trial showed statistically significant differences between groups for the outcomes; 
QoL, cough frequency and urge to cough, improvements were significantly greater in the 
PSALTI group compared with control. There were no significant changes in outcomes from 
4 weeks to 3 months suggesting that observed improvements were maintained.    
This thesis has identified the impact of chronic cough in Europe. It identified the need to 
improve the management of chronic cough and the information available for patients. This 
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thesis also provides the first evidence within a single blinded multi-centre RCT that 
PSALTI is an effective treatment option for people with refractory chronic cough.  
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The Cougher by Wendy Cope (Cope, 2011) 
(A poem given to me by one of my trial participants)  
 
“ There’s a tickle in my throat 
And you’ve hardly heard a note 
And you’re wishing you were in some other place 
In this silent listening crowd 
You’re the one who’ll cough out loud 
And you know you’re facing imminent disgrace 
Yes, right now you’re in a pickle 
And your unmanageable tickle 
Is a torment and it’s threatening your poise 
Can you hold out any longer 
As the urge to cough grows stronger 
Any moment you’ll emit a mighty noise 
If this bloody piece were shorter 
If you had a glass of water  
It would help 
Oh, if only you could be 
At home with a CD 
In a armchair free to cough the whole way through 
Do you hear a rallentando 
Does this mean the end’s at hand 
What a mercy! Yes they’re really signing off 
They perform the closing bars 
And you thank your lucky stars 
And its over. 
You’ve made it. 
You can cough.” 
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Overview of thesis 
 
Chronic cough is defined as a cough that lasts for greater than 8 weeks in duration 
(Morice et al., 2006). Initially chronic cough was only studied and evaluated as a symptom 
of other respiratory diseases. However this changed in the 1980s when chronic cough 
began to be studied and explored as a separate condition in its own right (Morice., 2008). 
Chronic cough has been shown to cause significant physical and psychological symptoms 
including chest and abdominal pains, lethargy, incontinence, syncope, vomiting, 
headaches, voice changes, anxiety and depression. It can also affect societal participation 
as people with chronic cough have complained their cough interferes with their work, 
personal relationships and has lead them to avoid societal activities. These physical and 
psychological symptoms of chronic cough can independently, or act together with the 
effects on societal participation to interfere with QoL (Birring et al., 2003c, Brignall et al., 
2008, French et al., 1998). Studies exploring the impact of chronic cough have tended to 
focus on patients attending specialist cough clinics (French et al., 1998, Birring et al., 
2003c, Brignall et al., 2008) few have looked into the effect of chronic cough in the wider 
community (Everett et al., 2007, Fujimura., 2012, Adams et al., 2009).  
In 1981, in an effort to improve the treatment of chronic cough, Irwin et al (1981) devised 
an anatomical diagnostic protocol which aimed to help clinicians systematically investigate 
patients with chronic cough. This protocol has developed over time and has informed the 
publication of three key chronic cough management guidelines: the European Respiratory 
Society (ERS) Chronic Cough Taskforce guideline in 2004 (Morice et al., 2004); the British 
Thoracic Society (BTS) guideline in 2006 (Morice et al., 2006), and the American College 
of Chest Physicians (ACCP) guideline in 2006 (Irwin et al., 2006).  These guidelines 
identify that the most common causes of chronic cough in adults with a normal chest x-ray 
are asthma, gastro-oesophageal reflux (GORD) and rhinitis. Despite these diagnostic and 
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management guidelines, it has been found that in up to 42% of chronic cough cases, the 
cough continues to persist (Haque et al., 2005). For this group of chronic cough cases 
various descriptors have been used including: refractory chronic cough (Patel et al., 
2011), idiopathic chronic cough (Morice et al., 2006), cough hypersensitivity syndrome 
(Morice et al., 2014), psychogenic cough (Vertigan et al., 2007a) and habit cough 
(Vertigan et al., 2007a).  One of the most widely used terms is “refractory chronic cough” 
which is the terminology used throughout this thesis.  
The focus for the management of people with refractory chronic cough has largely been in 
the development of antitussive medications. These have been found to be limited in their 
efficacy and many have undesirable side effects such as sedation and taste disturbances 
which affect their tolerability (Chung., 2014).  
Non-pharmacological management for refractory chronic cough is an emerging treatment 
option. These treatment approaches have primarily been delivered by Physiotherapists 
and Speech and Language therapists and therefore have consequently been named after 
the healthcare professional involved in treatment; ‘speech language pathology 
management’ (Ryan et al., 2010, Vertigan et al., 2006) or ‘cough-suppression 
physiotherapy’ (Patel et al., 2011). There has however been limited evaluation of these 
non-pharmacological treatments for refractory chronic cough and there had prior to this 
thesis been no systematic review of the current evidence.  
Due to the limited knowledge of the impact of chronic cough in the wider community and 
the limited research into non-pharmacological treatments for refractory chronic cough this 
thesis reports the findings from three studies that sought to:  
 review the literature for the non-pharmacological management of refractory chronic 
cough, which is presented as a systematic review in Chapter 2.  
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 investigate the impact of chronic cough in the community. This investigation was 
conducted as an internet based survey across Europe in collaboration with the 
ELF  and ERS Chronic Cough taskforce and is presented in Chapter 4.  
  explore the effectiveness of a non-pharmacological intervention for refractory 
chronic cough. This exploration was conducted as a multi-centred randomised 
controlled trial and is described in Chapter 5. 
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CHAPTER 1:  
INTRODUCTION AND LITERATURE REVIEW 
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1. Introduction and Literature Review 
 1.1 Chronic Cough 
 
1.1.2 Definition 
 
Cough is a three phased reflex defence mechanism which protects the airways from risk 
of aspiration, foreign bodies, infectious organisms and helps to keep the upper airways 
free from mucus and secretions (Lee and Birring, 2012., Chung and Pavord., 2008). The 
three phases of this mechanism consist of: an inspiratory phase, followed by a forced 
expiratory effort against a closed glottis and then a rapid expiration through the mouth 
after the glottis has reopened and closure of the nasopharynx has occurred (Widdicombe, 
2005., Chung and Pavord., 2008). A cough is classified as a chronic cough if it persists for 
greater than 8 weeks duration (Morice et al., 2006, Morice et al., 2004, Irwin et al., 2006).  
 
1.1.3 Epidemiology 
 
Most surveys (see table 1) that have tried to quantify the epidemiology of chronic cough 
have aimed to assess the prevalence of cough or phlegm as a symptom of respiratory 
disorders; mainly asthma, chronic obstructive pulmonary disease (COPD) and bronchitis 
(Barbee et al., 1991, Montnémery et al., 1998, Lundbäck et al., 1991, Cerveri et al., 2003, 
Coultas et al., 2001) tending to base their questionnaires on the Medical Research 
Councils’ definition and classification of chronic bronchitis (Medical Research Council, 
1965). Thus as Morice (2008) and Kauffmann and Varrasso  (2011) highlight these give 
an indication of the prevalence of cough symptoms but do not clearly identify a true 
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reflection of the prevalence of chronic cough. These surveys may well have captured 
acute as well as chronic cough and excluded chronic cough caused by anything other 
than COPD, asthma or bronchitis. The surveys have also varied in the questions they 
have asked regarding the prevalence of cough symptoms (see table 2) which may 
account for the varying prevalence observed in table 1. Despite this, these surveys 
reported associations between: smoking, increased body mass index (BMI) and chronic 
cough; and a predominance of females suffering with non-productive and nocturnal 
chronic cough.  
More recent surveys of chronic cough prevalence have focused on chronic cough as a 
separate condition. Ford et al (2006) surveyed 6416 of the general UK population in 
Yorkshire and found a prevalence of chronic cough as 12%. Adams et al’s (2009) 
community survey based in Adelaide, Australia found a prevalence of chronic cough as 
20.5% in all participants and 18.2% in those with no identified respiratory disease. Adams 
et al (2009) found for people who had chronic cough without identified respiratory disease, 
chronic cough was more common for those who currently smoked, were obese, aged less 
than 40 and greater than 55 years old and had psychological morbidity. In contrast to 
some of the epidemiology surveys in table 2, and to Ford et al’s (2006) survey which 
found prevalence of chronic cough to be higher in females, Adams et al (2009) found a 
higher predominance of chronic cough in males. Adams et al (2009) concludes that this 
difference could be due to men under-reporting their symptoms to clinicians and higher 
rates of women being treated in specialist cough clinics. This would explain differences in 
prevalence surveys based in primary and secondary care but does not account for the 
difference with Ford et al’s (2006) survey which was also community based. 
 Page 22 of 288 
 
Table 1: Prevalence of cough in the community by country (1981-2001) 
Year Country Cohort Chronic cough 
prevalence 
Features 
1981 Tucson, USA 
(Barbee et al., 
1991) 
1109 White Americans >3 
years old, of whom 1093 
completed smoking 
questions. 
17.9% 29.3% of smokers reported cough, compared to only 11.2% 
of non-smokers – strong link between smoking and cough. 
1985-
1986 
Norbotten, Sweden 
(Lundbäck et al., 
1991) 
6610, 35-36year olds, 50-51 
year olds and 65-66 year olds 
of which 5698 were analysed. 
11% 6.8% had symptoms of sputum production and cough 
simultaneously, strong association between smoking and 
cough. 
1992 Skåne, Sweden 
(Montnémery et al., 
1998) 
8469 responses 20-59  year 
old 
12.6% Higher prevalence of cough in smokers or ex-smokers. 
Smoking and cough symptoms were higher in females. 
1988-
1989 
South East 
England (Cullinan., 
1992) 
9077 responses  5-54 year 
old, 46% male 
14.1% males, 
10.6% females 
Reported cough every day or half the days of the year. 
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1988-
1994 
USA                 
(Coultas et al., 
2001) 
5743 white Americans ≥45 
years old, 52% female 
9.3% in 
responders with 
no airflow 
restriction 
Reported cough most days for 3 or more consecutive months 
per year 
Increasing cough symptoms with airflow restriction, cough 
present in 49.1% with FEV1<35%. 
1990 Uppsala, Sweden 
(Lúdvíksdóttir et 
al., 1996) part of 
the European 
community 
respiratory health 
survey 
623 responders 20-44 year 
olds 
11% non 
productive 
cough, 8% 
productive 
cough, 38% 
nocturnal cough. 
Significantly more female non-productive coughers (p<0.01) 
and nocturnal coughers (p<0.001). Significantly more 
smokers suffered with cough (p<0.001). No correlations 
found between age and cough. Anxiety and depression 
correlated with productive and non-productive cough.  
1998-
2000 
Italy (Cerveri et al., 
2003) 
18,645 responses 20-44 year 
olds 
11.9% (95% CI: 
11.4-12.4). No 
significant 
difference 
between 
genders. 
Reported cough and phlegm on most days for at least 3 
months of the year and for at least 2 successive years. 
Significantly more current smokers suffered with phlegm and 
cough (p<0.001). 
19.8% reported co-existing asthma.  
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2001 Europe (Janson et 
al., 2001) 
18,277 responses 20-48 year 
olds, mean age 34 years old 
30.7% nocturnal 
cough, 10.2% 
productive and 
non-productive 
cough. 
Higher prevalence of nocturnal, non-productive and 
productive cough among smokers. Females are twice as 
likely to suffer with nocturnal cough and 1.3 times more likely 
to suffer with non-productive cough than men. Increased BMI 
also increased prevalence of productive, non-productive and 
nocturnal cough. 
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Table 2: Questionnaires used in epidemiological surveys to assess coughs. 
Reprinted from, Pulmonary Pharmacology & Therapeutics, Vol 24, Kauffmann and 
Varraso, The Epidemiology of Cough, 289-294., Copyright (2011) (Kauffmann and 
Varraso, 2011), with permission from Elsevier.    
 
1.1.4 Patho-physiology of chronic cough 
 
The cough reflex arc consists of three phases: afferent pathway, central pathway and 
efferent pathway (Polverino et al., 2012).  The cough reflex is usually initiated by the 
stimulation of afferent nerve endings in the mucous membranes of the pharynx and larynx 
and in the mucosal lining of the upper tracheobronchial airway, (Bickerman and Barach., 
1954) which stimulates via the vagus nerve to a ‘cough center’ in the medulla (Polverino 
et al., 2012). An efferent signal is then generated and travels down the vagus, phrenic and 
spinal motor nerves to the respiratory expiratory muscles to produce a cough (Polverino et 
al., 2012).  
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1.1.4.1 Afferent cough pathway 
 
The cough reflex is initiated by a stimulation of c-fibres or subtypes of vagal afferents 
which respond to mechanical or chemical stimuli. A variety of receptors have been 
identified to date (Canning 2009): 
1. TRP Vanilloid 1 (TRPV1) receptors are stimulated by capsaicin, citric acid, low pH, 
temperature and bradykinin (Canning et al., 2006; Caterina et al., 1997) 
2. TRP Ankyrin 1 (TRPA1) receptors which are stimulated by pollutants as well as 
bradykinin; nicotine acetylcholine receptors which are stimulated by nicotine 
3. E series prostanoid receptors which are stimulated by prosanoids; Bradykinin 
receptors which are stimulated by bradykinin 
4. Ion channels responsive to chemical stimuli which are stimulated by acid from 
reflux or aspiration of gastric content.  
These innervations are found in the airways from the larynx to the large bronchi in 
humans (Canning 2009).  
Chemical stimuli that initiate cough are wide ranging, and clinical and laboratory setting 
examples include nicotine and other inhaled pollutants, capsaicin and citric acid, 
bradykinin, inflammatory mediators, as well as acid from reflux or aspiration of gastric 
content (Canning., 2009). Mechanical stimuli that initiate cough have been identified as 
mechanical probing of the tracheal, laryngeal and large bronchial mucosa as well as 
accumulated secretions and aspirate (Canning et al., 2006; Canning., 2009). 
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1.1.4.2 Central pathways and regulation of cough 
 
Canning et al (2014) reported that currently there are three main parts of the central 
regulation of cough that have been identified:  
1. Central processing of afferent signals in the brainstem;  
2. The brainstem control network organisation  
3. The involvement of emotions, consciousness and perception of cough in the higher 
brain areas (subcortical and cortical).   
Vagal afferent nerves have been shown to converge at sites of brainstem integration, 
particularly in the nucleus tractus solitarius (Canning et al., 2006, Canning et al., 2014). 
The nucleus tractus solitarius is connected to medullary respiratory neuronal network 
which coordinates efferent motor cough response such as bronchospasm (Shannon et al., 
1998, Canning et al., 2014). This neuronal network is commonly referred to in the 
literature as the cough centre or central cough generator (Chung and Pavord., 2008).  
The convergence of the vagal afferent nerves in the nucleus tractus solitaries causes 
synergistic regulation of the cough reflex. It is thought that this central sensitisation effect 
is similar to the central sensitisation observed in the study of pain (Mazzone, 2005).  
The wider brainstem network that is involved in organising input from afferent nerves 
includes neurons within the ventrolateral medulla, raphe nuclei, and pons. These neurons 
have been found to be involved in controlling the duration of all three phases of cough, 
inspiratory, compressive and expiratory phases as well as the magnitude of the 
respiratory muscle activation throughout (Canning et al., 2014).  
Similarly to swallowing, the cough reflex involves higher brain involvement (cortical and 
subcortical) which enables humans to voluntarily cough or inhibit cough. It is this cortical 
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processing of sensory inputs of the cough reflex that creates the perception of the need to 
cough also known as the perceived urge to cough. Farrell et al (2012) and Mazzone et al 
(2007) have conducted a number of studies using capsaicin induced cough to establish 
which areas of the cortex and subcortex are involved during cough reflex and have found 
a wide distributed network of brain regions activated including “the prefrontal, motor, 
somatosensory and cingulate cortices, insula, putamen, thalamus, midbrain, brainstem, 
and cerebellum” pg 1328 (Farrell et al., 2012).  
1.1.4.3 Efferent Cough Pathway 
 
Impulses are then sent from the cough centre via the vagus, phrenic, spinal motor and 
superior laryngeal nerves to the intercostal, diaphragm, abdominal wall muscles and 
glottis (Harsoliya et al., 2011). Resulting in the following stages of the efferent motor 
response to the cough reflex (Harsoliya et al., 2011, Chung and Pavord., 2008): 
1. The diaphragm (supplied by phrenic nerve) and external intercostal muscles 
(supplied by the segmental intercostal muscles) contract creating a negative 
pressure within the thorax.  
2. Air rushes into the lungs in response to the negative pressure. 
3. The glottis (supplied by laryngeal nerve) and vocal cords then close. 
4. The abdominal and other expiratory muscles simultaneously contract increasing 
the pressure within the lungs beneath the closed larynx. 
5. The vocal cords and glottis relax and open, causing a sudden quick release of air 
to remove the cough irritant from the airways. 
1.1.5 Impact and Burden of Chronic cough 
                                                                                                                                     
French et al (1998) were the first to identify that chronic cough is associated with physical 
and psychosocial deterioration in QoL. When the authors explored which adverse cough 
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occurrences best explained the deterioration in QoL the following adverse occurrences 
were identified: patient exhaustion; the need for reassurance that nothing was seriously 
wrong; the inability to go to the movies due to cough and spouses being unable to tolerate 
their cough. A number of subsequent studies have further investigated the effects of 
chronic cough on QoL and have identified a number of frequently reported adverse 
physical, psychological and social symptoms of chronic cough (see table 3) (Brignall et al., 
2008, Birring et al., 2003c, French et al., 2005, French et al., 2004, McGarvey et al., 2006, 
Dicpinigaitis et al., 2006).  
Table 3: Physical, Psychological and Social symptoms related to chronic cough 
 
Physical Psychological Social 
Chest  and stomach pains Anxiety Interference with work, 
communication 
Tiredness/ lack of energy Depression Interference with personal 
relationships 
Disturbed sleep Embarrassment Avoidance of social 
activities 
Voice changes Frustration  
Incontinence Worries of serious illness  
Syncope   
Vomiting   
Headaches   
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In 2006 two studies: Dicpingaitis et al (2006) and McGarvey et al (2006) highlighted the 
prevalence of psychological symptoms in people suffering with chronic cough. Dicpingaitis 
et al (2006), (n=100) found 53% of women and 52% of the men attending a specialist 
cough clinic with chronic cough scored positively for significant depression 
symptomatology. They were considered to be at risk of clinical depression at the point of 
their first clinical appointment. McGarvey et al (2006) (n=57) found that 21% of people 
with chronic cough attending his specialist cough clinic for their first appointment had 
borderline anxiety and 12.3% had clinically important anxiety. Borderline symptoms of 
depression were identified in 10.5% of the cohort and 5% had clinically important 
symptoms of depression. When assessing trait and state anxiety, 44.5% were found to 
have moderate trait anxiety and 28% had moderate state anxiety  (McGarvey et al., 2006).  
Dicpingaitis et al (2006) reported no significant differences in depressive symptoms for 
people with chronic cough related to age or gender and found no correlation between 
cough duration and depression. For QoL however French et al  (2004) identified a gender 
disparity,  women with chronic cough reporting significantly poorer QoL scores than males 
(67.1±1.3 vs 59.7±1.8 respectively, p=0.002). Women had significantly higher scores for: 
physical complaints (21.6±0.5 vs 19.0±0.7 respectively, p=0.004); psychosocial issues 
(14.7±0.3 vs 12.9±0.4 respectively, p=0.002) and extreme physical complaints (8.9±0.26 
vs 6.6±0.26 respectively, p<0.001) (French et al., 2004). 
All the above studies have served to identify the extent of physical and psycho-social 
morbidity of chronic cough. They have, however, predominantly focused upon specialist 
cough clinic attendees without exploring the impact of cough in sufferers within the 
community. 
Everett et al (2007) surveyed 373 community based subjects with self-reported chronic 
cough in the UK who had responded initially to a radio broadcast request for participants. 
Everett et al (2007) also found that chronic cough was associated with a significant 
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adverse impact on the physical, psychological and social wellbeing of the participants. 
Physical effects of the chronic cough reported by the majority of participants were ‘feeling 
tired/drained’ (72%), ‘disturbed sleep’ (70%), incontinence in women (55% of women), 
voice problems (67%). Psychological effects of the chronic cough reported by the majority 
of the participants were ‘anger and frustration’ (83%), lack of control of their body (76%), 
participants reported the cough made them worry about their health (69%), made them 
depressed (55%), upset (80%) and worried about what others thought (76%). Social 
effects of the chronic cough were also reported by the majority of participants, 67% of 
participants felt their chronic cough affected their social life and 81% reported their cough 
affected their ability to make phone calls (81%) (Everett et al., 2007). 
Fujimura et al (2012) surveyed 232 participants with self-reported cough registered with a 
research company via e-mail. This survey captured responses from participants with 
acute as well as chronic cough, the mean duration of cough reported was 3.8 weeks. Only 
23.2% of respondents reported having had a cough for ≥8 weeks duration; therefore this 
survey is less representative of a chronic cough specific population. However the study 
team did find that 79.3% of women and 68.4% of male respondents found their cough 
‘troublesome’ and affected their activities of daily living (Fujimura., 2012). 
Though the above surveys and studies discussed have explored the impact of chronic 
cough none have explored comprehensively the perspectives of chronic cough sufferers’. 
The omission of their lived experiences and their views upon the management and 
treatment received for their chronic cough indicates the absence of the patients’ voice. 
Previous studies and surveys have also been limited in exploring the impact specifically of 
chronic cough for people in the wider community who have not presented to specialist 
care.  
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1.1.6 Differential Diagnosis, Investigations, Treatments and management for main 
causes of chronic cough 
 
In an aim to help the systematic investigation and diagnosis of people suffering with 
chronic cough, the anatomical diagnostic protocol was designed by Irwin et al in 1981 
(Irwin et al., 1981). Over time this has developed and three key guidelines have been 
produced on the diagnosis and management of chronic cough: the ERS Chronic Cough 
Task Force guideline in 2004 (Morice et al., 2004) ‘The diagnosis and management of 
chronic cough’; the BTS guidelines in 2006 (Morice et al., 2006) ‘Recommendations for 
the management of cough in adults’; and the American College of Chest Physicians’ 
(ACCP) guideline in 2006 (Irwin et al., 2006) ‘Diagnosis and Management of Cough’. 
All of these guidelines agree on an initial approach to the differential diagnosis of chronic 
cough which consists of: initially discontinuing angiotension converting enzyme (ACE) 
inhibitor medication; promoting smoking cessation and conducting chest radiology to 
identify any abnormalities.  ACE Inhibitor medication is used to treat hypertension and 
heart failure but has been shown to cause chronic cough (McEwan et al., 1989). The 
mechanism by which ACE inhibitor medication causes chronic cough is thought to be due 
to bradykinin which is usually degraded by ACE sensitising the cough reflex (Fox et al., 
1996). Smoking cessation is advocated, as smoking is a common cause of cough and has 
been shown to be dose related (Morice et al., 2006). Chest radiology enables 
abnormalities to be detected such as an underlying respiratory disease for many of which 
cough can be a symptom including chronic obstructive pulmonary disease (COPD), 
bronchiectasis, interstitial lung disease and lung cancer. The reasons for respiratory 
diseases to cause chronic cough are many, but in productive respiratory disorders 
excessive sputum production is known to trigger the cough reflex (Wilson., 2005) and 
idiopathic pulmonary fibrosis sufferers have raised inflammatory markers (Hope-Gill et al., 
2003).Chest Radiology would also exclude Upper Respiratory Tract Infection (URTI)/ post 
viral infection which normally causes acute cough but can persistent in some cases 
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causing chronic cough (Morice et al., 2006, Irwin et al., 2006). URTI is thought to cause 
chronic cough by inflammatory markers triggering the cough reflex resulting in increased 
cough hypersensitivity (O'Connell et al., 1996).  
Once the above causes of cough have been excluded the consensus of the main clinical 
guidelines are that there are three main causes of chronic cough in adults who have a 
normal chest x-ray. These causes are GORD, rhinitis (which is called upper airways 
cough syndrome (UACS) in the ACCP guideline) and asthma/asthma syndromes (Morice 
et al., 2004, Morice et al., 2006, Irwin et al., 2006).  
GORD is thought to cause chronic cough by a number of mechanisms: by stimulating a 
esophagotracheobronchial cough reflex - it is hypothesised that cough afferent nerves are 
present in the distal oesophagus (Harding., 2006, Irwin et al 2000) as the presence of 
distal esophageal acid has been found to occur simultaneously with coughing (Ing et al., 
1992); Micro-aspiration or macro-aspiration of acid can irritate the lower respiratory tract 
stimulating the afferent limb of cough reflex; or stimulation of the upper respiratory tract 
(larynx) without aspiration (Harding., 2006); esophageal dysmotility has been found to be 
present in 67% of GORD related chronic coughers (Kastelik., 2003) and therefore is 
another mechanism which may cause cough in these individuals; it has also been 
hypothesised that non-acid reflux may also cause cough (Harding., 2006).  
Rhinitis is thought to cause chronic cough by excessive nasal secretions irritating the 
pharynx and stimulating the afferent cough reflex (Palombini and Araujo., 2005). 
The term asthma syndromes has been used when discussing asthma as a common 
cause of chronic cough as not all chronic cough patients suffering with asthma, present 
with typical asthma symptoms of airflow obstruction, hyper-responsiveness and 
inflammation. Some individuals can present with airway hyper-responsiveness but no 
airway obstruction a situation which has been termed as cough variant asthma (Morice et 
al., 2006). Others can present with airway inflammation but no airway hyper-
 Page 34 of 288 
 
responsiveness which has been termed as eosinophilic bronchitis (Morice et al., 2006, 
Morice et al., 2004, O'Bryne., 2005, Dicpinigaitis., 2004). Chronic cough sufferers 
diagnosed with asthma and bronchitis have been shown to have increased levels of 
prostaglandin E2, D2 and histamine compared to non-coughers (Birring et al., 2004b), 
which are known to elicit cough and increase cough reflex sensitivity (Choudry et al., 
1989). 
Despite the consensus in the guidelines (Irwin et al., 2006, Morice et al., 2007a, Morice et 
al., 2006) for the three main causes of chronic cough for adults with a normal chest x-ray. 
There is variation in the guidelines as to the order of investigations and treatments for 
these three main causes as well as the duration and intensity of treatment.  
The ACCP guideline (Irwin et al., 2006) promotes that an initial differential diagnosis 
should start with empirical treatment trials for Rhinitis/UACS; a first-generation 
antihistamine (no treatment dose or time period suggested) followed by sinus imaging if 
UACS is suspected but does not respond to the empirical treatment trial. Investigations for 
asthma should follow (spirometry, bronchodilator reversibility, bronchial provocation 
challenge) or empirical treatment trials for asthma. These trials should include inhaled 
bronchodilators and inhaled corticosteroids, and/or 1 to 2 weeks of oral corticosteroids if 
the patient suffers with severe asthma or has not responded to other asthma treatments 
but asthma as a cause is suspected. Lastly the ACCP guidelines recommend that people 
with chronic cough with or without GORD symptoms should complete an empirical 
treatment trial for GORD for 3 months as well as a pH monitoring test to evaluate acid 
reflux, and/or barium esophagography for non-acid reflux. If chronic cough persists then 
further investigations into GORD should be carried out. These include 24 hour 
oesophageal pH monitoring, endoscopic swallow evaluation, Barium esophagram as well 
as more in depth investigations for UACS and asthma including CT scan, bronchoscopy. 
Finally the guidelines advocate investigations into rarer causes of cough such as 
echocardiograms to assess for premature ventricular causes of cough. 
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In contrast the ERS chronic cough taskforce (Morice et al., 2004) guidelines advocate for 
asthma to be investigated and treated first, followed by rhinitis and GORD. The BTS 
guidelines (Morice et al., 2006) are less formalised regarding the order of treatment of the 
three main causes. The investigations for asthma in the BTS and ERS Chronic Cough 
Taskforce guidelines (Morice et al., 2004) are the same as the ACCP, however the 
empirical treatment trials of oral steroids vary; the BTS guidelines (Morice et al., 2006) are 
similar to the ACCP and recommend a two week trial whereas the ERS Chronic cough 
Taskforce guidelines (Morice et al., 2004) recommend a longer 1 month trial.   
For the treatment of Rhinitis the ERS Chronic cough Taskforce guidelines (Morice et al., 
2004) recommend the same treatment as the ACCP but unlike the ACCP guidelines they 
recommend a treatment duration of two weeks. The BTS guidelines (Morice et al., 2006) 
in comparison recommend 1 month of topical corticosteroids, however they explain that 
this difference is due to first generation sedating antihistamines not being available in the 
UK.  The ERS Chronic Cough Taskforce (Morice et al., 2004) also recommend an 
alternative Rhinitis treatment option of an oral decongestant for two weeks.  
The treatments for GORD also vary between the guidelines; the ERS Chronic Cough 
Taskforce (Morice et al., 2004) recommend a shorter two month trial of high dose proton 
pump inhibitors (PPI) or H2 antagonists ± alginates compared to the ACCP three month 
trial. The BTS guidelines (Morice et al., 2006) recommend at least an 8 week trial of PPI 
such as omeprazole 20-40mg twice a day before meals. 
For the majority of people with chronic cough when thorough investigation and empirical 
treatment trials have been completed a cause for the cough is found and successfully 
treated (Morice et al., 2006, Morice et al., 2004). In between 10-42% of cases however, 
the chronic cough can persist (Haque et al., 2005, Morice., 2002, Vertigan et al., 2006, 
Vertigan et al., 2007b). Within the literature there is significant variation in the terminology 
used to define these persistent cases, various terms have been used including: refractory 
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chronic cough (Patel et al., 2011), idiopathic chronic cough (Morice et al., 2006), cough 
hypersensitivity (Birring., 2011), psychogenic cough (Vertigan et al., 2007a) and habit 
cough (Vertigan et al., 2007a). For the purpose of this thesis the term refractory chronic 
cough will be used.  
 
1.2 Refractory chronic cough 
 
1.2.1 Definition 
 
Refractory chronic cough is defined as a cough greater than 8 weeks in duration that 
persists despite treatment trials and investigations for the main causes of chronic cough; 
those being asthma syndromes, GORD and rhinitis (Patel et al., 2011). 
 
1.2.2 Characteristics of refractory chronic cough 
 
Refractory chronic cough predominately affects middle aged women (Birring et al., 2004a, 
Haque et al., 2005). It has been found to start around the time of the menopause (Mund et 
al., 2005) or develop after a viral respiratory tract infection (Haque et al., 2005). Organ 
specific autoimmune disease has also been linked to refractory chronic cough, as it has 
been found to be present in up to 30% of people; with autoimmune hypothyroidism being  
particularly common (Birring et al., 2003a). 
Most refractory chronic cough patients describe their cough as being dry (62%) and their 
perceived location of the trigger for their cough to be in their throat (61%) (Vertigan and 
Gibson., 2011). The majority (94%) also report abnormal laryngeal sensations including 
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feeling tightness or tickle in throat, feeling like their throat is blocked, itch or dust in throat, 
feeling like there is something stuck in their throat or that something is pressing on their 
throat (Vertigan and Gibson., 2011). Numerous triggers have been identified by 
participants with refractory chronic cough as triggering their cough both tussive and non-
tussive triggers. Vertigan and Gibson (2011) identified that most refractory chronic cough 
patients report predominantly non-tussive cough triggers as their cough triggers. Non-
tussive triggers reported include talking, laughing/singing, exercise, change in air 
temperature or humidity, stress/anxiety, talking on the telephone, eating/drinking, air 
conditioning. Tussive agents reported include fumes, bleach and aerosols, smoke and 
shortness of breath.  
Poor vocal hygiene and hydration was also identified by Vertigan and Gibson (2011) in 
people who suffered with chronic cough, 71% had inadequate water intake 
(<1500ml/day), 39% were mouth breathers, 65% consumed ≥ 3 caffeinated drinks per 
day.  Poor vocal hygiene was found to be related to a greater urge to cough score 
(p=0.001) as rated on a 10 point Borg Scale. 
Up to 40% of people with refractory chronic cough also experience significant voice 
problems (Vertigan et al., 2007d). A number of reasons for these voice changes have 
been hypothesised; repeated coughing is thought to potentially cause vocal fatigue and 
people with refractory chronic cough are also thought to have increased laryngeal muscle 
tension. These changes have been demonstrated by increased breathiness scores for 
refractory chronic coughers indicating reduced adduction of the vocal folds during 
phonation shown in Vertigan et al (2007d) and the reduced vocal fold closure phase 
shown in Vertigan et al (2008b). The authors hypothesised that this reduced vocal fold 
adduction as well as being due to increased muscle tension could also indicate avoidance 
of full contact of irritated vocal folds, from repeated coughing, which may trigger cough. A 
high percentage, 56%, of people with refractory chronic cough have also been found to 
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suffer with paradoxical vocal fold movement (Ryan et al., 2009), which is the involuntary 
and episodic adduction of the vocal folds during inspiration (Vertigan et al., 2008b). 
 
1.2.3 Pathophysiology 
 
The pathophysiology of refractory chronic cough is still not fully understood. Several 
different features have been found in these sufferers including: lymphocytic airway 
inflammation (Birring et al., 2003a), increased number of mast cells in bronchoalveolar 
lavage fluid (McGarvey et al., 1999), and increased concentrations of tussive mediators; 
histamine, prostaglandin (PG)  D2  and  PGE2 in induced sputum (Birring et al., 2004b). 
PGE2  has been shown in healthy participants to increase cough reflex sensitivity; healthy 
participants post inhaling 0.76µmol of PGE2 were only able to tolerate Geometric 
mean(95% CI) 4.4 (2.4 to 7.9) nmol of capsaicin before coughing five or more times (C5) 
whereas at baseline they were able to tolerate 16.2 (14.3 to 18.3) nmol (Choudry et al., 
1989). Ho et al (2000) showed in rats that PGE2 increased excitability of C fibres to 
capsaicin and lung inflation. Cho et al (Cho et al., 2003) found that people with refractory 
chronic cough, who had increased cough sensitivity, had increased Substance P in nasal 
their lavage fluid.  
Chung and Pavord (2008) suggested that the effect of repeated coughing on the airway 
cells in people with chronic cough could cause the release of inflammatory mediators and 
tissue remodelling. Chung and Pavord (2008) also hypothesised that this could cause a 
positive feedback process increasing the cough duration and resulting in a change in the 
cough reflex sensitivity. Increased cough reflex sensitivity in people with refractory chronic 
cough has been demonstrated in other studies (Prudon et al., 2005, Johansson et al., 
2009).  
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Another cause of refractory chronic cough is thought to be sensitisation of the central 
cough mechanisms (Chung et al., 2013, Ryan et al., 2012) as refractory chronic cough 
has been found to share many characteristics to other hypersensitivity syndromes such as 
chronic pain. As previously described, people with refractory chronic cough have been 
shown to have an increased sensitivity to tussive triggers that usually cause cough 
(hypertussia) such as chili and smoke; an increased sensitivity to non-tussive triggers 
such as talking, laughing and changes in air temperature (allotussia); as well as abnormal 
throat sensations such as a tickle or lump in throat (laryngeal paraesthesia) (Vertigan and 
Gibson., 2011).   
Immune changes have also been shown in women around menopausal age which has 
been hypothesised as a possible cause of refractory chronic cough. Mund et al (2001) 
found an increase in T cells, T helper cells and an increased CD4/CD8 ratio in the lower 
airways in older females, with the biggest change occurring in women over the age of 43. 
They hypothesised from this that many women who develop chronic cough post 
menopause suffer an increase in previously subclinical airway inflammation (Mund et al., 
2001).  
Autoimmune disease has also been linked as a cause of refractory chronic cough and it 
has been hypothesised that aberrant homing of inflammatory cells to the lungs from a 
primary site of autoimmune inflammation could be a potential cause (Birring et al., 2003a, 
Birring et al., 2004a).                     
                                                            
1.2.4 Assessment of refractory chronic cough 
 
The assessment of refractory chronic cough has largely focused on measurement of the 
impairment; these assessments include cough reflex sensitivity testing, cough frequency 
and cough severity testing. Other assessments have focused on the measurement of 
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activity limitations, mood and societal participation restrictions including QoL 
questionnaires, vocal performance measures and questionnaires to assess mood.   
    
1.2.4.1 Cough reflex sensitivity 
 
In order to test the effectiveness of antitussive medications, agents that evoke a cough 
response in humans have been investigated. Thus the effectiveness of antitussives on the 
sensitivity of the cough reflex could be explored. In 1950 the first agent used to evoke a 
cough response in humans was ammonia vapour (Höglund and Michaëlsson., 1950), 
other early tussive agents used included ether and peppermint water that, via a 
endotracheal tube, was sprayed directly onto the larynx in anaesthetised patients (Hillis., 
1952). Later studies moved towards less toxic agents and invasive techniques.  
Bickerman and Barach (1954) undertook the first study to trial the use of inhaled citric acid 
and found there to be a dose response reaction to inhaled citric acid in both asthmatics 
and healthy volunteers.  Collier and Fuller in 1984 investigated the use of capsaicin (a 
chilli extract) and concluded that the capsaicin cough challenge had  good repeatability for 
the number of coughs produced at each capsaicin concentration for each patient, though 
limited data is provided in their paper on this. The authors also identified that there was a 
dose-response reaction to capsaicin; the stronger the dose the higher the number of 
coughs (Collier and Fuller., 1984).  
Both citric acid and capsaicin have been recommended by the ERS cough assessment 
guidelines as tussive agents to be used for cough reflex sensitivity testing (Morice et al., 
2007a). To increase standardisation of cough challenge testing the ERS Chronic Cough 
Taskforce produced recommendations on the equipment to be used, preparation of the 
solutions used and administration technique of the solutions. The endpoints for both tests 
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are identified as C2 and C5 which is the concentration at which participants’ cough 2 or 
more times and 5 or more times respectively (Morice et al., 2007a). 
Prudon et al (2005) explored the reliability of the capsaicin cough challenge and found for 
C2, ICC=0.89 and for C5, ICC=0.88 (Prudon et al., 2005). Dicpinigaitis (2003) showed 
that in healthy participants there is a good long term repeatability of the capsaicin cough 
challenge. As 83% of the 40 healthy participants who underwent capsaicin cough 
challenges in his study had C2 and C5 values within 1 doubling dose and 90% within 2 
doubling dosages when the capsaicin cough challenges were repeated between 6 to 62 
months apart (Dicpinigaitis., 2003). In healthy volunteers cough reflex sensitivity testing 
has identified that women have a significantly more sensitive cough reflex than males 
(Dicpinigaitis et al., 2001, Dicpinigaitis and Rauf., 1998a, Prudon et al., 2005). No ethnic 
or age differences have been identified (Dicpinigaitis et al., 2001, Prudon et al., 2005). 
Greater cough reflex sensitivity has been shown in people with refractory chronic cough 
when tested by the Capsaicin cough challenge (Prudon et al., 2005).   
 
1.2.4.2 Urge to cough assessment  
 
Urge to cough assessment has been identified as an important addition to the standard 
capsaicin cough challenge testing described (1.6.4.2). Urge to cough is defined as “a 
measure of the perceptual sensation of a need to cough” (pg 345) (Davenport et al., 
2007). Davenport et al  (2007) showed that in healthy adults the concentration required to 
elicit a reported urge to cough is significantly less that the concentration required to elicit a 
cough (motor response). Davenport et al (2007) also found a direct relationship between 
capsaicin concentration and the magnitude of urge to cough. They argued that this 
indicated that the sensation of the need to cough precedes the motor response of 
coughing; therefore if patients’ perception of the need to cough occurs before they actually 
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cough, modifying patients’ behaviour to the urge to cough may help them to suppress their 
cough (Davenport et al., 2007).  
Dicpinigaitis et al (2012) explored urge to cough response to capsaicin in 100 healthy 
participants and found similar results to Davenport et al (2007). For the majority of the 
participants (79 participants, 40 females and 39 males) the capsaicin concentration at 
which they reported an urge to cough was lower than their motor response (cough) to 
capsaicin. For most of these participants (77 participants) no more than 3 doubling doses 
of capsaicin were between their reported first urge to cough and their motor response. For 
40 of the 79 participants they coughed on the next doubling dose of capsaicin following 
the dose they reported their first urge to cough.  Dicpinigaitis et al (2012) also found a 
significantly moderate to strong relationship between urge to cough and C1 (concentration 
at which they first coughed), C2 and C5 (0.75, 0.74 and 0.57 respectively, p<0.0001).  
Dicpinigaitis et al (2012) explored the repeatability of urge to cough assessment and 
found that when repeating the cough challenge a week later for all participants the 
concentration at which they reported an urge to cough was reproducible within two 
doubling doses of capsaicin and for 88% of participants was reproducible within one 
doubling dose (Kappa 0.70 (95% CI 0.49-0.85)).  
In Dicpinigaitis et al’s (2012) and Davenport et al’s (2007) studies both used a modified 
Borg scale for participants to rate their urge to cough. Dicpinigaitis et al (2012) asked 
participants to rate their urge to cough after each concentration of capsaicin that did not 
result in a cough and Davenport et al (2007) asked their participants to rate their urge to 
cough after every capsaicin concentration delivered.   
Ryan et al (2010) explored urge to cough and cough reflex sensitivity pre and post speech 
pathology management in people with refractory chronic cough. Similarly to Dicpinigaitis 
et al’s (2012) and Davenport et al’s (2007), Ryan et al (2010) also used a modified Borg 
scale for participants to rate their urge to cough after each concentration of capsaicin 
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delivered. However they analysed the urge to cough data differently by calculating a 
median urge to cough score of all the ratings given across the different capsaicin 
concentrations for a given participant. Therefore this does not allow comparison with 
previous studies and does not give an indication of the average capsaicin concentration 
that initiated participants’ first urge to cough. Therefore it is not known whether there was 
a change in the capsaicin concentrations participants were able to tolerate before 
reporting an urge to cough post treatment.   
Young et al (2009) explored urge to cough in people with refractory chronic cough and 
healthy adults. Young et al (2009) asked the healthy adults to rate their urge to cough 
after each capsaicin concentration on a 0 to 100mm VAS scale, the refractory chronic 
cough patients were asked to do the same but to use a modified Borg scale similar to 
previous studies. At C5 the healthy participants’ urge to cough Median (IQR) VAS was 
92mm (69 to 99mm), for the refractory chronic cough patients at C5 their urge to cough 
Median (IQR) Borg was 4 (3 to 6.3). Unfortunately due to different measures being used 
for both groups the difference in urge to cough cannot be compared, also data is only 
given in the study as to the urge to cough reported at C5, so the concentration at which 
both groups reported their first urge to cough is not known.  
Urge to cough would appear to be an underexplored assessment method in refractory 
chronic cough but one with interesting potential. It might offer additional insights into the 
subtler aspects of the cough reflex; the patients’ perceptions and sensations experienced 
prior to coughing rather than just exploring the motor response.  
 
1.2.4.3 Cough severity assessment 
 
Cough visual analogue scales (VAS); a 0-100mm line with one terminal anchor 
representing worst cough ever and the other representing no cough, have been widely 
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used in cough literature to measure patients’/participants’ perception of cough severity 
(Birring et al., 2003c, Abdulqawi et al., 2014).  Birring et al (2003c) quantified the reliability 
of the cough severity VAS for a chronic cough population when repeated two weeks apart 
as ICC=0.84 (Birring et al., 2003c). These scales are also recommended by the ERS 
cough assessment guidelines to measure cough severity (Morice et al., 2007a).  
The minimal important difference for VAS in chronic cough has not been established yet 
although for acute cough it is identified as 17mm (Lee et al., 2013).  
 
1.2.4.4 Cough frequency assessment 
 
A variety of subjective scoring systems and diaries have been used to document cough 
frequency. Due to the psychological effects cough has and the effects it has been shown 
to have on QoL there is doubt as to whether these subjective scoring systems or diaries 
are a true representation of cough symptoms and frequency or affected by patients’ mood 
(Smith and Woodcock., 2008). Also, due to the episodic nature of cough, it may be difficult 
for patients to notice slight changes in cough unless they are extremely vigilant. Currently 
it is not known exactly how large the change in cough frequency needs to be in order for 
patients with chronic cough to notice a subjective significant improvement or deterioration 
benefit (Smith and Woodcock., 2008). In children poor agreement has been found 
between reported and recorded nocturnal cough (Falconer et al., 1993). 
A number of cough monitoring devices have been developed to objectively quantify cough 
frequency; these vary in their mechanisms of quantifying coughs by either just 
recording/detecting cough sounds (Matos et al., 2007) or combining this with also 
detecting chest wall motion or EMG during inspiration or expiration phase of the cough 
reflex (Coyle et al., 2005). They also vary as to whether the cough monitor software has 
the facility to automatically count the number of coughs with some user operator input 
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(Birring et al., 2008) or whether the coughs are manually counted (McGuinness et al., 
2012).  
Five ambulatory cough monitoring devices have been developed to objectively assess 
cough frequency: the LifeShirt® System (VivoMetrics, Inc., Ventura, CA, USA)(Coyle et 
al., 2005); Hull Automatic Cough Counter (Barry et al., 2006); LR102 device (Hsu et al., 
1994); Leicester cough monitor (LCM) and VitaloJAK. The use and the validation of the 
LifeShirt® System, Hull Automatic Cough Counter and LR102 device have been limited 
compared to the LCM and VitaloJak which are the most widely used cough monitoring 
devices. 
The LifeShirt® System is a portable vest monitoring system which detects cough from a 
combination of sounds measured via a throat microphone and monitoring of volume and 
timing ventilatory variables via non-invasive respiratory inductance plethysmography 
(Coyle et al., 2005, Smith and Woodcock., 2008). The LifeShirt® System’s sensitivity, 
specificity and accuracy have however only been explored in a study of 8 COPD sufferers 
for whom cough was a predominant symptom (Coyle et al., 2005). In Coyle et al’s (2005) 
study participants were videoed whilst they wore the vest for up to 24 hours and manual 
counting of coughs was compared to coughs detected by the vest. Sensitivity of the 
Lifeshirt was found to be 0.781 and specificity 0.996, agreement between the video 
surveillance and the LifeShirt was kappa = 0.807, (Coyle et al., 2005). 
The Hull Automatic Cough Counter uses digital signal processing and a probabilistic 
neural network to label sounds detected from 24 hour recordings via a lavalier microphone 
as a cough event or not. User input is then required to determine the number of coughs in 
each event (Barry et al., 2006). The Hull Automatic Cough Counter has only been 
explored in thirty-three smokers for their first waking hour. Despite this though the study 
found the sensitivity was 0.80 (range 0.55 to 100), specificity (0.96 (0.92 to 0.98) and the 
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repeatability of the analysis software was reported as 100%. The average false positive to 
true positives was 20% (Barry et al., 2006). 
The LR102 device simultaneously records cough sounds via a microphone whilst also 
recording electromyogram (EMG) signals of the intercostal muscles via 3 surface EMG 
electrodes (Hsu et al., 1994, Leconte et al., 2011). A study of four hour recordings in 10 
participants (4 cystic fibrosis, 5 viral infection and 1 other) found that there was a 
significant difference between counting coughs from video surveillance compared to the 
LS107 for single coughs per hour with a difference between the measures of 12.5 coughs 
(p<0.01) (Leconte et al., 2011).  
The most widely used cough monitoring devices are the VitaloJAK and LCM (Spinou and 
Birring., 2014).  The VitaloJAK is a 24 hour recording device with two microphones; a free 
air condenser microphone and one chest wall air-coupled condenser microphone. 
Subjects wearing the device initially voluntarily cough at different lung volumes so 
acoustic parameters can be set to each individual patient (Smith., 2008).  With the 
VitaloJak the 24 hour cough recordings are compressed into shorter recordings lengths 
and then the coughs are manually counted by the operator, a recent abstract showed that 
for the VitaloJak compressing the 24 hour recordings to a mean 37.2 minutes still 
reproduced a 99.3% sensitivity when compared to manual counting of the full recording 
(McGuinness et al., 2012).  
The LCM consists of a MP3 recording device with an external microphone and, similar to 
the VitaloJak, participants wear the device for 24 hours. Recordings are then analysed 
using semi-automated cough detection software which is based on the Hidden Markov 
model (Birring et al., 2008). Validation of the LCM has been completed by comparing 
automated cough counts with manual cough counts over a 2 hour (n=9 chronic cough 
patients) (Birring et al., 2008), 6 hour (n=23, 15 chronic cough patients (Birring et al., 
2008), 8 controls) and 24 hour period (n=12 respiratory disease patients) (Yousaf et al., 
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2013).  For the 2 hour comparison the automated cough analysis was found to have a 
high specificity of 99% and sensitivity of 91%. Median false positive rate was 2.5 coughs 
per hour. The inter-class correlation between automated and manual cough count was 0.9 
(p<0.001).   For the 6 hour comparison the interclass correlation between automated and 
manual cough counts was similar at 0.93 (p<0.001), the specificity was the same at 99% 
however the sensitivity was less at 86%. The false positive rate decreased with increased 
time comparison to 1 cough per hour. The automated cough count was found to have a 
higher repeatability (ICC=0.9).  
For the 24 hour recording the interclass correlation was even stronger at 0.98, specificity 
was higher at 99.9% but sensitivity was lower at 83.8%. Interestingly in this study they 
found that females coughed more than men, this was true for those with respiratory 
disease and those who were controls (p=0.012 and p<0.001 respectively) (Yousaf et al., 
2013). Though it is advocated by the LCM authors for the device to be worn for 24 hours, 
a recent study by Lee et al (2012) showed that recordings as short as four hours 
correlated strongly with 24 hour recordings.   
In 2007 the ERS cough assessment guidelines concluded that for objective cough 
monitors there was no gold standard and there was ‘little to commend any particular 
method of quantifying cough over any other’ pg 1256 (Morice et al., 2007a). Since this 
guideline there have been significant developments in objective cough monitoring and a 
number have been used in treatment trials for chronic cough, especially the VitaloJAK and 
LCM. Today there still is no consensus as to which monitor is the gold standard and there 
have been no comparison studies between the different devices.  
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1.2.4.5 Health related QoL measures 
 
The short-form 36 Version 2 questionnaire (SF-36 v2) is a widely used short self-
administered health survey which measures eight health domain scales on a 0 -100 point 
scale (Physical Functioning (PF), Role participation with physical health problems, Bodily 
Pain, General Health, Vitality, Social Functioning, Role participation with emotional health 
problems, and Mental Health) (Ware et al., 2000). These domains can then be further 
summarised into two component summary measures – domains of Physical Component 
Summary (PCS)/ Physical health and Mental Component Summary (MCS)/ Mental 
Health. All health domain scales are scored such that higher scores indicate better health 
(Ware et al., 2000). The SF-36 has been used for many different patient groups, however 
it has not been validated for use specifically with refractory chronic cough and as the ERS 
guidelines for assessment of cough (Morice et al., 2007a) state as it is a generic QoL tool 
it lacks the specificity of disease specific QoL tools. The cough assessment guidelines 
therefore advocate the use of cough specific QoL measures which have been shown to be 
more reflective of chronic cough patients’ symptoms than generic QoL tools (Kalpaklioglu 
et al., 2005). 
There are two main cough specific quality of life measures that have been developed to 
evaluate cough related QoL; the cough-specific QoL questionnaire (CQLQ) and the 
Leicester cough questionnaire (LCQ) (Birring et al., 2003c, French et al., 2002) both of 
which are recommended by the ERS cough assessment guidelines (Morice et al., 2007a). 
The CQLQ is a 28-item questionnaire comprised of six domains: physical complaints, 
extreme physical complaints, psychosocial issues, emotional well-being, personal safety 
fears and functional abilities (French et al., 2002). It has been shown to have strong test-
retest reliability in all six domains (r>0.75 for all domains) and shows significant 
differences between acute coughers, chronic coughers and smokers (French et al., 2002). 
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The MID of CQLQ has been established as 13 units in total CQLQ score for chronic cough 
(Fletcher et al., 2010).  
The LCQ is a 19 item questionnaire which measures the effect of cough in three domains: 
psychological, physical and social, thus it creates four scores: a psychological domain 
score, physical domain score, social domain score and total score. The LCQ has been 
showed to have a significantly strong correlation with cough severity VAS (rs=-0.72) and a 
strong repeatability in all its scores (physical 0.93, psychological 0.90, social 0.88 and 
total score 0.96). The MID for LCQ has been established as 1.3 in chronic cough (Raj and 
Birring., 2007). The LCQ has been used in a number of chronic cough and refractory 
chronic cough clinical trials (Ryan et al., 2012, Yousaf et al., 2010, Patel et al., 2011, Ryan 
et al., 2010). 
 
1.2.4.6 Mood/ anxiety  
 
 A number of different measures have been used in chronic cough to assess anxiety and 
depression including: the Center for Epidemiologic studies Depression Scale (CES-D) 
(Dicpinigaitis et al., 2006) which is a 20 item self-reported questionnaire, with a score ≥16 
indicating significant depressive symptomatology and risk for clinical depression; Hospital 
anxiety and depression scale (HADS) (Zigmond and Snaith., 1983) a 14 item self-reported 
questionnaire, with a score of 8-10 indicating a borderline and a score ≥11 indicating 
probable anxiety and depression disorder; State Trait Anxiety Inventory (STAI) 
(Spielberger et al., 1984) a 40 item questionnaire (20 items for State anxiety, 20 items for 
trait anxiety but subsets can score between 20-80)  which measures the underlying 
tendency and current state of anxiety, a higher score indicates a greater anxiety (Julian, 
2011); and Crown Crisp Experiential Index (CCEI)(Crown and Crisp, 1966) a self-rating 
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48-item questionnaire which measures 6 scales of  free floating anxiety, phobic anxiety, 
obsessionality, somatic anxiety, depression and hysteria (McGarvey et al., 2006).  
Dicpinigaitis et al (2006) found that of 100 (79% female: 21% male) new chronic cough 
patients referred to secondary care, 53% had significant depressive symptomatology as 
rated by CES-D which was not influenced by gender (53% females, 52% male) or  
duration of cough. McGarvey et al (2006) found that of 57 (70% females) new patients 
referred to a chronic cough specialist clinic, 21% had borderline anxiety scores, 10.5% 
had borderline depression score, 12.3% had clinically important anxiety score and 5.3% 
had clinically important depression scores as rated by HADS. Forty-four percent of 
participants had moderate trait anxiety scores, 3.8% had high levels of trait anxiety and 
28% had moderate state anxiety scores as measured by STAI. Mean phobic anxiety, 
obsession, somatisation and depression scale scores as part of the CCEI were all higher 
than values for healthy population. Similarly to Dicpinigaitis et al (2006), McGarvey et al 
(2006) found no significant gender differences in anxiety or depression scores and only a 
weak correlation between cough duration and HADS depression scores (r=0.321, p<0.05).  
Vertigan et al (2007c) unlike the previous two studies explored anxiety and depression in 
participants who had a diagnosis of refractory chronic cough and therefore had undergone 
extensive medical interventions and treatments and found significantly higher scores for 
anxiety and depression when compared to healthy controls (p<0.001). Vertigan et al 
(2007c) analysed anxiety and depression in participants with refractory chronic cough, by 
splitting them into two groups; those who had refractory chronic cough with no signs of 
PVFM and those who had refractory chronic cough and PVFM. Mean depression scores 
for both groups were within normal range as scored by HADS. The mean anxiety score for 
the chronic cough only group was also within normal range for anxiety as scored by 
HADS. In contrast the participants who had chronic cough and PVFM, the mean anxiety 
score was identified as borderline for anxiety symptomology.  
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Vertigan et al (2007c) may have found lower rates of anxiety and depression compared to 
Dicpinigaitis (2006) and McGarvey et al (2006) as the participants in their study had 
undergone multiple investigations and treatment trials for their cough. Participants in 
Dicpingaitis et al (2006) and McGarvey et al (2006) studies were assessed for anxiety and 
depression on their first visit to secondary care. In Dicpinigaitis et al (2006) study they did 
repeat anxiety and depression assessment and found scores for both significantly 
reduced following investigations and treatment for cough.  
Despite a range of measures being used in the studies of Dicpinigaitis et al  (2006) and 
McGarvey et al  (2006) to explore anxiety and depression in chronic cough population, 
HADS is the only measure that has been used in a refractory chronic cough clinical trial 
(Ryan et al., 2010).  McGarvey et al (2006) found strongly significant concurrent validity 
when HADS anxiety subscale was compared to STAI state anxiety and trait anxiety 
(r=0.621 and r=0.607 respectively, p<0.01) as well as CCEI free floating (r=0.867, p<0.01) 
and CCEI phobic anxiety (r=0.603, p<0.01). Strongly significant concurrent validity was 
also found for HADS depression subscale and CCEI depression score (r=0.633, p<0.01). 
Therefore it could be argued that any of these measures could be used to explore mood 
with people with refractory chronic cough. 
 
1.2.4.7 Voice/vocal related symptoms 
 
A number of outcome measures have been used to assess vocal problems in people with 
refractory chronic cough. These include: perceptual voice analysis (Vertigan et al., 2007d, 
Vertigan et al., 2008a), which is a subjective voice assessment undertaken by a trained 
listener (Vertigan et al., 2007d, Vertigan et al., 2008a); acoustic voice analysis (Vertigan et 
al., 2008b, Vertigan et al., 2008a), which is an objective electronic measure of vocal 
function (Dejonckere et al., 2001), and electroglottography (Vertigan et al., 2008b), which 
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measures vocal fold activity reflecting glottal closure (Bier and Watson., 2012). These 
measures all require a trained experienced clinician in voice analysis for them to be 
undertaken; unfortunately this resource is not consistently available in all chronic cough 
centres.  
There are a number of patient self-reporting questionnaires available that have been used 
to measure patient perceived voice dysfunction of which the following have been studied 
in depth recently (Carding et al., 2009): The Voice Handicap Index (VHI) a 30 item 
questionnaire comprising three domains namely, functional, emotional and physical 
aspects of voice. A total score >33 indicates a mild voice impairment, >44 moderate and 
>61 severe (Jacobson et al., 1997). The Vocal Performance Questionnaire (VPQ) is a 12 
item questionnaire for which a score >12 indicates patient perceived voice dysfunction 
(Carding and Horsley., 1992); and the Voice Symptom Scale (Dreary et al., 2003)  which 
is a 30 item scale  with three domains (impairment, physical symptoms and emotional 
response), the higher the total score the higher voice impairment. 
Carding et al (2009) argues that patient self-reporting scales have the benefit of collecting 
data on patients’ experienced disability from their vocal problems as well as information 
regarding the quality of their voice. As vocal problems tend to have variable effects over 
time it enables the patient to report how their voice condition is in general rather than a 
clinician rating their voice on a single episode in clinic. A single clinical measurement may 
not be representative of the patient’s voice at other times other than during the 
assessment.  All three scales (VHI, VPQ and VSS) have been shown to have excellent 
internal consistency (Cronbach’s coefficient VPQ 0.81, VHI 0.95 and Voice Symptom 
Scale 0.89) and repeatability (VHI =0.83, VPQ=0.75 and Voice Symptom Scale = 0.63) 
(Webb et al., 2007). Significantly strong concurrent validity (VHI vs voice symptom scale 
r=0.87, VHI vs VPQ r=0.76, VPQ vs voice symptom scale r=0.78) (Webb et al., 2007) as 
well as sensitivity to change post voice therapy (VPQ SD= 1.04, VHI SD=0.62, Voice 
Symptom Scale SD= 0.78) [128]. Webb et al’s (2007) who compared all three scales 
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concluded they were all reliable and valid patient reported questionnaires for assessing 
patient’s perceived voice dysfunction. 
 
1.2.5 Pharmacological Treatment options 
 
Table 4 shows a number of medications that are discussed in the literature (Cohen and 
Misono., 2013, Chung., 2007, Morice et al., 2006, Belvisi and Geppetti., 2004) as 
potentially being effective for refractory chronic cough. 
Table 4. Medications for Refractory Chronic Cough 
 
Medication Group Medications 
Opiates Codeine, Morphine, 
Diamorphine 
Neuro-modulating agents Baclofen, Gabapentin, 
Pregablin, Amitriptyline 
Local Anaesthetics Lignocaine 
Non-narcotic Antitussive 
agents 
Dextromethorphan, Menthol, 
ATP gated channel antagonist 
AF-219 (P2X3 receptor 
antagonist) 
 
Although these medications are mentioned as potentially being effective for refractory 
chronic cough, the literature supporting the use of some of these recommended 
medications in adults with refractory chronic cough is sparse or none existent. Exploration 
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of the literature failed to identify any studies investigating the use of dextromethorphan or 
diamorphine with refractory chronic cough adults specifically. Menthol (Morice et al., 1994) 
and lignocaine (Choudry et al., 1990) have been investigated in healthy volunteers but 
again no studies were found looking at their effects for people with refractory chronic 
cough. Only one study was found that explored the effect of Pregablin, this study looked 
at the effect of Pregablin in 12 patients diagnosed with laryngeal sensitivity dysfunction 
with or without chronic cough as a chief compliant (Halum et al., 2009). Only 3 participants 
with chronic cough as a chief compliant were included in the study,  two had chronic 
cough with throat discomfort and 7 had throat discomfort alone. Of those that completed 
treatment all reported improvements in chronic cough severity on a 0 to 5 rating scale post 
four weeks of Pregablin which was mostly initially started at 75mg twice a day raised to 
150mg twice a day over four weeks (n=1 had to be increased to 150mg three times a 
day). Of the five participants whose chief complaint was chronic cough two withdrew from 
the study due to side effects only three completed the study. The side effects for those 
who withdrew were difficulty thinking and worsening of Charcot-Marie tooth disease leg 
pain. The other three although they did not withdrew all complained of sedation as a side 
effect. Limited conclusions can be made about the effect of Pregablin for refractory 
chronic cough due to the limited sample size.  
More evidence was found for the effectiveness of morphine, amitriptyline, gabapentin, 
baclofen and ATP gated channel antagonist AF-219 (P2X3 receptor antagonist) 
medications for refractory chronic cough and this has been summarised in table 5. 
Only one study has investigated slow release morphine sulfate (MST) for refractory 
chronic cough, Morice et al  (2007b) found 5mg of MST BD for four weeks significantly 
improved QoL, with the mean improvement  in LCQ greater than its MID (Raj et al., 2009) 
(Mean improvement 3.2, p<0.01).  MST also reduced self-reported daily cough counts 
(p<0.01), but no significant differences in cough reflex sensitivity were found.  
 Page 55 of 288 
 
Two studies have investigated Amitriptyline for refractory chronic cough; Bastian et al’s 
(2006) cohort study found 92% of their 12 participants reported a reduction in their cough 
symptoms within 10 days of taking 10mg Amitriptyline daily for 21 days. Jeyakumar et al’s 
(2006) RCT found only 23% of their 13 participants who took Codeine/Guaifenesin for 
10days reported any improvement in their cough and showed any improvement in their 
QoL scores by Day 10. However in the Amitriptyline group 87% of the 15 participants 
reported a greater than or equal to a 50% improvement in their cough and 93% reported a  
greater than or equal to a 10 point decrease in their CQLQ, reflecting an improvement in 
their cough related QoL. 
Two studies have investigated the use of Gabapentin for refractory chronic cough; Mintz 
and Lee (2006) found 5 of their 6 patient case studies reported significant improvements 
in their cough symptoms. However the use of Gabapentin in these case studies lacks 
standardisation as there was a large range in the dosages and duration of the medication 
used from 100mg BD to 800mg BD; and time period ranged from 3 months to 1 year 
duration. Ryan et al’s (2012) RCT of Gabapentin was more standardised in the duration 
and dosage of Gabapentin and found significantly greater improvements in QoL (mean 
change 2.5, p=0.004) in the treatment group. This change in QoL was greater than the 
MID for LCQ (Raj et al., 2009). Ryan et al (2012) also found significant improvements in 
cough frequency (p=0.028) and cough severity (p=0.029) in the Gabapentin group 
compared to placebo. 
Dicpinigaitis and Rauf (1998b) was the only study found that has investigated the use of 
oral Baclofen for refractory chronic cough. They found that for two female case studies 
following 14 days of oral Baclofen 10mg TDS the participants reported a decrease in their 
daily reported coughing bouts.  Whilst taking placebo medication neither participant had a 
change in their cough reflex sensitivity however after 14 days of Baclofen participant 1 
was able to tolerate 3 doubling dosages more of capsaicin before reaching C5 and 
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participant 2 was able to tolerate a further 5 doubling dosages of capsaicin before 
reaching C5. 
The latest medication to be investigated for refractory chronic cough has been AF-219 
(P2X3 receptor antagonist). When compared to placebo in a dose of 600mg BD over two 
weeks AF-219 (P2X3 receptor antagonist) was found to significantly reduce cough 
frequency (daytime and 24 hour), reduce day-time cough severity, urge to cough and 
improve QoL as measured  by CQLQ . There was however, no difference in night time 
cough frequency (Jeyakumar et al., 2006).  
Slow release morphine, amitriptyline, gabapentin and AF-219 (P2X3 receptor antagonist) 
have all shown beneficial results for refractory chronic cough. Codeine/Guaifenesin was 
found to be ineffective in the majority of the participants studied in Jeyakumar et al’s 
(2006) study and no other studies investigating the effect of codeine in refractory chronic 
cough adults could be found.  
The mechanism of action of these medications for refractory chronic cough is described 
by many of the authors of the above studies as poorly or not clearly understood and there 
is limited discussion of mechanism of action included in their papers (Dickinson et al., 
2014, Morice et al., 2007b, Jeyakumar et al., 2006). Of the studies that do discuss 
mechanism of actions or hypothesised mechanisms of action.  Ryan et al’s (2012) 
Gabapentin study discusses that Gabapentin has been shown in chronic pain studies to 
affect the central calcium channels inhibiting the release of excitatory neurotransmitters 
such as substance P. However the mechanisms of action for refractory chronic cough are 
not discussed. Baclofen has been shown to have a centrally acting antitussive effect in 
guinea pigs and cats, though the mechanism by which this occurs needs further 
exploration (Bolser et al., 1994). AF-219 (P2X3 receptor antagonist) is thought to work by 
inhibiting the P2X3 receptors which are ATP-gated ion channels found on vagal afferent C 
fibres (Abdulqawi et al., 2014).  
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Despite the promising results found for slow release morphine, amitriptyline, gabapentin 
and P2X3, there are a number of limitations to the studies investigating these 
medications. The starting sample sizes for these studies are very small and compounded 
by attrition; the largest number of participants who completed their treatment trial within 
one intervention group was 26 in Ryan et al’s (2012) study. All the other intervention 
groups in the other studies had fewer participants complete their treatment trials. There is 
also (in the context of medication trials) a surprising and disappointing absence of 
validated objective cough outcome measures in some of the studies. Bastian et al (2006) 
and Mintz and Lee (2006) used no validated objective outcome measures at all and relied 
on patient reported improvement in symptoms. The remainder of the studies did use a 
validated QoL measure; either CQLQ or LCQ. Only Morice et al  (2007b) and Ryan et al 
(Ryan et al., 2012) objectively measured cough reflex sensitivity and only Abdulqawi et al 
(2014) and Ryan et al (2012) investigated cough frequency and severity objectively. Ryan 
et al (2012) did however; use their objective cough monitor, the LCM, for a non-validated 
duration, only recording participants for 1 hour. Lee et al (2012) had previously identified 
that only cough recordings as short as four hours via the LCM had an acceptable 
correlation with 24 hour recordings and therefore could be used with confidence.  
Another issue related to the pharmacological management of refractory chronic cough are 
the side effects of medications. Side effects were found for all the medications discussed 
in table 5 apart from Amitriptyline and Baclofen for which no side effects were reported. 
Gabapentin and AF-219 (P2X3 receptor antagonist) had a significant number of side 
effects which were associated with attrition. For AF-219 (P2X3 receptor antagonist) all the 
participants suffered taste disturbances. 
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Table 5: Pharmacological treatment options for Refractory Chronic cough 
Drug group Drug Name Trial methodology Treatment efficacy Drop outs and 
adverse/side effects 
Opioids Morphine  
Morice et al., 
2007b 
 
n= 27 (18 females, mean (SD) age 
55(10.6) years) participants with 
refractory chronic cough. 
Double blind placebo-controlled 
crossover study. 
4 weeks of slow release morphine 
sulfate (MST) 5mg twice daily or 4 
weeks of matched placebo. 
 
Significant improvement in LCQ at end of 
treatment in the MST group (Mean 
improvement 3.2, p<0.01). No significant 
difference in LCQ score at end of treatment 
for placebo. Significant difference between 
groups at end of treatment (p<0.02). 
Significant reduction in participant daily 
cough diary scores in MST group (3.4 (1.8), 
p<0.01). No significant change in placebo 
group. 
No significant change in cough reflex 
sensitivity in either group as measured by 
citric acid cough challenge testing. 
 
No drop out due to 
adverse events. 
Most common side 
effects: constipation 
(affected 40% of study 
group), drowsiness 
(affected 25% of study 
group). 
Other side effect not listed 
in paper. 
Neuro-
modulating 
agents 
Amitriptyline 
Bastian et al., 
2006 
 
 
 
 
                
 
n=12 (4 females, median (range) age 
52 (20 to 75) years) participants with 
refractory chronic cough. 
Cohort uncontrolled study 
21 days of amitriptyline 10mg OD 2 
hours before bedtime.  
 
                                                     
 
11 participants self-reported reduction in their 
cough symptoms within 10 days of starting 
amitriptyline, median maximum improvement 
was 5 days (range 1 to 10 days). 4 
participants reported 100% improvement 
 
 
                                                                                           
 
No drop outs or side 
effects reported. 
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Jeyakumar et al., 
2006 
  
 
n=28 (15 females, Amitriptyline group 
median age 54.6 years, 
Codeine/Guaifenesin 49.7 years) 
participants with idiopathic chronic 
cough 
Randomised controlled trial 
10 days of amitriptyline 10mg OD at 
bedtime or 10 days of  10 to 100 
mg/5 mL, 10 mL Codeine/guaifenesin   
10 of the 13 participants who took 
Codeine/Guaifenesin reported 0% 
improvement by Day 10, 2 reported 25% 
improvement and only 1 reported 50% 
improvement.                                                                             
4 of the 15 participants who took Amitriptyline 
reported 100% improvement, 7 reported 75% 
improvement, 2 reported 50% improvement, 
1 reported 25% improvement and only 1 
reported no improvement.. 
10 of the Codeine/Guaifenesin participants 
reported no improvement in QOL as 
measured by the CQLQ by Day 10 however 
14 of the Amitriptyline participants reported 
>10 point decrease in CQLQ by Day 10. 
Amitriptyline was found to be a significant 
predictor of greater than 50% improvement 
compared to Codeine/Guaifenesin 
(p=0.0007). 
No drop outs or side 
effects reported. 
Gabapentin 
Ryan et al., 2012  
 
 
 
 
 
 
n= 62 (40 females, Mean (SD) age 
62.7(14) in placebo group, 60.9 
(12.9) in Placebo group) participants 
with refractory chronic cough 
Randomised, double-blind, placebo-
controlled trial 
Gabapentin gradually increased over 
6 initial days to 1800mg dose which 
was maintained over 10 weeks then 
was withdrawn gradually over 6 days, 
 
26 participants in the Gabapentin group and 
25 participants in the placebo group 
completed the trial. The Gabapentin group 
had a significantly greater improvement in 
QoL (as measured by LCQ, Mean (95%CI) 
1.80 (0.56 to 3.04) greater improvement in 
the Gabapentin group, p=0.004), cough 
frequency (as measured by LCM, -27.31      
(-51.75 to -2.88) greater reduction in the 
gabapentin group, p=0.028) cough severity 
(as measured by VAS,                                     
-12.23 (-23.22 to -1.25 greater reduction in 
There were 11 dropouts in 
total: 
 1 did not receive 
full dose of drug 
so was 
withdrawn. 
 2 were lost to 
follow up.  
 3 discontinued 
their intervention 
due to side 
effects of 
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or 12 weeks of placebo  
 
 
 
 
 
 
 
 
 
 
the Gabapentin group, p=0.029) by end of 
treatment period. 
No significant difference between groups in 
cough reflex sensitivity at end of treatment 
trial (p=0.72), urge to cough score (measured 
during capsaicin cough challenge) (p=0.30). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
intolerable 
fatigue, rash, 
gastroenteritis 
 1 withdrew as 
they were 
concerned with 
side effects 
 1 withdrew as 
received 
treatment for 
comorbidity 
 2 withdrew as no 
perceived efficacy 
 1 withdrew to 
personal reasons 
Side effects in the 
treatment group occurred 
in 10 participants and 
were: 
 Blurred vision 
(n=1) 
 Disorientation, 
confusion (n=2) 
 Dizziness (n=3) 
 Dry/very dry 
mouth (n=2) 
 Fatigue (n=3) 
 Headache (n=1) 
 Memory Loss 
(n=1) 
 Nausea, stomach 
pain (n=4) 
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 Mintz and Lee., 
2006 
n=6 patients with idiopathic chronic 
cough. 
Clinical case studies 
Up to 1 year duration of Gabapentin 
100mg BD increased until 
improvement or a daily dose of 
1600mg is reached.  
3 participants reported complete resolution of 
their cough (however 1 participant’s cough 
only had 3 month resolution then had to 
double their Gabapentin dose), 1 participant 
reported their cough greatly decreased, 1 
participant reported a decreased cough 
frequency and intensity and 1 participant 
reported cough was 10-15% better. 
 
1 participant stopped after 
3 weeks due to symptoms 
of fatigue but restarted 
Gabapentin and 
symptoms stopped. 
1 participant had transient 
drowsiness that resolved 
after 1 week. 
 
 
 Baclofen 
Dicpinigaitis and 
Rauf., 1998b 
 
n=2 (69 year old woman and 37 year 
old woman) patients with refractory 
chronic cough. 
Clinical case studies 
Double blind crossover design 
14 days 10mg TDS oral Baclofen or 
placebo, followed by 14 days 10mg 
TDS oral placebo or Baclofen. 
 
 
 
Both participants reported a decrease in 
cough frequency, participant 1 reported a 
decrease in daily coughing bouts by 5 after 
receiving Baclofen compared to no reduction 
whilst on placebo. Participant 2 reported a 
decrease in 10 cough bouts a day after 
receiving Baclofen compared to an increase 
in daily cough bouts of 6 when on placebo. 
There was no change in cough reflex 
sensitivity as measured by C5 after receiving 
placebo for either participant. However after 
receiving Baclofen Participant 1 was able to 
tolerate 3 doubling doses more of capsaicin 
before reaching C5 and Participant 2 was 
able to tolerate 5 doubling doses of capsaicin 
before reaching C5. 
 
None reported 
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ATP gated 
channel 
antagonist 
AF-219 (P2X3 
receptor 
antagonist) 
Abdulqawi et al., 
2014 
 
 
n=24 (18 females, Age Median(IQR) 
54.5 (24-70) years old) refractory 
chronic cough participants 
Double-blind, placebo-controlled, 
two-period crossover study 
Two weeks of either AF-219 (P2X3 
receptor antagonist) 600mg BD or 
placebo then a two week washout 
period followed by the alternative 
therapy. 
 
 
AF-219 (P2X3 receptor antagonist) 
significantly reduced daytime cough 
frequency (as measured by VitaloJAK) 
compared to placebo at end of  2 weeks 
(Difference between group -75% (-88 to 50), 
ITT p=0.0003); 24 hour cough frequency 
(Difference between group -74% (-87 to -46) 
ITT p=0.001); day-time cough severity (as 
measured by VAS) (Mean difference 
between groups -25.6 (-41.5 to -9.6), ITT 
p=0.003); urge to cough (as measured by 
VAS) (Mean difference between groups -21.3 
(-41.0 to -1.5), ITT p=0.035) and QoL (as 
measured by CQLQ) (Mean difference 
between groups -9.2 (-16.8 to -10.7), ITT 
p=0.0018). 
However there was no significant difference 
in night-time cough frequency (ITT p=0.057) 
 
 
Six participants dropped 
out of the study due to 
side effects of AF-219 .  
Side effects experienced 
by participants taking AF-
219: 
 Dysgeusia (n=21) 
 Hypogeusia 
(n=13) 
 Nausea (n=9) 
 Oropharyngeal 
pain (n=5) 
 Headache (n=3) 
 Salivary 
hypersection 
(n=3) 
 Cough (n=3) 
 Anosmia (n=2) 
 Constipation 
(n=2) 
 GORD (n=2) 
 Glossodynia 
(n=2) 
 Depressed mood 
(n=2) 
 Blurred vision 
(n=2) 
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1.2.6 Non-pharmacological Treatment options 
 
Due to the limited effectiveness and side-effects of many of the antitussive medications 
(Chung., 2007) non-pharmacological interventions began to be investigated as an 
alternative treatment for people with refractory chronic cough. A number of terms have 
been used to describe these interventions usually associating the treatment with the 
professional group involved in delivery e.g. ‘speech pathology management’(Vertigan et 
al., 2006, Ryan et al., 2010, Ryan et al., 2009), ‘cough-suppression physiotherapy’ (Patel 
et al., 2011) or identifying with the treatment intervention e.g. ‘respiratory retraining’(Murry 
et al., 2010) and ‘psychotherapy’(Blager et al., 1988). Non-pharmacological treatments for 
patients with refractory chronic cough have generally been delivered by respiratory 
physiotherapists or speech and language therapists linked to respiratory, Ear-Nose-
Throat, voice and allergy services (Patel et al., 2011, Vertigan et al., 2006).  
A detailed review of the treatment components and efficacy of non-pharmacological 
interventions is the focus of chapter 2. 
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CHAPTER 2 
SYSTEMATIC REVIEW NON-PHARMACOLOGICAL INTERVENTIONS FOR 
REFRACTORY CHRONIC COUGH 
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2. Systematic Review Non-Pharmacological Interventions for Refractory Chronic 
Cough 
 
This chapter has been previously published by Springer in Lung Journal, titled 
'Nonpharmacological Interventions for refractory chronic cough patients: systematic 
Review’, Volume 192, 2014, pg 75-85, Chamberlain, S., Birring, S.S., Garrod, R, 
Copyright 13 Oct 2013 (Chamberlain et al., 2014a), with permission from Springer 
Science+Business Media. Number of figures and tables have been changed for this thesis 
but no changes to the content have been made. 
 
2.1 Introduction 
 
Chronic cough; defined as a cough present for greater than 8 weeks (Morice et al., 2006) 
is a common problem with an estimated prevalence of 12% (Ford et al., 2006). Chronic 
cough is known to cause significant physical and psycho-social morbidity with associated 
symptoms of vomiting, chest pain, voice changes, sleep deprivation, incontinence, 
embarrassment, interference with work, relationships and social activities (Brignall et al., 
2008).  
Most common diagnoses for chronic cough sufferers with a normal chest X-ray are: 
asthma, gastro-oesophageal reflux (GORD) and rhinitis (also known as upper airway 
cough syndrome)(Morice et al., 2006). In most, extensive medical management and 
investigations (Morice et al., 2006, Morice et al., 2004) are effective; however chronic 
cough can persist in up to 10-42% of cases (Haque et al., 2005, Morice, 2002, Vertigan et 
al., 2006, Vertigan et al., 2007b).There is significant variation in terminology used to 
define chronic cough for which there are negative investigations or failed treatments for its 
main causes. The various terms used include refractory chronic cough (Patel et al., 2011), 
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idiopathic chronic cough (Morice et al., 2006), cough hypersensitivity (Birring, 2011), 
psychogenic cough (Vertigan et al., 2007a) and habit cough (Vertigan et al., 2007a, 
Blager et al., 1988). For this review, we use the term refractory chronic cough, which 
indicates cough that is persistent for more than 8 weeks, of no known cause, and resistant 
to medical treatment for the main causes of cough (Morice et al., 2006, Morice et al., 
2004). 
Refractory chronic cough is more prevalent in females than males, with onset around 
middle-age (Haque et al., 2005, Birring, 2011). The pathophysiology of cough in this group 
of patients is unclear; however, changes to both the peripheral and central mechanisms of 
cough are thought to be contributing factors. People with refractory chronic cough have 
been shown to have increased cough reflex sensitivity to tussive agents (Prudon et al., 
2005, Johansson et al., 2009). In a recent Lancet article (Chung et al., 2013) authors 
hypothesised that changes in afferent neurons’ sensitisation could induce spontaneous 
primary afferent firing (absent of the initial stimuli). Refractory chronic cough shares 
similarities to other hypersensitivity syndromes such as chronic pain, and central 
mechanisms are thought to be involved since refractory chronic cough patients have 
abnormal laryngeal sensations, increased sensation to nontussive stimulus, and a 
heightened response to tussive stimulus (Vertigan and Gibson, 2011). Similar to the 
pathophysiology of pain, it has been hypothesised that convergence of central inputs from 
oesophageal, airway nociceptors, and/or airway afferent nerves could lead to central 
sensitisation of the cough reflex (Chung et al., 2013).  An association between organ-
specific autoimmune disease and refractory chronic cough has been identified (Birring et 
al., 2004a), and there has been a significant increase in people with bronchoalveolar 
lymphocytosis compared to those with cough and a known pathological cause (Birring et 
al., 2003a).  
Treatments for patients with refractory chronic cough have focused mainly on 
pharmacological antitussive medications; however, these appear to have limited 
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effectiveness and side-effects such as sedation have been reported (Chung, 2007). 
Fortunately, there is now emerging evidence of the benefits of alternative 
nonpharmacological interventions for people with refractory chronic cough. Depending on 
the professional group delivering the care, these interventions have been named “speech 
pathology management” (Vertigan et al., 2006, Ryan et al., 2010, Ryan et al., 2009), 
“cough-suppression physiotherapy” (Patel et al., 2011), or, after the interventions used, 
“respiratory retraining” (Murry et al., 2010) and “psychotherapy” (Blager et al., 1988). Most 
recent studies have included a combination of treatments comprising four key 
components: education, cough suppression techniques (including breathing exercises), 
vocal hygiene and hydration and psycho-educational counselling (Vertigan et al., 2006, 
Patel et al., 2011, Ryan et al., 2010, Ryan et al., 2009). Older studies (Riegel et al., 1995, 
Blager et al., 1988) have included some of these treatment techniques or completely 
different interventions such as biofeedback therapy (Riegel et al., 1995). However, the 
aims of these treatments have been similar: to reduce laryngeal, neck, and shoulder 
muscle tension, and reduce laryngeal hypersensitivity and stimulation and cough reflex 
hypersensitivity.  
Up to 40% of people with refractory chronic cough suffer significant voice problems 
(Vertigan et al., 2007d), and around 56% also have paradoxical vocal fold movement 
(PVFM), i.e., the  adduction of the vocal folds during inspiration and sometimes expiration 
(Ryan et al., 2009). In these patients the effect of treatment on voice as well as cough has 
been explored. However, consideration of the literature evaluating the effects of 
nonpharmacological interventions on voice is outside the scope of this review.  
The aim of this review was to critically consider the literature on the effectiveness of 
nonpharmacological interventions for people with refractory chronic cough using the 
PRISMA statement (Moher et al., 2009) and the Cochrane handbook for systematic 
reviews (Higgins and Green, 2011). 
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2.2 Methods  
 
Search Process 
The study population included adults (≥18 years old) with refractory chronic cough who 
either had negative investigations or failed medical management. Intervention was any 
nonpharmacological treatment or intervention. Neither the frequency nor the duration of 
the treatments was defined a priori and neither were follow-up times or comparison 
groups defined. This was done in order to avoid exclusion of too many studies in this new 
treatment area. Outcomes searched were any subjective or objective measure of cough 
severity, frequency, sensitivity and cough-related quality of life. We did not define 
parameters of reliability or sensitivity for outcomes used so as to again not exclude 
studies in this new treatment area. 
Comprehensive searches were conducted using the following electronic databases: 
EMBASE (1980 to present), AMED (Allied and Complimentary Medicine 1985 to present), 
Medline, CINAHL (Cumulative Index to Nursing and Allied Health Literature 1981 to 
present) and PsycINFO (1806 to 2012). Bibliographies of all studies and systematic 
reviews were searched by hand.  Figure 1 shows the search strategy used. 
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Figure 1: Search strategy for systematic review 
 
 
 
 
 
 
 
 
 
 
 
Eligibility Criteria, Identification and Selection of Studies 
Full-text, English language, prospective and retrospective observational studies, 
experimental studies, and randomised control trials that investigated the effects of 
nonpharmacological interventions/treatments for chronic cough were included. One 
reviewer identified and reviewed all titles and abstracts and then the full text of each 
article.   
Exclusion criteria were studies with participants ≤18 years old, studies that did not include 
cough-specific outcome measures, and studies where sample size was ≤5 participants. 
 
 
1= ‘chronic cough’ 
2= ‘refractory cough’ 
3= ‘idiopathic cough’ 
4= ‘cough hypersensitivity’ 
5= ‘psychogenic cough’ 
6= ‘habit cough’ 
7= 1 or 2 or 3 or 4 or 5 or 6  
8= ‘physiother*’ 
9= ‘speech*’ 
10= ‘behavio*’ 
11= ‘cognitive*’ 
12= ‘psycho’ 
13= 8 or 9 or 10 or 11 or 12 
14= ‘cough frequency’ 
15= ‘cough severity’ 
16= ‘cough intensity’ 
17= ‘quality of life’ 
18= 14 or 15 or 16 or 17 
19= 7 and 13 and 18 
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Critical Appraisal and Summary of Measures 
Critical appraisal was carried out by one reviewer using the SIGN appraisal tools (SIGN, 
2011) and Cochrane handbook for systematic reviews (Higgins and Green, 2011). Studies 
were classified using the SIGN (2011) and NICE (2009) study algorithms. Results were 
collated into a summary using the SIGN evidence tables (SIGN, 2011). 
 
2.3 Data Analysis  
 
Analysis was carried out by one reviewer. A meta-analysis was not performed because of 
heterogeneity of study populations, treatment interventions, and outcome measures used 
in the studies included. 
 
2.4 Results 
 
Study Selection 
In total 184 studies were retrieved: 75 were excluded after duplications were removed and 
104 were excluded after abstracts were screened (Figure 2). The remaining 5 articles are 
included in this review. 
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Figure 2: PRISMA flow diagram of studies screened for systematic review 
 
 
 
 
180 of records identified 
through database searching 
4 of additional records 
identified through other sources 
109 of records after duplicates removed 
109 of records screened   101 of records excluded: 
       
 
5 studies included in 
qualitative synthesis  
 12 as paediatric 
studies 
 30 as non-
interventional 
refractory chronic 
cough studies 
 55 as non-
refractory chronic 
cough studies 
 2 as 
pharmacological 
intervention studies 
 1 as no full text. 
 1 as no cough 
outcome measures 
in study 
 3 as sample size 
(n≤5) 
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Study Characteristics of Included Studies 
A summary of the studies’ characteristics is provided in table 6. The five trials included 
were conducted in three different countries (Australia, USA and UK) by three different 
research groups. All of the studies were published in the last 7 years.  Only one study was 
a randomised control trial (Vertigan et al., 2006), three studies were noncomparative 
prospective studies, and the study by Murry et al (2010) was a noncomparative 
retrospective study. 
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Citation Study 
Type 
Number 
of 
Patients 
Patient 
characteristics 
Intervention Comparison Length of 
follow up 
Outcome 
measures 
Treatment outcome Source of 
funding 
Vertigan 
et al 2006 
RCT n=97, but 
10 
dropped 
out (4 in 
Rx group, 
6 in 
control). 
Patients 
studied 
n=87 
(n=43 in 
Rx arm, 
44 in 
control 
arm) 
Adult refractory 
chronic cough 
sufferers 
(mean(SD) age =  
59.4 (13.6),          
range = 23-84); 64 
female, 23 male. 
No details on 
participants’ cough 
duration apart from 
> 2months 
duration. 
All had treatment 
for asthma, post-
nasal drip, GORD 
and had been 
withdrawn from 
ACE inhibitors. 
Participants were 
excluded if had 
URTI, untreated 
allergy, respiratory 
disease, 
neurological voice 
disorders. Two 
smokers included 
Speech 
pathology 
evaluation and 
intervention for 
chronic cough 
(SPEICH-C) 
Consisting of: 
*Education 
*Strategies to 
reduce cough 
*Psycho-
educational 
Counselling 
*Vocal hygiene 
education 
Four 30-min 
sessions over 
a 2 month 
period 
Placebo 
Intervention 
consisting of 
healthy 
lifestyle 
advice 
sessions 
covering: 
*Relaxation 
*Stress 
Management 
*Exercise 
*Diet 
Four 30-min 
sessions 
over a 2 
month period 
No follow 
up post 
treatment 
Patient rated 
subjective 
symptom 
severity and 
frequency 
scores on a 5-
point Likert 
scale, 23 in 
total covering 
cough, 
respiratory, 
voice, and 
upper airway 
symptoms. 
Limitations on 
daily activities 
were also 
rated. Treating 
clinician also 
rated patients 
post treatment 
as having a 
successful, 
partially 
successful or 
unsuccessful 
outcome. 
Significant 
improvement in cough 
scores for Rx group 
(95% CI 3-4.9, 
p<0.001) and placebo 
groups (95% CI 0.3-
2.2, p<0.001).  
However, 
improvement was 
significantly greater in 
Rx group (95% CI 1.3-
4.0, p<0.001)  
Significant 
improvements in total 
symptom score (95% 
CI 9.0-16.1, p<0.001) 
and limitation to daily 
activities (95% CI 0.4-
1.0, p<0.001) in 
treatment group only.  
88% reported having a 
successful outcome in 
the treatment group 
compared to only 14% 
in the control 
treatment. 
Grant from 
Jennifer 
Thomas 
through the 
Hunter 
Medical 
Research 
Institute. 
 
 
 
 
Table 6: Evidence table for non-pharmacological interventions for adult refractory chronic 
coughers. 
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Ryan et 
al 2009 
NCS n=24 but 
only 14 
had 
speech 
pathology 
treatment 
(2males, 
12female
s).Four 
others 
dropped 
out of 
speech 
pathology 
treatment 
Adult Refractory 
chronic cough 
sufferers, non- or 
ex-smokers with no 
cardiac or 
respiratory disease. 
As part of the 
study, all had 
treatment trials for 
asthma, GORD, 
rhinosinusitis and 
sleep apnoea. Then 
the participants with 
PVFM and cough 
had speech 
pathology 
management. 
Median (IQR)   age 
= 56 (40) years old, 
range 22-78. 
Cough duration 
median (IQR) = 18 
(48) months 
4 weekly 
sessions of 
speech 
pathology 
management 
as per 
Vertigan et al 
2006 
treatment 
regime. 
No 
Comparison 
Post 
treatment 
Ax 8 
weeks 
after 
speech 
pathology 
treatment. 
Cough-related 
quality of life: 
leicester 
cough 
questionnaire 
(LCQ) at 
baseline and 
at follow-up. 
Generic quality 
of life 
measure: SF-
36 at baseline 
and at follow-
up. 
Cough reflex 
sensitivity: 
capsaicin 
cough 
challenge 
performed at 
baseline 
Cough-related quality 
of life significantly 
improved (LCQ 
p=0.001) post 
treatment. 
Cough reflex 
sensitivity significantly 
improvement (C5 
p=0.008) post 
treatment. 
No information given in 
article regarding SF-36 
scores or changes. 
PHD 
scholarship 
Murry et 
al 2010 
NCS  n=16 (no 
gender 
details 
given, 
age range 
29-69) 
Adult chronic cough 
sufferers, who were 
on twice daily PPI 
therapy for at least 
3 months, had no 
active sinonasal 
disease, laryngeal 
surgery, or 
documented 
pulmonary disease.  
2-13 sessions 
of respiratory 
retraining 
exercises over 
a 4-23 week 
period 
No 
Comparison 
Final Ax 3 
months 
after initial 
visit 
Subjective 
patient report 
of cough as a 
problem 
Question 7 of 
Reflux 
Symptom 
Index (RSI) 
(“troublesome 
or annoying 
Post Rx only 1 of the 
16 participants 
reported cough as still 
a problem (p≤0.01). 
Only 12 of the 16 
patients repeated the 
RSI at end of 
treatment. 
 
No funding 
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Cough duration 
mean (SD) = 8.4 
(5.3) months 
cough”)  For those who 
completed it the mean 
difference was 3.76 
(p=0.05). 
Ryan et 
al 2010 
NCS n=17 (8 
male, 9 
female). 
Mean 
(IQR) age 
= 61 (20), 
range = 
34-83  
Cough 
duration 
median 
(IQR) = 
60 (147) 
months 
Refractory chronic 
cough sufferers 
(>18years old), all 
non-smokers. 
Up to four 30-
min sessions 
of speech 
pathology 
management 
(same as 
Vertigan et al 
2006) 
n=1  had 1 
session 
n=3 had 2 
sessions 
n=4 had 3 
sessions 
n=9 had 4 
sessions 
Baseline 
assessments 
and four Rx 
sessions were 
carried out 
over 11-15 
week period. 
No 
Comparison 
Final Ax 
2-3 weeks 
after final 
treatment 
session 
Cough 
frequency: ~1 
hour Leicester 
Cough monitor 
performed at 
each session 
and at follow 
up 
Cough reflex 
sensitivity: 
Capsaicin 
cough 
challenge 
performed at 
each session 
and follow up. 
Cough-related 
quality of life: 
LCQ at 
baseline and 
follow up. 
Significant decrease in 
cough frequency post 
treatment (p=0.009). 
Significance of 
difference was 
reached only after 
treatment session 3 
and continued to 
decrease at treatment 
session 4 and post-
treatment session. 
Cough reflex 
sensitivity significantly 
decreased post 
treatment (mean  SD 
log C5, 1.65  0.88, 
p<0.0001).  Cough 
reflex sensitivity 
significantly reduced 
after each session. 
Cough threshold and 
urge to cough also 
significantly improved 
post treatment 
(p=0.001; p=0.01 
respectively).  
 
                         
PhD 
scholarship 
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NCS noncomparative study, RCT randomised control trial, ENT ear, nose and throat, PVFM paradoxical vocal fold movement, GORD gastro-
oesophageal reflux, Ax assessment, Rx treatment, URTI upper respiratory tract infection
Significant 
improvement in cough-
related quality of life 
(p=0.002) post 
treatment. 
Patel et 
al 2011 
NCS n=23 (13 
females, 
10 males) 
Adult refractory or 
idiopathic chronic 
cough sufferers. 
Nonsmokers at the 
time of the study, 
normal chest x-ray 
and spirometry. 
Age mean(SD) = 
60 (2) years. Cough 
duration mean (SD) 
= 42 (10) months. 
Up to 3 
sessions of 
cough 
suppression 
physiotherapy: 
Session 1 – 
education and 
lifestyle 
advice; cough 
control 
techniques, 
breathing 
pattern 
retraining and 
vocal 
hydration. 
Session 2 – 
review 
compliance, 
holistic advice 
and 
reinforcement 
No 
Comparison 
Final Ax  
2 months 
after end 
of 
treatment. 
Cough-related 
quality of life: 
LCQ 
measured at 
baseline and 
2-month follow 
up. Cough 
frequency was 
measured with 
a 7-point Likert 
scale. 
Cough-related quality 
of life significantly 
improved (mean 
difference 2.7, 95% CI 
of difference -4.1, -1.3; 
p<0.001). In all three 
domains of the LCQ, 
physical (p=0.001), 
psychological 
(p<0.001) and social 
(p<0.04). Reported 
cough frequency 
significantly reduced 
(mean difference 1.1; 
95% CI of difference 
0.5-1.8; p=0.002). 
No funding 
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Risk of bias of included studies 
The study by Vertigan et al (2006) had the lowest perceived risk of bias as it was the only 
randomised control trial.  
Allocation 
Only the Vertigan et al (2006), randomised controlled trial gave full details on the 
participants who were referred for the study and details on those who were excluded. The 
randomisation was computer-generated; treating clinicians were not involved in 
randomisation to reduce possible selection bias.  
Blinding 
Double-blinding in these types of therapy intervention studies is very difficult because the 
therapists are involved in the delivery of treatments. Only two of the included studies 
(Patel et al., 2011, Ryan et al., 2010) clearly mentioned blinding of the administered 
questionnaires; however, blinding of the other objective measures used in Ryan et al 
(2010) is unknown.  All other studies lacked detail regarding blinding of the therapists 
providing treatment (Vertigan et al., 2006, Ryan et al., 2009, Murry et al., 2010). In Murry 
et al (2010), PVFM was verified by two independent raters before and after treatment, but 
no details were provided concerning verification of  the Reflux Symptom Index (RSI) score 
used to assess cough severity. The Vertigan et al (2006) study was a single-blinded 
randomised control trial and the only study that kept treatment allocation from the 
participants until the end of the study. Whether treating therapists were involved with both 
the intervention group and the control group is not reported.  Since clinician judgement 
regarding improvement was one of the outcome measures used in the study, there may 
be potential risk of bias.  Furthermore, there is no indication of whether the results of 
patient rating scales were blinded from the treating therapists; performance bias risk is 
thus difficult to determine. 
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Incomplete outcome data 
In general, all intended outcome measures and details on any drop outs were reported in 
the prospective studies (Vertigan et al., 2006, Patel et al., 2011, Ryan et al., 2010). 
However Ryan et al (2009) despite describing SF-36 in the methodology, provided no 
results for this outcome.  
Selective Reporting 
The intended outcome measures were reported in all of the studies.  
Other Biases 
In three of the five studies (Vertigan et al., 2006, Patel et al., 2011, Ryan et al., 2009), the 
treatment interventions were provided in a standardised manner with respect to duration 
and frequency. However, in Ryan (2010), the number and frequency of sessions varied, 
making it difficult to compare results.  
Study Population 
There was significant heterogeneity in the populations studied with respect to age and 
cough duration. Across most of the studies, mean and median ages were quite similar, 
ranging from 56 (Ryan et al., 2009) to 61 years old (Ryan et al., 2010). However, a large 
variation in the age range across the studies was evident (Table 6).  
Participants also varied with respect to the duration of their cough, with median cough 
duration ranging from 18 (IQR 48) months (Ryan et al., 2009) to 60 (IQR 147) months 
(Ryan et al., 2010). Participants in Vertigan et al (2006) all had cough duration > 2 
months. 
The studies also varied with respect to inclusion or exclusion of smokers. Patel et al 
(2011) excluded smokers and ex-smokers, whilst Ryan (2009) included ex-smokers with 
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less than 10 pack years. Vertigan et al (2006) included two current smokers. Only Ryan et 
al (2009) provided objective evidence of smoking cessation.  
Medical management, including the investigation and treatment regimens trialled before 
investigating nonpharmacological interventions, also varied across the studies. However, 
all studies completed investigations for and/or tried medications for asthma, GORD, and 
rhinitis before starting nonpharmacological interventions. Ryan et al (2009) investigated 
the presence of PVFM in their participants and investigated only the efficacy of speech 
pathology management for refractory chronic cough in participants with PVFM. 
The dominance of females across four studies was very similar; Murry et al (2010) failed 
to report gender data.  
Intervention 
A summary of the interventions used in the different studies is provided in table 7. 
Although there were differences among the studies, in general a composite approach was 
used and consisted of education on cough and/or identification of  cough triggers and 
instruction in  cough suppression techniques, breathing exercises, and sometimes vocal 
hygiene and hydration techniques; interventions also included some form of counselling 
(Vertigan et al., 2006, Patel et al., 2011, Ryan et al., 2010, Ryan et al., 2009). The 
terminology of the breathing exercises varied among the studies, but breathing 
control/diaphragmatic breathing and relaxed breathing control techniques have all been 
described as aiming to relax the throat, neck, and shoulder muscles whilst increasing 
abdominal excursion and reducing upper chest movement (Mathers-Schmidt, 2001, 
Bruton et al., 2011). Pursed lip breathing has been described as a technique intended to 
help interrupt coughing (Blager et al., 1988) and reduce some of the adductor activity  of 
the vocal folds during expiration in patients with PVFM (Mathers-Schmidt, 2001). 
Treatments in the studies generally ranged from two to four sessions of speech 
pathology/physiotherapy for cough suppression, and the frequency of the sessions varied 
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from  weekly (Ryan et al., 2009) to completed over 2 months (Vertigan et al., 2006), or 
within 11 to 16 weeks (Ryan et al., 2010). The Murry et al (2010) study was the only one 
to investigate breathing exercises as a sole intervention rather than a composite package 
of care. 
Table 7: Different Interventions included in studies investigating non-
pharmacological interventions in refractory chronic cough 
 
Interventions Vertigan 
et al 2006 
Ryan et 
al 2009 
Murray et 
al 2010 
Ryan et 
al 2010 
Patel et al 
2011 
Education on chronic  
cough 
 
√ √  √ √ 
Education on identifying 
cough triggers 
√ √  √ √ 
Cough suppression 
techniques  
√ √  √ 
 
√ 
 
Breathing 
exercises 
Pursed Lip 
breathing 
√ √ √ √ √ 
Relaxed 
Throat 
Breathing  
√ √ √ √ √ 
Breathing 
control 
/diaphragmatic 
breathing 
    √ 
Vocal hygiene and 
hydration strategies 
√ √  √ √ 
Counselling √ √  √ √ 
Throat massage     √ 
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Effects of Interventions 
Effectiveness of Nonpharmacological Treatments on Cough Frequency 
All three of the studies (Vertigan et al., 2006, Patel et al., 2011, Ryan et al., 2010) that 
investigated cough frequency reported a decrease in frequency following intervention. 
Only one study (Ryan et al., 2010) used a validated objective outcome measure; the 
others used subjective rating scores (Vertigan et al., 2006, Patel et al., 2011).  Patel et al 
(2011) reported a significant reduction in cough frequency, with a mean reduction of 1.1 
[CI 0.5-1.8] points on a 7-point Likert scale (p=0.002). Ryan et al (2010) used the 
Leicester Cough Monitor (Matos et al., 2007, Birring et al., 2008) to assess cough 
frequency and found a significant reduction post treatment (p=0.009). However, in the 
Ryan et al study they used the cough monitor for only 1h despite validation data advising 
4- and 24-h use (Lee et al., 2012). Participants were not exposed to their usual cough 
triggers as they wore only the device during their study visit and a cough provocation test 
was performed during this hour. Therefore interpretation of these findings as a measure of 
participants’ cough frequency is difficult.   
Although cough frequency was recorded in Vertigan et  al (2006), individual scores for 
cough frequency were not reported.  Instead, a composite score for cough, derived from 
scores of cough severity, frequency, throat clearing and nocturnal cough score, was 
given. 
 
Effectiveness of Nonpharmacological Treatments on Cough Severity 
Of the two studies that investigated the effect of non-pharmacological interventions on 
cough severity (Vertigan et al., 2006, Murry et al., 2010), both reported improvements. 
These studies varied the outcomes they used to measure cough severity. Murry et al 
(2010) used question seven of the RSI (“troublesome or annoying cough”) as an outcome 
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of cough severity and found a mean difference in 3.76 points post intervention (p=0.05). 
As mentioned above, Vertigan et al (2006) used a composite score to measure the 
change in cough symptoms and found a significant improvement in the intervention group 
(95% CI 3 to 4.9, p<0.001) compared with the placebo group (95%C1 1.3 to 4, p<0.001). 
In Murray et al (2010) despite showing statistical improvement in question 7 of the RSI, no 
significant improvement was found for the overall score and no details on the baseline 
scores were given, making it difficult to characterise the participants with respect to 
severity.  An 80% improvement, as rated by clinicians, was reported in Vertigan et al 
(2006) however, these results need to be reviewed with caution due to the potentially high 
risk of bias of clinician ratings.  
 
Effectiveness of non-pharmacological treatments on cough related quality of life 
Four of the included studies (Vertigan et al., 2006, Patel et al., 2011, Ryan et al., 2010, 
Ryan et al., 2009) investigated the effect of nonpharmacological interventions on quality of 
life; all four found there to be beneficial results. Patel et al (2011) and Ryan et al (2010, 
and Ryan et al (2009) used the Leicester cough questionnaire (LCQ), a validated and 
reliable cough-related quality-of-life outcome measure (Birring et al., 2003c). All three 
studies found there to be improvements in the LCQ score greater than the minimal 
importance difference, which has been reported as 1.3 (Raj et al., 2009). In two studies, 
the median difference in LCQ was 5.7 (p=0.001) (Ryan et al., 2009) and 3.4 (p=0.002) 
(Ryan et al., 2010) and in Patel et al (2011), the mean difference 2.7 (95% CI -4.1 to -1.3). 
Patel et al (2011) was the only study to report individual domain results and found 
improvements in all: physical (p=0.001), psychological (p<0.001), and social domains 
(p<0.04). Vertigan et al (2006) found significant improvements in limitation to daily 
activities (95% CI 0.4-1, p<0.001). 
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Effectiveness of Non-pharmacological Treatments on Cough Sensitivity 
Only Ryan et al (2010) and Ryan et al (2009) explored the effect of nonpharmacological 
interventions on cough reflex sensitivity, and significant improvements were found in both 
studies as assessed by capsaicin cough challenge C5 (p=0.008) (Ryan et al., 2009) and 
C5 (p<0.0001) (Ryan et al., 2010). Ryan et al (2010) also found cough threshold and urge 
to cough significantly improved (p=0.001 and p=0.01 respectively). 
 
2.5 Discussion 
 
This review aimed to assess the effect of nonpharmacological interventions for adults with 
refractory chronic cough.  Results from five studies with 157 active participants were 
reviewed. Overall, the nonpharmacological interventions investigated yielded 
improvements in cough frequency (Vertigan et al., 2006, Patel et al., 2011, Ryan et al., 
2010, Ryan et al., 2009), severity (Vertigan et al., 2006, Murry et al., 2010), cough reflex 
sensitivity (Ryan et al., 2010, Ryan et al., 2009), and quality of life (Vertigan et al., 2006, 
Patel et al., 2011, Ryan et al., 2010, Ryan et al., 2009). Vertigan et al (2006) was the only 
comparative study and found significant improvements in cough symptom scores in the 
interventional group compared to the control group in which healthy lifestyle advice and 
education were used.  
Improvements in assessing cough need to be made in future studies because of the lack 
of valid and reliable outcome measures used in the studies reviewed. Only for cough 
reflex sensitivity and cough-related quality of life, were valid and reliable outcome 
measures used. Further studies are required to assess these different components of 
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cough as, for example, only two of the five studies evaluated cough reflex sensitivity (27 
participants) (Ryan et al., 2010, Ryan et al., 2009).  
The interventions tested in these studies differed in the components included, and the 
descriptions of techniques were often profession-specific. Generally, the interventions 
“package” included education, cough suppression techniques, breathing exercises, vocal 
hygiene and hydration, and counselling, which for the majority of participants was over 
two to four sessions.  This package of treatment significantly reduced cough reflex 
sensitivity (Ryan et al., 2010, Ryan et al., 2009) and improved cough-related quality of life 
by a median/mean difference of 2.7-5.7 (Patel et al., 2011, Ryan et al., 2010, Ryan et al., 
2009) points on the LCQ; which is greater than the minimal important difference score of 
1.3 (Raj et al., 2009). The effects of intervention on cough frequency were less consistent 
across the studies. Patel et al (2011) found a mean decrease of 1.1 points on a 7-point 
Likert scale for cough frequency; however, the clinical significance of this change is 
unknown and the study was uncontrolled. Ryan et al (2010) explored cough frequency 
using a valid objective measure, the Leicester cough monitor; however, this was not used 
in accordance with developers’ recommendations. Vertigan et al (2006) reported a 
significant improvement in cough symptom scores compared to healthy lifestyle advice 
alone. 
Murry et al [20] was the only study to investigate one aspect of the other studies’ package 
of care: respiratory retraining exercises. However, conclusions on the effectiveness of 
respiratory retraining exercises for chronic cough could not be made from that study 
because of the small sample size (n=16), the lack of standardisation of intervention 
duration (2-13 sessions over 4 to 23 weeks) and the lack of valid and objective outcome 
measures used.  
Many of the limitations of the studies were due to risk of bias. Only one randomised 
control trial was included in this review and therefore risk of selection and allocation bias 
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was high for many of the studies. Blinding was also a limitation as intervention is delivered 
by a therapist so it was difficult to double-blind the studies. Only two studies mentioned 
that the therapists were blinded from the outcome measures (Patel et al., 2011, Ryan et 
al., 2010).  
Compliance is an interesting limitation of nonpharmacological interventions which was 
raised in Ryan et al (2010) study. Based on a clinician’s opinion, they reported only 53% 
of their participants were adherent to treatment. As these interventions rely on the 
participants to practice these treatments over a long period of time, compliance is an 
important issue for nonpharmacological interventions that may be difficult to measure.  
 
Potential Biases in review process 
This review included only studies that looked at the effect of nonpharmacological 
interventions on cough-related outcome measures. There are other studies that have 
explored the effect of these interventions on voice but they were not included. Also, for 
this review only English Language studies were included. The authors of the studies were 
not contacted to provide further details on the studies; this potentially affected the 
judgements made regarding risk of bias and study methodology. 
 
2.6 Conclusion 
 
Implications for practice 
A package of treatment over three to four sessions and consisting of education on chronic 
cough; identifying cough triggers; cough suppression techniques; breathing exercises 
aimed to increase abdominal excursion, relax neck, throat and shoulders and decrease 
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laryngeal muscular tone; and vocal hygiene and hydration advice, appears  to improve 
cough-related quality of life and decrease cough reflex sensitivity. Further research using 
valid and reliable outcome measures is needed to more comprehensively establish the 
treatments’ effects on cough frequency and severity. There is currently limited data that 
compares different components of this package of care to establish the most effective 
components or the most effective treatment duration or frequency. Ryan et al (2010) 
commented that in a pilot study they compared supportive counselling to isolated cough 
suppression therapy and found no change in cough reflex sensitivity after 1 h of 
intervention. However, more in-depth studies comparing different aspects of 
nonpharmacological interventions and treatment durations and frequency are needed in 
order to deliver the most effective care.  
Implications for Research 
This review points out that more randomised control trials evaluating the effects of 
nonpharmacological interventions on cough frequency, sensitivity and severity are 
required. Studies should be rigorously designed with particular attention to blinding of 
assessors, use of valid and reliable objective outcome measures, and sample sizes that 
are adequately powered. Standardisation of the use of terms that describe techniques that 
are multidisciplinary would reduce current confusion in the literature. Studies exploring the 
optimum treatment frequency, duration and individual components are needed. Future 
studies should provide comprehensive patient characteristics to determine if different 
treatment options are required in differing populations, e.g., duration and severity of cough 
may influence outcomes. Comparisons of nonpharmacological interventions with 
antitussive medications with cost effectiveness analysis would also help establish this 
treatment as a mainstream treatment option. 
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2.7 Summary 
 
 
Chapters 1 and 2 have identified the need to explore the impact of chronic cough in the 
wider community; that is to say those individuals with chronic cough, who have not 
presented to primary or secondary care. There is also a need to explore the impact of 
chronic cough across countries rather than investigating the impact within a single country 
and to seek the patient experience or perspective on the management and treatment 
received for their chronic cough. This is a key perspective that is conspicuously absent 
from existing research. 
Chapters 1 and 2 also identified the current lack of treatment options for refractory chronic 
cough patients. Current pharmacological treatment options have shown some promising 
results but are often associated with side effects which are not tolerated by all patients. 
Emerging non-pharmacological interventions have also shown evidence of potential. It is 
however noted that studies that have explored the effectiveness of this group of 
interventions have mostly been limited in sample size, have been cohort studies and used 
outcome measures of variable rigour. Only one RCT has been conducted in this area 
which did not include use of validated objective outcome measures. Therefore there is an 
opportunity to undertake a robust study of the effects of non-pharmacological 
interventions in a RCT that is adequately powered with the inclusion of validated objective 
outcome measures. 
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2.8 Aims of the Study 
 
The main research questions identified from Chapters 1 and 2 were: 
1. What is the impact of chronic cough in the wider community across Europe? 
2. What are chronic cough sufferer’s opinions on the management and treatment 
they may have received for their cough and what are their perspectives of current 
treatment options? 
3. What is the efficacy of a combined Physiotherapy, Speech and Language Therapy 
non-pharmacological intervention for refractory chronic cough compared to 
placebo/ control  for cough related QoL, cough reflex sensitivity, cough frequency, 
cough severity, patients’ perceived voice dysfunction, anxiety and depression? 
Therefore two aims were identified namely:  
1. To explore the impact of chronic cough across Europe as well as explore the 
opinions of people with chronic cough regarding any management and treatment 
they may have received for their cough. 
 
2. To evaluate the effectiveness of a combined Physiotherapy, Speech and 
Language Therapy intervention (PSALTI) for refractory chronic cough compared to 
control for cough  related QoL, cough reflex sensitivity, cough frequency, cough 
severity, patients’ perceived voice dysfunction, anxiety and depression.  
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3. Methodology 
3.1 Overview 
 
The two aims of this thesis were addressed via different methodological approaches in 
two different studies. This chapter will explore the rationale for the studies’ methodological 
choices. The detailed and specific methodologies related to each of the studies 
undertaken as part of this thesis will be explored in chapters 4 and 5.  
The aim of exploring the impact of chronic cough across Europe as well gaining the 
opinions of people with chronic cough regarding any management and treatment they 
may have received for their cough was investigated via a European survey of chronic 
cough sufferers.  
The aim of evaluating the effectiveness of a combined Physiotherapy, Speech and 
Language Therapy intervention (PSALTI) for refractory chronic cough on cough related 
QoL, cough reflex sensitivity, cough frequency, cough severity, patients’ perceived voice 
dysfunction, anxiety and depression was investigated via a multi-centred randomised 
controlled trial (RCT). 
 
3.2 European Chronic Cough Survey 
 
Discussions between the members of the ERS Chronic Cough Taskforce and the ELF 
identified that there was a need to explore the impact of chronic cough across Europe and 
to gather the opinions’ of people with chronic cough regarding any management and 
treatment they may have received for their cough. It was decided that the most feasible 
method for data collection for this study was a survey, as per previous studies that have 
explored prevalence and the impact of chronic cough discussed in chapter 1. Alternative 
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models for this research such as multiple interviews were not feasible due to the scale of 
the study as well as staffing and resource limitations.  
Although surveys have been identified as an appropriate approach when gathering 
information from a large population, Groves (1989) identified four different types of error 
that survey based research can be at risk of:  
 Coverage error -  the survey may not reach or capture the sections of the target 
population;  
 Nonresponse error - the survey may not collect sufficient data on the population 
being investigated; 
 Sampling error - the survey selected population may not be a true reflection of the 
entire population under  investigation;  
 Measurement error - inaccuracies in responses received from the survey due to 
inability of the respondents to answer the given questions. This may be due to 
wording of the survey and/ or inappropriate selection of the mode of data 
collection.  
To help to reduce these errors Check and Schutt (2012) advise careful consideration 
regarding sampling framework, measurement and questionnaire design including the 
wording and layout of the survey.  
These considerations were thought through during the development of the European 
chronic cough survey in this thesis. Initially during the survey design previous reviews of 
chronic cough quality of life literature and published surveys of chronic cough were 
reviewed so questions included in the new survey built upon the existing literature. This 
approach is also hoped to avoid crucial questions from being omitted and ensure the 
relevance of questions included (Check and Schutt., 2012). The survey was designed to 
include both closed and open questions as both quantitative and qualitative data was 
intended to be gathered from the survey. Original questions chosen for inclusion in the 
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survey were discussed within the ERS Chronic Cough taskforce (which included 15 
respiratory physicians from nine countries), a multidisciplinary team (respiratory physician 
and physiotherapists at King’s College Hospital) and the ELF. This expert involvement in 
the question development was undertaken to minimise the measurement error of the 
survey, members reviewing the survey were asked to check that the proposed questions 
were not biased in their wording and avoided confusing phrasing which are identified as 
common errors in surveys by Check and Shutt (2012). The relevance of the questions and 
omission of questions was also considered during the expert involvement.  
Check and Shutt (2012) state that once questions to be included in surveys are identified 
and have been refined via review and pretesting, it is important to then group the 
questions into clear categories that will make sense to the potential respondents. For the 
European chronic cough survey the final survey questions where grouped into 5 broad 
categories: “About your cough,” “How are you affected by your cough?” “Diagnosis of your 
cough,” “Treatment of your cough” and “Support for patients with cough”.  
There are a number of different strategies to conduct research via a survey including 
mailed surveys, group-administered surveys, telephone surveys, internet surveys or 
mixed model surveys (Check and Schutt, 2012). The approach chosen for the European 
chronic cough survey was an internet based survey. This was chosen as it was an easy 
method of making the survey available across Europe and additionally enabled responses 
to be collected from people with chronic cough who may not have sought medical help for 
their chronic cough symptoms; thus increasing our chance of gathering responses from 
people with chronic cough within the wider community. Check and Shutt (2012) identify 
the increasing popularity of internet based surveys as they are easy and cheap to 
administer, enable data to be analysed quickly and minimise data entry errors as data can 
be recorded directly into researchers’ databases. There are however limitations to their 
use as they require responders to be computer literate and to have access to a computer 
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device and the internet. Not all households have this access and those without  tend to be 
from lower socioeconomic backgrounds. 
As the survey was intended for a pan European population it was translated into a number 
of languages to optimise response rates. This translation was undertaken using forward-
back translation methodology by native speakers and the back translated surveys were 
checked by the principal investigator. This methodology of translation has been used in 
numerous studies to translate questionnaires (Huisman et al., 2007, Han et al., 2014, 
Felisbino et al., 2014) and with the resource base available for the European cough 
survey it was the best methodology available to the research team. There are other more 
in depth translation methodologies e.g. having two separate translators translate the 
survey which is then reviewed by independent translators, discussed at a team meeting 
and signed off by an adjudicator. This method is recommended by the Cross-Cultural 
Survey guidelines (Harkness., 2011). Unfortunately though such an approach was 
impossible for the European chronic cough survey in this thesis with the study resources 
available.  
 
3.3 Effectiveness of a combined Physiotherapy, Speech and Language Therapy 
intervention (PSALTI) for refractory chronic cough study  
 
Chapter 2 identified that investigations into non-pharmacological interventions for 
refractory chronic cough have mostly been small sample sized cohort studies with only 
one RCT having been completed that did not include objective outcome measures. 
Chapter two concluded “that more randomised control trials evaluating the effects of 
nonpharmacological interventions on cough frequency, sensitivity and severity are 
required. Studies should be rigorously designed with particular attention to blinding of 
assessors, use of valid and reliable objective outcome measures, and sample sizes that 
are adequately powered” (Chamberlain et al., 2014a). In addressing this need our study 
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was designed to fit these conclusions and therefore expand on and improve upon 
previous research in this field.  
RCTs are considered to be the most rigorous and stringent way of determining a cause-
effect relationship of treatment and determining the cost-effectiveness of that treatment 
(Sibbald and Roland., 1998). Well-designed RCTs reduce selection bias, observer bias, 
confounding variables and random errors compared to other study designs (Kendall., 
2003). There are four main types of RCT: parallel group trials, crossover trials, cluster 
randomised trials and delayed start trials for sample sizes n>1.  
Parallel group trials consist of two groups for which participants are randomly allocated to, 
one group receives the treatment being tested and the other receives either a  
placebo/control  or conventional ‘usual care’ intervention. The outcomes are then 
compared between the two groups (Tilling et al., 2005, Kendall., 2003). In parallel group 
RCTs as the two groups are compared to evaluate treatment effectiveness it is essential 
that the baseline characteristics are similar across both groups to reduce the influence of 
confounding variables (Kendall., 2003). 
In a cross-over designed RCT both groups will experience both treatments but at different 
times. Therefore one group will receive the placebo/control or conventional care first 
followed by the intended treatment to be tested; whereas the other group would start with 
the intended treatment and then receive the placebo/control  or conventional care 
afterwards (Tilling et al., 2005). It is vital therefore in crossover designed studies that an 
adequate ‘washout period’ is kept between groups switching from one intervention to the 
other otherwise residual effects from the group’s previous treatment may affect the results 
of the subsequent treatment received (Jones and Kenward., 2015). This RCT study 
design has the benefit that participants act as their own controls so it explores within 
subject changes, rather than comparing changes that occurs in two different groups of 
participants as in a parallel group RCT design (Jones and Kenward., 2015). 
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Cluster randomised trials run similar to parallel group RCTs however, instead of 
participants being randomised individually, they are randomised in clusters. This approach 
is useful for interventions that may not be individual participant dependant but are looking 
at groups of patients. For example GP management of conditions or if there is the risk of 
contamination between participants e.g. different members of the same family being 
involved in the same study (Kendall., 2003). 
Delayed start trials are advocated for use in studies of slowly progressive diseases such 
as Parkinsons Disease, Alzheimer’s Disease, COPD and Rheumatoid Arthritis as it is 
important in these long term conditions to try to separate the effects of interventions from 
changes in disease progression (D'Agostino., 2009).  These trials run similarly to 
crossover designed RCTs however instead of the group which has received the active 
treatment first switching to receive  placebo/control  or conventional care which the 
alternative group has received, both groups in the second phase of the trial receive the 
active treatment. Analysis therefore of the first phase of treatment compares active 
treatment vs placebo/control  or conventional care. However the analysis at the end of the 
treatment when both groups have received active treatment allows analysis of the 
disease-modifying effects of the treatment (D'Agostino., 2009). This study design however 
requires extensive knowledge of the progression of the disease being investigated so that 
the different phases of the trial are the correct lengths based on the disease progression 
(D'Agostino., 2009).    
For our study into the effectiveness of a combined Physiotherapy and Speech and 
Language Therapy intervention (PSALTI) for people with refractory chronic cough, a 
parallel group designed RCT was chosen. A crossover design trial was not chosen as the 
non-pharmacological interventions are taught therapies and the carry-over of taught 
treatment cannot be determined as easily as with drug trials.  Also the long term effect of 
non-pharmacological interventions (as discussed in Chapter 2) have not been explored 
therefore the ‘washout period’ needed for a crossover design was unknown. In addition a 
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fundamental principle of RCT studies is for participants to be blinded as to whether the 
intervention they receive is the active treatment or placebo/control /conventional care 
treatment. Again this circumstance is different to that of drug trials and it would be difficult 
with a taught therapy to apply a cross-over design and for participants to remain blinded to 
their treatment allocation. A cluster RCT design was not appropriate to the study purpose 
as the group was interested in the experience of individual participants and not groups of 
participants. A delayed start RCT is an alternative to a parallel group RCT design that 
could have been chosen for our study however this type of design has not been used in 
previous chronic cough trials. The progressive nature and/or stability of refractory chronic 
cough has not been fully explored in the literature and therefore determining the point at 
which to switch phases of the trial would have been challenging. 
Once a parallel group RCT design was decided, strategies were put in place to reduce the 
errors and biases previously identified. Careful consideration of the randomisation, 
treatments included, blinding of participants and assessors were all made.  
Consideration needs to be given to the randomisation processes included in RCTs to 
ensure that the randomisation approach chosen does reduce selection and confounding 
biases (Schulz and Grimes., 2002). Distance randomisation is a randomisation approach 
which involves investigators contacting a central randomisation service who then issue the 
patients’ treatment allocation. This method of randomisation has been advocated as the 
most effective method at reducing selection bias when compared to other methods. 
Methods such as concealment of treatment allocation via sealed envelopes are at a 
greater risk of being tampered with (Torgerson and Roberts., 1999). Restricted 
randomisation procedures and stratification are other randomisation processes that can 
help to reduce the risk of confounding biases.  Blocking is a type of restrictive 
randomisation that can help to ensure sample sizes of different groups in a trial remain 
similar sizes even at early interim analysis points. Blocking ensures that for every 
determined number of participants randomised a certain number of participants are 
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allocated to either group. It is important in trials that are not double blinded that blocking 
sizes are varied as without varied numbers the allocation of future participants could be 
anticipated by the treating investigator (Schulz and Grimes., 2002). Stratified 
randomisation is useful for smaller RCTs when normal randomisation can still produce 
imbalances in baseline characteristics in groups within the RCT. Stratification helps to 
create an equal balance in baseline characteristics between the two groups for pre-
randomisation determined factors (Schulz and Grimes., 2002).  
Considering all these factors regarding randomisation it was decided that for our RCT we 
would use a distance randomisation process run by the clinical trials unit (CTU) at King’s 
College London. That process required participants’ baseline characteristics to be entered 
anonymously into the CTU’s online service who then emailed the participants’ treatment 
allocation to the treating therapist only. It was also decided that in order to avoid selection 
biases randomisation would only be conducted once the participants’ baseline 
measurements had been completed. The randomisation process was discussed with the 
study statistician and it was determined that block sizes of 2 and 4 would be used (as our 
sample size was relatively small and not double-blinded). The randomisation would also 
be stratified according to age (< 50 and >50 years old) and gender as, as identified in 
Chapter 1, refractory chronic cough is more common in older females.  
Designing control or placebo based interventions for therapies that involve cognitive and 
behavioural treatment methods is a significant challenge (Hart et al., 2008) and unlike 
drug trials when the drug being investigated can be compared against a similar looking 
placebo pill. Therapy based treatments involve “cognitive, affective and behavioural 
change processes such as learning and teaching, practising, developing skills and habits, 
implementing strategies, and developing mechanisms for coping and adaptation.” (pg2) 
(Hart et al., 2008) and therefore it is virtually impossible for therapeutic studies to be 
compared to a true placebo that can be as inactive as a placebo drug. 
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There are a number of options though to support control interventions for therapy studies 
including: no treatment as a control when participants receive no intervention at all; 
delayed start for intervention when participants are monitored prior to starting intervention; 
attention control interventions when participants receive no intervention but same 
attention from therapists or study personnel; sham treatments or  placebo/control  
treatments which are plausible treatments but irrelevant to the target problem; and usual 
or standard care which is when usual care is compared to the treatment being 
investigated (Tilling et al., 2005, Whitehead., 2004). 
For our study the original study team decided that a control treatment would be best 
model of intervention to compare our active treatment against for a number of reasons. 
One of the risks with no intervention, delayed start intervention and attention control 
interventions are attrition of participants and for our study, which was a relatively small 
RCT, the risk of attrition had to be minimised. Usual/standard care would have been the 
control group of choice but currently in the UK standard care for refractory chronic cough 
patients is not established. As identified in Chapter 1 there are no guidelines written 
specifically for the management of refractory chronic cough, so treatment options tend to 
be dependent on the treating Consultant and the availability of access to other services 
such as Respiratory Physiotherapy or voice specialist Speech and Language Therapists 
which not all units have. Therefore a control treatment group was the main option 
available for the research team to use and was also the option chosen by Vertigan et al’s 
(2006) study to investigate the effectiveness of Speech Pathology management. 
Therefore our study repeated this control intervention by covering the same topics as 
Vertigan et al’s (2006) study, however the specific information covered could not be 
replicated as only the topic titles were given in the Vertigan et al’s (2006) article. To 
ensure changes in outcome were not due to changes in attention received by either 
group, both groups were treated for the same time duration, same number of sessions, 
same frequency and both saw a trained healthcare professional. The decisions regarding 
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the non-pharmacological interventions investigated in the RCT were decided based on 
previous non-pharmacological interventions for refractory chronic cough (Chamberlain et 
al., 2014a) identified in Chapter 2 and which will be discussed further in Chapter 5.  
Lastly blinding of assessors and participants was vital to reduce allocation biases. Blinding 
of participants was conducted as thoroughly as possible, participants were only informed 
of their treatment allocation post their 3 month follow up. However as Whitehead (2004) 
and Hart et al (2008) discuss it is difficult to keep participants in behavioural therapy 
interventions blinded to their treatment allocation as they can sometimes, without being 
informed, be aware as to whether they are receiving an active treatment intervention or 
not. This is a potential limitation of placebo/control interventions. Due to the resources 
available to the RCT separate assessors were not available for all outcome measure 
testing. Where a treating assessor did conduct an objective outcome measure for either 
baseline or end of treatment they did not conduct the testing for the other stage so they 
were at least blinded to change. Participants completed questionnaires included in the 
study protocol independently; these were placed in sealed envelopes so assessors were 
unaware of the participants’ responses. The treating therapists could not be blinded to the 
treatment as they were delivering it and at two of the three research sites, which were 
delivering intervention, the same therapist delivered both the control and treatment 
intervention, which standardised the professional delivering the treatment, but is a 
limitation as the study was not double blinded.  
 
 
 
 
 
 
 Page 100 of 288 
 
3.4 Summary 
 
This chapter outlined the methodological considerations that informed the choice of 
methods used to conduct the research studies in this thesis. Subsequent chapters will 
report the studies introduced in this chapter in detail, those studies are: 
 
 Impact and Management of Chronic cough across Europe 
 
 Physiotherapy, Speech and Language Therapy Intervention (PSALTI) for patients 
with refractory chronic cough: a multi-centre RCT. 
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 CHAPTER 4 
IMPACT AND MANAGEMENT OF CHRONIC COUGH ACROSS EUROPE
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4. Impact and management of Chronic Cough across Europe 
 
This chapter has been previously published by Springer in Lung Journal, titled 'The impact 
of Chronic cough: a cross sectional European Survey’, 2015, DOI 10.1007/S00408-015-
9701-2, Chamberlain, S.A.F., Garrod, R., Douiri, A., Masefield, S., Powell, P., Bücher, C., 
Pandyan, A., Morice, A.H., Birring, S.S. Copyright 19 Mar 2015 (Chamberlain et al., 
2015a), with permission from Springer Science+Business Media. This version of the 
manuscript included in this thesis has been updated to include a published erratum for 
Table 1. Number of figures and tables have been changed for this thesis but no changes 
to the content have been made. 
 
4.1 Introduction 
 
The prevalence of chronic cough has been estimated as affecting 11-13% of the 
population (Montnémery et al., 1998, Ford et al., 2006, Cullinan., 1992, Lundbäck et al., 
1991). Chronic cough is associated with significant physical and psychological morbidity 
(Brignall et al., 2008, Birring et al., 2003c). Adverse physical symptoms associated with 
cough include syncope, incontinence, chest pain, headaches and sore throat. Depression, 
anxiety and social embarrassment are also common (Brignall et al., 2008, McGarvey et 
al., 2006, Dicpinigaitis et al., 2006). The impact of chronic cough has largely been 
investigated in patients attending specialist cough clinics (French et al., 1998, Birring et 
al., 2003c, Brignall et al., 2008). Few studies have investigated the impact of chronic 
cough in patients based in the community. The aim of this study, in collaboration with the 
European Lung Foundation (ELF), was to investigate the impact of chronic cough from the 
patients’ perspective in a wide range of European countries. An internet-based survey 
 Page 103 of 288 
 
was developed to investigate the impact, medical consultations, diagnoses, treatments 
and needs of patients with chronic cough. 
4.2 Methods 
 
Subjects 
Adults with chronic cough (duration >8 weeks) of any cause were recruited using an 
internet-based survey. Exclusion criteria were acute and sub-acute cough, age <18 years 
and non-European country of residence. A patient information sheet was provided online 
on the ELF website. Participants who selected to complete the online survey were 
considered to have given implied consent. Secondary anonymised data from the survey 
was analysed.  
Survey Development 
Phase 1: Item generation 
A preliminary survey (21 items) was developed following a review of the chronic cough 
healthrelated quality-of-life (QoL) literature and published surveys of chronic cough. The 
survey was also reviewed and discussed within the European Respiratory Society (ERS) 
Chronic cough Taskforce (15 respiratory physicians from nine countries), a 
multidisciplinary team (respiratory physician and physiotherapists, Kings College Hospital) 
and the ELF. The survey contained both open-ended and closed questions with response 
scales. 
Phase 2: Survey refinement 
The survey was adapted for use on the internet and reduced to 17 items in response to 
feedback received during the item generation phase. The items were grouped into five 
categories: “About your cough,” “How are you affected by your cough?” “Diagnosis of your 
cough,” “Treatment of your cough” and “Support for patients with cough” (Appendix 1). 
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Phase 3: Translation of survey 
The survey was translated by Web-Translations (Leeds, UK). Forward-back translation 
methodology was used by native speakers to ensure accuracy. The back-translated 
survey was checked by the original author (SSB) for accuracy, and differences were 
reconciled during a harmonisation process. The survey was translated into 12 languages: 
English, German, French, Spanish, Greek, Romanian, Lithuanian, Swedish, Italian, 
Bulgarian, Polish and Russian.  
Internet survey 
The survey was launched by the ELF on their website www.european-lung-foundation.org 
(website has now changed to www.europeanlung.org) using a Survey Monkey survey 
package. Google AdWords was used to advertise the survey on Google searches. This 
used keywords or search terms entered into a Google search website to return the cough 
survey in the Google results page and advertisement sidebar. The keywords set for this 
survey were “chronic cough,” “cough survey,” “a cough that won’t go away” and “can lung 
disease make you cough”. These key words were identified by the ELF, following review 
of the literature and online resources for cough. Keywords were translated and applied for 
each survey language. The survey was promoted by the ELF by developing 
advertisement posters in all survey languages with dissemination to all ERS members 
(>10,000) and ELF patient organisation network (>160 organisations). The posters were 
available on the ELF website to download. The survey was also promoted in the ELF 
monthly newsletter and via social media (Twitter and Facebook). 
 
4.3 Data Analysis 
 
Count data were expressed as frequencies and percentages of the total number of 
participants responding to each question. The data were analysed as a whole sample and 
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then as sub-groups according to country of residence (countries with >50 responders) and 
gender. Categorical data for “the impact of cough” questions (questions 5-8, Appendix 1) 
were summarised as binary variables to enable calculation of the proportions of 
participants with the symptom. Open questions (questions 2, 16, 19 and 20; Appendix 1) 
were analysed by frequency content analysis. Preliminary categories were further refined 
to generate consolidated themes. The data generated by questions relating to further 
information and support were merged for analysis (questions 19 and 20). 
 
4.4 Results 
 
The survey was available between January 2012 and April 2013. 1968 participants 
responded and completed the survey; 1120 met the inclusion criteria. The reasons for 
excluding participants are stated in Figure 3. Sixty-seven percent of respondents were 
female, the mean age of respondents was 51 years (SD 15, range 18-87) and 83% were 
non-smokers (participant demographics are presented in Table 8). The respondents 
resided in 29 European countries (Figure 4). The countries with the five highest response 
rates were United Kingdom (UK) (n=136, 20%), Germany (n=114, 18%), France (n= 76, 
11%), Italy (n= 70, 10%) and Poland (n= 67, 10%). 
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Figure 3: Flowchart of survey responses and exclusions. 
 
 
 
 
 
 
 
 
 
 
 
 
Data presented as number of survey responses.  
 
 
 
 
 
 
  519 responses excluded as   
acute cough 
 
1968 survey responses 
1449 survey responses 
  54 responses excluded as   
             Age <18 
 
  52 responses excluded as   
             Non-European 
 
1395 survey responses 
1343 survey responses 
1120 survey analysed 
 223 responses excluded as   
no cough questions answered 
 
 Page 107 of 288 
 
Figure 4: Chloropleth map of survey respondents’ country of residence. 
 
Data presented as percentage of survey responses who met inclusion criteria 
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Table 8: Respondents Demographics 
Subjects (n) 1120 
Age (years)           All 
                             Male 
                             Female 
  51  
  51  
  51 
(15) 
(17) 
(14) 
 
Female n (%) 
 
489  
 
(67) 
   
Ethnicity n (%)     
   White Caucasian 540 (90) 
   Black Caribbean     3 (0.5) 
   Black African     3 (0.5) 
   East Asian e.g. Japan, China     3 (0.5) 
   South Asian e.g. India,  
   Bangladesh 
    4 (0.7) 
   Mixed     5 (0.8) 
   Other   42 (7) 
   
Current smokers n (%) 185 (17) 
   
Seen a doctor regarding cough at least once n (%) 1043 
 
(93) 
Seen a doctor regarding cough ≥3 times n (%) 807 (72) 
 
Attended specialist cough clinic (%) 135 (13) 
Data presented as mean (standard deviation) unless otherwise stated 
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Diagnosis 
Median duration of cough was between 2 and 5 years. There were two peaks of cough 
duration; twenty-two percent, reported an early chronic cough (3-6month duration) and a 
similar number, twenty percent reported a cough duration of 10 or more years (Figure 5). 
Fifty-three percent (n=562) of respondents reported they had been given a diagnosis for 
their cough (Figure 6). Seven percent of respondents who had been given a diagnosis 
had been given two or more diagnoses. Asthma was the most common diagnosis 
reported (23%; Figure 6). 
 
Figure 5: Cough Duration of Survey Respondents. 
 
 
Data presented as percentage of survey respondents 
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Figure 6: Cough Diagnoses of Survey Respondents. 
 
 
Data presented as number of survey respondents. GORD – Gastro-oesophageal reflux; 
PND – Post-nasal drip; COPD – Chronic Obstructive Respiratory Disease; ACE-I – 
Angiotensin-converting-enzyme Inhibitor; ILD – Interstitial Lung Disease; Other – includes 
non-disclosed diagnoses of cough; PCD – Primary Cillary dyskinesia. First, second and 
third diagnoses were defined as the first, second and third diagnoses listed by survey 
respondents in response to Survey Question 10. 
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Impact of chronic cough 
Ninety-six percent (n=1055) of responders reported that their cough affected their QoL. 
Eighty-one percent (n=890) reported that their cough affected the activities they liked to 
do. Ninety-one percent (n=1000) reported feeling fed-up and depressed because of their 
cough and 94% (n=1030) reported that their cough disturbed or worried their family and 
friends. The impact of cough was consistent across the top five countries of residence of 
the respondents (Table 9). 
 
Table 9: Impact of chronic cough (top five response countries). 
Data presented as % of responders (95% Confidence Intervals) 
 
There were significant gender differences in the limitation of activities due to cough; a 
significantly higher proportion of women (87%; Confidence Interval (CI) 84-90%) than men 
(77%; 95 CI 72-82%) reported limitations (difference in proportion 10%; CI 4-16%). More 
women (94%; CI 92-96%) than men (90%; CI 85-93%) reported feeling fed up or 
depressed due to their cough (difference in proportion 5%; 95 CI 0-9%). No significant 
differences in population proportions were found between gender for impact on QoL or on 
family and friends. 
Country Negative 
Impact on 
activities  
Feeling fed 
up or 
depressed 
Negative 
Impact on 
quality of life 
Worrying or 
disturbing family 
or friends 
UK 87 (80-91) 94 (89-97) 96 (91-98) 98 (94-99) 
Germany 85 (77-90) 98 (94-100) 98 (94-100) 90 (83-94) 
France 75 (64-83) 92 (84-96) 97 (91-99) 95 (87-98) 
Italy 74 (63-83) 90 (81-95) 96 (88-99) 94 (86-98) 
Poland 90 (80-95) 90 (80-95) 97 (90-99) 99 (92-100) 
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Management and treatment of chronic cough 
The majority of respondents had seen a doctor about their cough (Table 8). Seventy-two 
percent of respondents had seen a doctor ≥3 times in relation to their cough. Thirteen 
percent reported that they had attended a specialist cough clinic. Only 30% of 
respondents felt their doctor had dealt with their cough thoroughly. Respondents were 
asked in an open-ended question why they had first consulted their doctor. This question 
generated seven themes: the characteristics of the cough (n=422), physical symptoms 
associated with cough (n=380), possible viral infection symptoms (n=140), psychological 
symptoms associated with cough (n=88), to consult a doctor about existing respiratory or 
other health condition (n=80), social symptoms associated with cough (n=76) and for 
diagnosis/assessment and treatment for the cough (n=31), (Appendix 2). Some examples 
of quotations from respondents are listed in Appendix 3. 
Most respondents reported limited (57%) or no (36%) effectiveness of medications they 
had tried for cough. Only 7% reported that medications they had tried for their cough were 
effective. Medications found helpful for their cough were reported by 222 (Question 16 – 
open ended question; see Table 10).  Sixty-nine percent of respondents reported that 
over-the-counter medications were not effective. 
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Table 10: Effective medications for cough reported by respondents 
 
Medication % 
Corticosteroids  (oral and inhaled) 37 
Antibiotics 23 
Bronchodilators 21 
Over the counter cough medications 17 
Gastroesophageal Reflux medications  
(proton-pump inhibitor (PPI), non-PPI and unspecified reflux 
medications) 
10 
Antihistamine/anti-allergy medications 7 
Opiates 6 
Mucolytics (tablets and nebulised) 6 
Unspecified asthma treatment 4 
Nasal sprays (decongestant and corticosteroids) 4 
Homeopathy/herbal medications 4 
Leukotriene antagonists 3 
Amitriptyline    0.5 
Bronchovaxon (immunostimulant, Bacterial Lysate)    0.5 
NSAID    0.5 
Gabapentin    0.5 
  
Other  1 
Data presented as percentage of the number of respondents who reported 1 or more 
effective medications.  73% of respondents listed one medication only, 19% listed two 
medications and 8% listed ≥ 3 medications.  
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Information and support 
Eighty-eight percent of respondents reported that they would like more information on 
chronic cough to be available and 78% reported that they would like to receive more 
information about the ERS/ELF Chronic cough Task Force. The open-ended questions 
concerning further information and support needs of the respondents generated 20 
themes (Table 11). The two most common themes were the need for further patient 
information relating to the treatment and causes of cough. Examples of quotations from 
respondents requesting further information and support are listed in Appendix 4. 
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Table 11: Information requested by respondents: a qualitative analysis 
 
Themes N 
(Total = 991) 
Treatment 308 
Causes 127 
Self-help and alternative therapies  103 
General information in a variety of formats  95 
Better understanding, awareness and support from doctors  74 
Assessment 68 
Information on access to specialist cough clinics  65 
Where to get help  33 
Information on cough related symptoms  20 
Further research and sharing of knowledge between specialists  19 
Cough prevention  18 
Better public awareness of chronic cough  17 
Being able to liaise with other people who suffer with chronic cough  13 
Psychological support  11 
Information on triggers for cough  6 
Why chronic cough reoccurs 4 
Information on how to stop smoking  4 
Information on prognosis and long term effects of chronic cough  2 
Information on types of chronic cough 2 
Definition of chronic cough  2 
Data presented as number of responses (n) for each theme. 
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4.5 Discussion 
 
This community-based survey investigated the impact of chronic cough in a large number 
of participants living in 29 European countries. The demographics of respondents to this 
survey were consistent with previous studies of chronic cough that report a middle aged, 
female predominance (Birring et al., 2003b, Morice et al., 2014, Morice et al., 2006, 
Morice, 2002) There was an adverse impact of cough on health-related QoL in most 
respondents, which was consistent across the top five response countries.  The impact on 
activities was more significant in females compared to males.   Most respondents reported 
that their doctor had not ‘dealt with their cough thoroughly’ and that medications were 
largely ineffective. 
This survey has highlighted the significant adverse impact of chronic cough to the 
individual.  The respondents had consulted their physician for a wide range of reasons, 
such as the severity of cough, adverse physical and psychological symptoms associated 
with cough and the social impact.   The effect on health-related QoL was consistent with 
previous studies conducted in specialist Cough Clinics by French et al (1998) and Birring 
et al (2003c). In contrast to French et al (2004), a gender difference was not found in the 
impact on health-related QoL. This may be because we did not use validated 
questionnaires such as the cough-specific QoL questionnaire (CQLQ), (French et al., 
2002) and the Leicester cough questionnaire (LCQ), (Birring et al., 2003c) to assess 
health-related QoL. Most respondents also reported feeling ‘fed up or depressed’ because 
of their cough. This finding is consistent with those of Dicipingaitis et al (2006) and 
McGarvey et al (2006), who also reported significant depressive symptomatology in up to 
50% of participants. The prevalence of depressive symptoms in our study was greater 
than this (91%), though again this was not measured by validated questionnaires; hence 
the severity of these reported symptoms in our respondents is unknown.  
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Only 53% of the survey respondents had been given a suggested diagnosis for their 
cough. This was despite the respondents having consulted their doctor on multiple 
occasions. However, it is possible that some respondents were still undergoing 
investigations for the cause of their cough and only 13% of our participants had been 
assessed in specialist cough clinics.   These factors may have contributed to the high 
prevalence of unexplained chronic cough.   Only 30% of respondents felt that their doctor 
had dealt with their cough thoroughly. When a diagnosis was suggested, the most 
common cause was asthma (23%). Gastro-oesophageal reflux disease and upper airway 
cough syndrome (post-nasal drip) were also common causes, consistent with previous 
studies of cough that investigated subjects with the anatomical diagnostic protocol as 
recommended by chronic cough guidelines (Irwin and Madison., 2000, Morice et al., 2004, 
Morice et al., 2006, Irwin et al., 2006). As expected, some respondents reported multiple 
causes of cough.    
Our study findings suggest that there is room for improvement in the management of 
patients with chronic cough.  One approach is to increase awareness of this condition, 
and improve the implementation of chronic cough management guidelines in both primary 
and secondary care. Another approach could be to improve patient access to specialist 
cough clinics, by increasing the number of such clinics.  A key finding reported by 
respondents was that their medications, including over-the-counter medications, were 
ineffective. The reasons why other prescribed and over-the counter medications were 
ineffective are unclear, and was beyond the scope of this study. Inadequate assessment 
of patients, dose/duration and non-compliance of medications and misdiagnosis could all 
be potential explanations (Morice et al., 2004, Irwin and Madison, 2000). The reasons for 
treatment failure warrant further investigation.   
A novel internet-based survey was used in this study to investigate the impact of chronic 
cough. This method was simple to set up, low-cost and one that provided data output in 
an electronic format that was ready to analyse. It also facilitated the recruitment of 
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participants from across Europe. The use of the internet did not inhibit elderly participants; 
the age range of our study was 18-87 years. Few surveys have specifically assessed the 
impact of chronic cough in detail. Everett et al (2007) surveyed 373 subjects with chronic 
cough in the community based in the UK that responded initially to a radio broadcast. 
Everett et al (2007) also found that chronic cough was associated with a significant 
adverse impact on physical, psychological and social wellbeing of subjects. The strength 
of our study in contrast to Everett et al (2007) was a larger sample size of participants with 
chronic cough, recruitment from 29 European countries and the additional capture of 
qualitative data (for example, participants’ views on information and support for cough). 
Fujimara et al (2012) surveyed 232 participants with chronic cough registered with a 
research company via e-mail. The recruitment of volunteers from a research company 
database is likely to have introduced a selection bias.  Seventy-four percent of participants 
were male, which is in sharp contrast to most studies of chronic cough, which report a 
female predominance. Forty-four per cent of participants had not consulted their doctor 
regarding their cough, and 75% were satisfied with over-the-counter cough medications.  
This reflects the high number of participants with acute and sub-acute cough in their 
study. Cough, however, was associated with significant psycho-social impact on the 
subject, and females were more affected than males. Ford et al (2006) identified 481 
participants with chronic cough in a survey of a community based in Yorkshire, UK. The 
cough was considered severe in approximately half of these subjects based on the 
disruption to activities of daily living. However, this study did not report the psychosocial 
impact, access to specialist care or treatments used for cough.   Adams et al (2009) 
identified 611 participants with chronic cough in a survey of a community based in 
Adelaide, Australia. Chronic dry cough was more common in participants who were male, 
current smokers and elderly. Cough was associated with significant psychological 
morbidity and impairment in health-related QoL, but this study also did not investigate the 
access to specialist care, treatments and information/support for participants. 
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There are a number of limitations with this study. Validated health-related QoL, activity or 
depression questionnaires were not used.  We used a small selection of questions derived 
from literature review of health-related QoL literature and multi-disciplinary discussion.  
This was to keep the survey brief, and therefore encourage completion by respondents.   
A significant number of respondents were excluded as they did not answer any of the 
cough related questions. This may have been minimised by using a shorter questionnaire. 
The diagnoses and medications were not verified by checking medical records, as this 
was not feasible in this study. The use of the internet to recruit participants seeking 
medical advice may have led to bias, although the wide age range of our participants and 
a clinical phenotype consistent with previous studies of chronic cough suggests that this 
bias may not have been as much as expected (Birring et al., 2003b, Morice et al., 2014, 
Morice et al., 2006, Morice., 2002). Studies of the general population, perhaps by 
telephone, would minimise selection bias but are likely to be costly and unfeasible. The 
recruitment of participants is likely to have been greater if we had used a commercial 
Google search strategy, for example a featured advertisement, rather than the Google 
AdWords account. The use of other search engines and strategies may have increased 
recruitment of subjects.  Our data does, however, suggest that the internet has the 
potential to recruit a large number of participants for survey-based research. Our survey 
focused on exploring the impact of chronic cough however acute cough is also known to 
cause a significant impact on quality of life (Yousaf et al., 2011). Future studies might 
explore usefully the impact of acute cough across Europe and serve to allow comparison 
with the findings of this present study. 
In conclusion, chronic cough was associated with a significant impact on their daily 
activities and health-related QoL in this European study. Cough was undiagnosed in 47% 
of respondents.  The majority of respondents said that they would like further information, 
support and access to specialist cough clinics.  This suggests that much more work needs 
to be done to promote awareness of this condition, implement clinical guidelines and 
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improve access to specialist care. This is best achieved in collaboration with patient and 
healthcare professional societies, such as the ELF and the ERS.  
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CHAPTER 5 
PHYSIOTHERAPY, SPEECH AND LANGUAGE THERAPY INTERVENTION FOR 
PATIENTS WITH REFRACTORY CHRONIC COUGH: A MULTI-CENTRE 
RANDOMISED CONTROLLED TRIAL.  
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5.  Physiotherapy, Speech and Language Therapy intervention for patients with 
refractory chronic cough: a multi-centre randomised controlled trial.  
 
This chapter contains the draft manuscript for this RCT which is being prepared for 
submission. 
 
5.1 Introduction 
 
Chronic cough, defined as a cough lasting more than 8 weeks, (Morice et al., 2006) is a 
prevalent disorder in both the community (Ford et al., 2006) and secondary care sectors, 
accounting for up to 40% of respiratory out-patient clinic referrals (Morice., 2008, Morice 
et al., 2006). The most common causes of cough in a non-smoking patient with a normal 
chest radiograph and spirometry are asthma, gastro-oesphageal reflux and rhinitis (upper 
airway cough syndrome) (Morice et al., 2004, Morice et al., 2006, Irwin et al., 2006). For a 
significant number of patients, the cough may remain unexplained or refractory to 
treatment despite extensive investigation and therapeutic trials (Haque et al., 2005).   
Cough is associated with significant physical, psychological morbidity and impaired QoL 
(Brignall et al., 2008, Birring et al., 2003c, French et al., 1998). There are few effective 
antitussive therapies for refractory chronic cough (Chung., 2009, Belvisi and Geppetti., 
2004). Recent studies suggest a potential role for Gabapentin and P2X3 receptor 
inhibitors but both have significant side effects (Ryan et al., 2012, Abdulqawi et al., 2014).  
 
Non-pharmacological therapies for refractory chronic cough have however shown 
promising results in a few preliminary studies as discussed in chapter 2 (Chamberlain et 
al., 2014a).  Non-pharmacological therapies are generally delivered by Physiotherapists or 
Speech and Language Therapists (Chamberlain et al., 2014a). Whilst there are no firm 
guidelines concerning the treatment components of Physiotherapy and Speech and 
Language Therapy management of chronic cough it generally includes four key 
components: education, cough suppression techniques including breathing exercises, 
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vocal hygiene and hydration and psycho-educational counselling (Chamberlain et al., 
2014a, Chamberlain et al., 2013b, Vertigan et al., 2006, Patel et al., 2011, Ryan et al., 
2010, Ryan et al., 2009). Vertigan et al (2006) is the only randomised controlled trial 
(RCT) of a non-pharmacological intervention for refractory chronic cough and found 
significantly greater improvements in patient reported symptoms of cough for Speech 
Pathology management compared to placebo (general healthy lifestyle advice). The 
benefits of Speech Pathology management on objectively measured cough frequency, 
cough reflex sensitivity and cough QoL have not been assessed in a controlled clinical 
trial, limiting the generalisability of the findings. Furthermore, the longer term effect of 
therapy is not known. A recent study by Patel et al (2011) investigated cough-suppression 
Physiotherapy for refractory chronic cough in 23 participants and found a significant 
improvement in cough related QoL, but this study did not include a control group. Ryan et 
al (2010) evaluated objective measures of cough after an uncontrolled trial of Speech 
Pathology management using Capsaicin cough challenge and the Leicester Cough 
Monitor (LCM) as well as evaluating QoL with the LCQ. Whilst their findings were positive, 
the lack of a control group and the application of the LCM in a non-validated manner 
similarly limits the interpretation of the findings. RCTs that evaluate the effectiveness of 
Physiotherapy and Speech Pathology interventions for refractory chronic cough are 
needed to support/ develop the existing limited evidence base. 
 
This study aimed to assess the effect of an intervention utilising both Physiotherapy and 
Speech and Language therapy techniques (Physiotherapy, Speech and Language 
Therapy Intervention, PSALTI) on cough related QoL, severity, objective cough frequency 
and cough reflex sensitivity using a RCT design.  
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5.2 Methods 
 
A multi-centre, single blinded RCT was conducted initially across two Foundation Trust 
hospitals (Research site - King’s College Hospital NHS Foundation Trust, Recruitment site 
– Guy’s and St Thomas’ NHS Foundation Trust) in December 2011. By August 2012 the 
trial was extended across five Foundation Trust hospitals within the UK (King’s College 
Hospital NHS Foundation Trust, Lancashire Teaching Hospitals NHS Foundation Trust 
and Northumbria Healthcare NHS Foundation Trust;  Recruitment sites – Royal Brompton 
& Harefield NHS Foundation Trust and Guy’s and St Thomas’ NHS Foundation Trust). 
The study began in December 2011 and was completed in April 2014. 
 
Eligible patients were identified as adults with chronic cough (defined as >2 months 
duration), with normal chest x-ray, minimal sputum production (<10ml sputum a day) and 
who had had negative investigations and/or failed treatment trials for asthma, 
gastroesophageal reflux and rhinitis (Morice et al., 2006).  
 
Patients were excluded if they: were suffering with active aspiration, had had an upper 
respiratory tract infection in past 4 weeks, were taking ACE inhibitor medication, were 
current smokers or had known respiratory disease (lung cancer, pneumonia, pulmonary 
fibrosis, sarcoidosis, pleural effusion, bronchiectasis). Patients were also excluded if they 
had vocal cord pathology and/or suspicious malignancy. All participants were assessed 
for presence of abnormal vocal cord pathology, suspicious malignancy and active 
aspiration by undergoing a Modified Fibreoptic Endoscopic Evaluation of Swallowing 
(FEES) by a trained Speech and Language therapist or an Ear-Nose and Throat 
assessment by an ENT specialist (see Appendix 5). 
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Once participants had given written consent (Appendix 6) and completed baseline 
assessments (Appendix 7 – 15), their data were added to the online randomisation 
service provided by the King’s CTU supplied by King’s College London 
(http://www.ctu.co.uk/). This strategy prevented foreknowledge of treatment assignment 
for researchers. Treatment assignment was concealed from participants, they were not 
aware of which treatment group was expected to be more beneficial for chronic cough. 
Patients were blocked randomised, stratified by age (<50 and >50 years old) and gender. 
In this trial random block sizes of two and four were used.  
 
Participants were allocated to one of two interventions; Control and PSALTI. For each 
intervention participants attended four weekly one to one sessions. The initial session was 
an hour long and the subsequent sessions were 45 minutes long. The timings of the 
sessions were determined from a Patient Public involvement event that was held with 
chronic cough patients who were familiar with PSALTI and the outcome measures 
included in the trial. Initially it was intended that the treatment sessions would be 30 
minutes long but the patients felt this was too short to cover the issues adequately and 
therefore timings of an hour for initial sessions and 45 minutes for subsequent sessions 
were agreed by the researchers and patients involved in the event. 
 
 Control arm 
Participants attended four weekly one to one standardised healthy lifestyle advice 
sessions with a health care professional (nurse (Northumbria Healthcare NHS Foundation 
Trust), physiotherapist (King’s College Hospital NHS Foundation Trust) or speech and 
language therapist (Lancashire Teaching Hospitals NHS Foundation Trust)). As identified 
in chapter 3 the control intervention was based on Vertigan et al’s (2006) previous RCT 
placebo intervention which included healthy lifestyle advice and education on diet, 
exercise, stress management and relaxation.  
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The participant’s initial session covered general advice on exercise and physical activity 
covering what it is, what happens when you exercise, the benefits of exercise, what the 
Department of Health’s (2011) recommended guidelines are for physical activity and 
exercise and how the participants could meet these recommended guidelines (see 
Appendix 16). The second session covered dietary and nutritional advice, for this session 
participants were asked to record their diet for the past week and bring this diet diary to 
this session (Appendix 17 shows a participant’s example diary). This diet diary was then 
reviewed and advice was made on healthy eating, including 5 portions of fruit and 
vegetables a day, portion sizes of different food groups, reducing salt, sugar and 
saturated fat intake as well as recommended guidelines for fluid intake, this was all based 
on advice from the National Health Service (NHS), (see Appendix 18). The third session 
was on stress management, for which a stress management booklet (Appendix 19) that 
had previously been used for COPD patients in pulmonary rehabilitation at King’s College 
Hospital was used. It covered what is stress, how patients can notice they are stressed, 
what causes stress, how stress can make you feel breathless and tired, as well as giving 
patients strategies to help deal with their stress. During this session participants were 
involved in an active activity of writing down what their stresses were in order to illustrate 
to themselves their stress levels and tolerances for stress by using the analogy of a stress 
jug. The participants’ final session was a progressive relaxation session which was based 
on a NHS progressive relaxation technique (Appendix 20).  
 
The material covered in each session was based on healthy lifestyle advice by the 
Department of Health and NHS. Sessions were standardised for all sites as the same 
written prompts or information for the education was given by all sites (Appendix 16 to 20) 
and face to face training was provided for all therapists who delivered the healthy lifestyle 
intervention by the main study researcher (thesis author).   
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PSALTI arm 
 
Participants received this treatment by either a Physiotherapist (King’s College Hospital) 
or Speech and Language Therapist (Northumbria Healthcare NHS Foundation Trust, 
Lancashire Teaching Hospitals NHS Foundation Trust). The intervention was based on 
previous Speech Pathology management and cough-suppression Physiotherapy studies 
for refractory chronic cough (Vertigan et al., 2006) as well as Vertigan et al (2007a) tutorial 
guide for Speech-Language Pathologists on chronic cough (Vertigan et al., 2007a). The 
first session focused on educating the participants about chronic cough, what it is, what 
causes it and how this treatment aimed to improve their symptoms. Participants were 
introduced to laryngeal hygiene and hydration techniques of promoting nose breathing 
rather than mouth breathing, increasing their non-caffeinated and reducing their 
caffeinated fluid intake. Cough suppression/distraction techniques were also introduced 
including taking sips of water and sucking a non-medicinal sweet to help suppress cough. 
Participants were advised to eliminate triggers for cough that they could and realistic goals 
were set and discussed with the patients (Appendix 21). All participants were issued with 
an information booklet on the treatment (Appendix 22) at their initial treatment session.  
 
The second and third treatment sessions (Appendices 23 and 25) covered cough control 
techniques in more detail including teaching relaxed breathing control to promote relaxed 
diaphragmatic breathing technique. Laryngeal hygiene and hydration were re-emphasised 
during these sessions, if participants were struggling with breathing via their nose, nasal 
douching or steam inhalations were discussed. In the third session psycho-educational 
counselling techniques were also covered. All participants were issued with a stress and 
anxiety handbook related to chronic cough, which was developed by the thesis author and 
a clinical psychologist at the primary research site prior to the start of the study (Appendix 
26). If participants were progressing well the reintroduction of triggers for their cough that 
they were avoiding was discussed.  
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The fourth treatment session consisted of reinforcing all aspects of PSALTI and exploring 
the participants’ coping strategies for their cough (Appendix 27). All components of 
PSALTI were delivered, however the focus and emphasis on individual techniques varied 
for each participant, determined by the treating therapist. Airway clearance techniques 
were included in the PSALTI treatment if the participant’s sputum production was close to 
the upper limit of sputum exclusion criteria (Appendix 24). The standardisation of 
treatment between different hospitals was increased by the use of written treatment plans 
(written by thesis author) and standardised educational material (Appendix 21 to 27). All 
therapists delivering the treatment were trained prior to commencing the study by the 
main study researcher (thesis author).  
 
Efficacy Endpoints 
 
Primary Efficacy Endpoint 
 
Cough related QoL was assessed using the Leicester Cough Questionnaire (LCQ) at 
week 4 (after 4th treatment session) as the primary endpoint (Birring et al., 2003c). The 
LCQ is a validated 19-item cough-specific health-related QoL questionnaire. Overall 
scores range from 3 to 21 with a higher score indicating a better cough related QoL 
(Appendix 10). The minimal important difference for this outcome is 1.3 (Raj et al., 2009). 
Participants independently completed LCQ at baseline, 4 weeks (after the 4th treatment 
session) and at 3 month follow up. Questionnaires were then placed in sealed envelopes 
to avoid influencing the treating therapist. 
 
Secondary Efficacy Endpoints 
 
Objective cough frequency was assessed with the Leicester Cough Monitor (LCM) (Birring 
et al., 2008) a validated, objective, ambulatory cough monitoring device. The LCM 
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consists of a MP3 recording device (Phillips 662 MP3 recorder, UK), external microphone 
and cough detection software. The LCM has been used in previous clinical trials of 
Gabapentin and Erythromycin (Ryan et al., 2012, Yousaf et al., 2010).  Participants wore 
the device for 24 hours at baseline, 4 weeks (after the 4th treatment session) and 3 month 
follow up and were instructed to resume their normal daily activities during this time 
period. The number of coughs per hour (CFperhour) were recorded (Appendix 9). 
 
Capsaicin cough challenge was assessed in a subset of the trial participants (Kings 
College Hospital Foundation Trust and Northumbria Healthcare NHS Foundation Trust) to 
measure participants’ cough reflex sensitivity at baseline and 4 weeks (after the 4th 
treatment session). Capsaicin solutions were prepared as per the standard operating 
procedure written for the study based on the ERS Chronic cough assessment guidelines 
(Morice et al., 2007a) (Appendix 28).  Capsaicin cough challenge was administered via a 
dosimeter (Koko-Digidoser, nSpire health Inc, Hertford, UK) connected to a 30 p.s.i air 
cylinder as per manufacturer’s instructions.  A modified characterised nebuliser (model 
646, DeVilbiss Health Care Inc, Somerset, PA, USA) and mouthpiece were then attached 
to the dosimeter (Koko-Digidoser, nSpire health Inc, Hertford, UK). Two different 
characterised nebulisers were used (1.232ml per minute and 1.205 per ml per minute). 
Both of these nebulisers were modified to have an inspiratory flow regulator valve (nSpire 
health Inc, Hertford UK) to limit the inspiratory flow to 0.5L.S-1. This was done to 
standardise inspiratory flow rate during each inhalation of aerosol.  
To standardise nebuliser output and ensure the same amount of aerosol was delivered 
per inhalation, nebuliser output was set at 10µl which has been previously used in 
capsaicin cough testing (Prudon et al., 2005). To do this the nebuliser output duration was 
altered according to the nebuliser aerosol delivery rate. This was done separately for both 
nebulisers used: 
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Since 10µl = 0.01ml, 0.01ml was the target volume of aerosol to be delivered with each 
breath. 
Since volume (ml) = rate (ml per second) x duration (seconds) 
 
Nebuliser 1     (1.232ml per minute)             Nebuliser 2   (1.205ml per minute) 
 
 
 
 
Capsaicin cough challenge testing was completed as per the standard operating 
procedure written for the study (Appendix 29) which was based on the ERS cough 
assessment guidelines (Morice et al., 2007a). A dose-response capsaicin cough testing 
method was used (Morice et al., 2007a). Doubling concentrations of capsaicin solution 
ranging from, 0µm (saline), 0.49µm to 1000µm were administered. The test was 
discontinued when five or more coughs were induced (C5). In addition, the dose that 
induced two or more coughs (C2) was recorded (Appendix 7). After each inhalation 
participants were asked whether they felt an urge to cough (Young et al., 2009). The 
concentration at which they reported their first urge to cough was recorded (Cu), 
(Appendix 8).   
 
Cough severity in the past 2 weeks was assessed by a visual analogue scale, (VAS), (0-
100mm), (Appendix 13), (Morice et al., 2007a) at baseline, 4 weeks (after the 4th 
treatment session) and 3 month follow up. A modified 1 week VAS scale for cough 
severity was used at the begining of participants’ second treatment session as they had 
0.01 = (1.232/60) x duration 
Duration = (0.01 x 60) / 1.232 
Duration = 0.49 s 
 
0.01 = (1.205/60) x duration 
Duration = (0.01 x 60) / 1.205 
Duration = 0.5 s 
 
 Page 131 of 288 
 
only received 1 week of treatment at this point (Appendix 12). The Vocal Performance 
Questionnaire (VPQ), (Carding and Horsley., 1992) a 12 item tool was used to assess 
patients’ perceived impact on their voice (Appendix 15). A score >12 indicates dysphonia 
(Chamberlain et al., 2013a).  General health and mood was assessed by Short-Form 36 
(SF-36) (Brazier et al., 1992) and Hospital anxiety and depression scale (HADS) 
(Zigmond and Snaith, 1983). HADS is 14-item questionnaire, a higher score indicates 
greater anxiety or depression. A score for either subscale ≥8 indicates mild symptoms, 
≥11 moderate and ≥15 severe (Appendix 14). SF-36 generates two summary scores, 
physical component summary score (PCS) and mental component summary score 
(MCS); both range from 0 to 100 and a higher score indicates better self-reported health 
(Lacson et al., 2010), (Appendix 11). VPQ, HADS and SF-36 were independently 
completed by participants at baseline, 4 weeks (after the 4th treatment session) and at 3 
month follow up. All questionnaires were then placed in sealed envelopes to avoid 
influencing the treating therapist as per the completion of the LCQ described above. 
 
Objective respiratory assessment of participants’ breathing pattern was assessed for 
participants this included assessing and documenting the participants’ respiratory rate, 
route of breathing (nose or mouth breathing) and primary region of movement (upper 
thoracic expansion or abdominal expansion), (Bruton et al., 2011). This was assessed in 
all participants at baseline and a subgroup of participants at 4 weeks (after the 4th 
treatment session). 
 
Ethics and trial registration 
 
All protocols were approved by the London-Chelsea National Research Ethics Service 
(NRES) Committee (Appendix 30). During the study period two substantial amendments 
were made by the thesis author post the initial London-Chelsea NRES Committee 
approval. The first substantial amendment was approved on 23rd November 2011 to 
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include the Vocal Performance Questionnaire in the study (Appendix 31), the second 
substantial amendment was approved 17th May 2012 (Appendix 32) to include the HADS 
questionnaire in the study. 
 
 All participants provided written informed consent (Appendix 6), and the study was 
registered with the UK Clinical Research Network (UKCRN ID 10678) and ISRCTN 
(ISRCTN 73039760).  
 
5.3 Data Analysis 
 
Sample size calculation was completed by the study Statistician (Appendix 33). For each 
of the variables analysed, univariate descriptive statistics were summarised by 
randomised group to provide an overview of the data. Summary measures for the 
baseline characteristics of each group were presented as mean and standard deviation for 
continuous normally distributed variables, medians and interquartile ranges for non-
normally distributed variables, and frequencies and percentages for categorical variables. 
Normality testing was completed using Shapiro-Wilk tests (Appendix 34), for baseline 
variables for which one treatment group was non-normally distributed both groups’ 
baseline data was presented as non-normality distributed data to allow comparisons. 
Univariate analyses were performed to compare study groups at baseline using 
appropriate statistical tests according to the type and the distribution of the data: 
independent t-test for normally distributed variables, Mann-Whitney for non-normally 
distributed variables and Chi Square for categorical variables. Cough frequency data was 
log transformed prior to any analysis. Capsaicin cough challenge data was analysed 
without log transformation for univariate analyses and summary measures at baseline. 
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For both primary efficacy endpoint analysis and secondary efficacy endpoint analysis, 
analysis of covariance (ANCOVA) adjusted for the baseline variables were completed for 
all variables. Analysis of both the primary and secondary efficacy endpoint analyses were 
completed as a per-protocol analysis, only observed data was included without imputation 
for missing data. A p-value of less than 0.05 was considered statistically significant.  
Within group changes from baseline to 4 weeks and 4 weeks to 3 month follow up were 
analysed using paired T-tests. For the secondary efficacy endpoint analysis for capsaicin 
cough challenge (C2 and C5) data was log transformed. 
 
All analyses were made using SPSS 21 software (IBM, UK) and were verified by the study 
statistician using STATA version 12 software (StataCorp LP, College Station, TX).   
 
5.4 Results 
 
Participants 
 
Seventy-six participants were randomised post baseline assessment. Four patients in 
control group and nine patients in the PSALTI group did not receive or complete treatment 
for reasons stated in Figure 7. Primary outcome (LCQ) analysis was therefore completed 
on 63 participants post treatment. 49 participants completed 3 month follow up. The 
consort study flow diagram is described in Figure 7.    
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Figure 7: Trial CONSORT study flow diagram  
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Completed three month follow up 
(n=22) 
 Lost to follow up (n=4) 
 
[DNA (n=2), did not return 
questionnaires or cough monitor 
(n=1), patient declined=1)] 
 
Completed three month follow up 
(n=27) 
 Lost to follow up (n=10) 
 
[DNA (n=6), UTA as patient’s partner 
had terminal illness (n=1), patient 
declined (n=2), nasal surgery post 
trial not suitable for follow up (n=1)] 
Follow up 
Assessed for eligibility (n=163) 
PSALTI group (n=35) 
 Received allocated intervention 
and primary outcome analysis 
as per protocol (n=26) 
 
 Did not receive allocated 
intervention (n=9) 
[unable to attend due to work (n=2), 
unable to attend due to time 
commitments of study (n=2), unable 
to attend due to distance to travel to 
hospital for study (n=1), Myocardial 
infarction prior to treatment (n=1), 
DNA (n=1), Protocol deviations – 
did not meet inclusion criteria for 
medical work up prior to study 
(n=2)] 
Control group (n=41) 
 Received allocated 
intervention and primary 
outcome analysis as per 
protocol (n=37) 
 
  Did not receive allocated 
intervention (n=4) 
 [DNA (n=1), undisclosed Illness prior 
to start of treatment (n=1), Protocol 
deviations - gastroesophageal 
reflux related cough (n=1), 
Abnormal epiglottis posture contact 
pharyngeal wall during pre-swallow 
and triggers cough identified during 
Modified FEES (n=1) ] 
Treatment 
Excluded (n=87) 
 Did not meet inclusion 
criteria (n=42) 
 Declined to participate / no 
contact from patient (n=36) 
 Unable to attend (n=3) 
 Had had previous PSALTI 
type treatments (n= 6) 
Randomised post baseline 
assessment (n=76) 
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The baseline characteristics of the randomised participants are described in Table 12. The 
two groups were balanced with no statistically significant differences at baseline with the 
exception of SF-36 Physical Component Summary Scores (higher-positive in the control 
group).   
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Table 12: Baseline demographic and clinical characteristics of study participants 
recruited. 
 
Characteristic 
 
Control (n=41)    PSALTI (n=35) p value 
n  N   
Age (years) 41 56 (48 to 67) 35 61 (53 to 67) 0.239 
Female, n (%) 41 26 (63) 35 25 (71) 0.459 
Cough duration (months) 39 48 (24 to 126) 31 60 (30 to 126) 0.279 
FEV1 (L, observed), 
mean(SD) 
36 2.7 (0.9) 30 2.6 (0.7) 0.517 
FEV1/FVC (%), mean(SD) 36 76 (8.2) 30 76  (5.0) 0.686 
LCQ, mean(SD) 41 11.9 (3.5) 34 10.4 (3.6) 0.073 
Cough Severity VAS 37 65 (40 to 83) 32 63 (49 to 75) 0.652 
SF-36 PCS,  41 47.1 (41.7 to 
53.6) 
31 41.1 (35.6 to 
49.1) 
0.033* 
SF-36 MCS 41 47.7 (38.3 to 
54.9) 
31 49.9 (40.5 to 
57.0) 
0.763 
HADS –Anxiety  33 7 (3 to 10) 26 7 (4 to 10) 0.785 
HADS – Depression 33 4 (1 to 8) 26 5 (2 to 6) 0.620 
VPQ 40 17 (11 to 22) 28 21 (13 to 27) 0.158 
CFperhour,  Geometric mean (log 
SD) 
39 17 (0.36) 30 17 (0.38) 0.983 
C2 (µm) 35 3.90 (1.95 to 
7.80) 
25 3.9 (1.47 to 
15.60) 
0.749 
C5 (µm) 35 7.80 (3.90 to 
15.60) 
25 7.80 (3.90 to 
31.25) 
0.994 
Cu (µm) 33 0.00 (0.00 to 
2.93) 
22 0.00 (0.00 to 
0.98) 
0.810 
Data presented as median (IQR) unless otherwise stated. 
 
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; LCQ, Leicester cough 
questionnaire; VAS, visual analogue scale; SF-36, short-form 36 questionnaire; PCS, Physical 
component score; MCS, Mental component score; HADS, hospital anxiety and depression scale; 
VPQ, vocal performance questionnaire; CFperhour, average cough frequency per hour over a 24 hour 
period; C2, capsaicin cough challenge –  concentration that resulted in two or more coughs;  C5, 
capsaicin cough challenge –  concentration that resulted in five or more coughs; Cu, capsaicin 
cough challenge – first capsaicin concentration that caused participants to report a perceived urge 
to cough 
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Cough related QoL - Primary Efficacy Endpoint 
 
Total LCQ score at 4 weeks improved by a mean 1.53 (95% CI [0.21 to 2.85]) units more 
in the PSALTI group than in control (p=0.024) (see table 13). The LCQ improvement was 
sustained at 3 month follow up for both groups (see table 13). Table 14 shows the within 
group differences for LCQ.  
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Table 13: Primary and Secondary efficacy endpoint analysis: Change between PSALTI and control groups at baseline to four 
weeks and four weeks to three month follow up 
 
 Between group difference 
Baseline to four weeks 
Between group difference 
Four weeks to three month follow up 
Mean Difference (95% 
CI) 
p value Mean Difference (95% CI) p value 
LCQ Total      1.53 (0.21 to 2.85)  0.024* 0.01 (-1.62 to 1.64) 0.994 
CFperhour(Geometric Mean (log 95% 
CI)
†
 
 0.30 (-1.01 to -0.06) 0.030 
 
1.02 (-0.59 to 0.62) 0.966 
VAS severity  -9.72 (-20.80 to 1.36) 0.084  1.6 (-15.48 to 18.74) 0.848 
SF36 PCS 0.56 (-2.52 to 3.64) 0.717 0.48 (-3.27 to 3.37) 0.977 
SF36 MCS 0.81 (-3.10 to 4.72) 0.680 0.72 (-3.06 to 4.51) 0.703 
VPQ 3.90 (-0.33 to 8.12) 0.070        -0.20 (-3.43 to 3.03) 0.901 
HADS – Anxiety      -0.42 (-1.96 to 1.13) 0.590 0.88 (-0.57 to 2.34) 0.225 
HADS – Depression      -0.44 (-1.69 to 0.81) 0.486        -0.18 (-1.36 to 0.99) 0.753 
Cu 3.12 (0.61 to 5.64)  0.016* NA NA 
C5 Geometric Mean (log 95%CI)    1.28 (-0.22 to 0.43) 0.512 NA NA 
 
 
Between group differences were calculated using ANCOVA adjusted for baseline values.  
*p<0.05 
Positive change in LCQ, SF36 PCS, SF36 MCS, Cu and C5 indicates improvement in symptoms. 
Negative change in VAS, HADS and VPQ indicates improvement in symptom.  
† 
Interpret CFperhour as a ratio. 
 
LCQ, Leicester cough questionnaire; logCFperhour, average log cough frequency per hour over a 24 hour period; VAS, visual analogue scale; SF-
36, short-form 36 questionnaire; PCS, Physical component score; MCS, Mental component score; VPQ, vocal performance questionnaire 
HADS, hospital anxiety and depression scale; Cu, concentration of capsaicin which participants’ first rated a perceived urge to cough; 
C5,concentration of capsaicin that caused ≥5 coughs.  
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Table 14: Primary and Second Efficacy Endpoints: within group change  
  
 Change from baseline to  four weeks Change from four weeks to three month follow up 
PSALTI 
Mean Difference 
(95% CI) 
P Control  
Mean Difference 
(95% CI) 
P PSALTI 
Mean Difference 
(95% CI) 
P Control         
Mean Difference 
(95% CI) 
P 
LCQ Total 
mean(SD) 
3.40  
(2.26 to 4.55) 
0.000* 1.66  
(0.78 to 2.54) 
0.000* -0.17  
(-1.49 to 1.15) 
0.794 0.27  
(-0.82 to 1.35) 
0.616 
CFperhour
†
 
(Geometric Mean 
(log 95% CI) 
0.20  
(-1.12 to -0.29) 
0.002 
 
0.63 
 (-0.51 to 0.11) 
 
0.2053 1.70  
(-0.18 to 0.64) 
0.236 0.81 
 ( -0.52 to 0.33) 
0.655 
VAS severity -21.18  
(-29.83 to -12.53) 
0.000* -11.84  
(-20.11 to -3.57) 
0.007* 9.74  
(-3.60 to 23.08) 
0.143 0.79  
(-10.73 to 12.31) 
0.888 
SF36 PCS 1.62  
(-0.96 to 4.21) 
0.208 0.50  
(-1.30 to 2.31) 
0.574 0.54  
(-1.82 to 2.89) 
0.639 0.76  
(-1.66 to 3.18) 
0.522 
SF36 MCS 0.53  
(-2.69 to 3.75) 
0.736 -0.26  
(-2.92 to 2.40) 
0.843 1.09  
(-1.91 to 4.09) 
0.456 0.49  
(-2.35 to 3.32) 
0.727 
VPQ 4.04  
(0.12 to 7.97) 
0.044* 0.73  
(-1.94 to 3.39) 
0.582 -1.63  
(-4.17 to 0.91) 
0.193 -0.57  
(-3.29 to 2.15) 
0.666 
 
HADS – Anxiety -1.27  
(-2.51 to -0.032) 
0.045* -0.90  
(-1.96 to 0.17) 
0.095 -0.11  
(-1.16 to 0.94) 
0.826 0.95  
(-0.22 to 2.11) 
0.104 
HADS – 
Depression 
-0.68 
 (-1.57 to 0.21) 
0.126 -0.21  
(-1.11 to 0.69) 
0.641 0.06  
(-1.42 to 1.53) 
0.937 0.05  
(-0.66 to 0.76) 
0.878 
*p<0.05 
Positive change in LCQ, SF36 PCS, SF36 MCS indicates improvement in symptoms.  
Negative change in VAS, HADS and VPQ indicates improvement in symptoms. 
† 
Interpret CFperhour as a ratio. 
 
LCQ, Leicester cough questionnaire; CFperhour, average log cough frequency per hour over a 24 hour period; VAS, visual analogue scale; SF-36, short-form 36 questionnaire; PCS, Physical 
component score; SF-36 MCS, Mental component score; VPQ, vocal performance questionnaire HADS, hospital anxiety and depression scale. 
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Objective Cough Frequency 
 
There was a significant reduction in cough frequency after four weeks of treatment in the 
PSALTI group; geometric mean 17.0 (2.4) to 9.0 (3.3) coughs per hour (p=0.002) versus 
17.0 (2.3) to 16.0 (2.2) coughs per hour after control (p=0.205), (Figure 8). The control-
adjusted reduction in cough frequency per hour in PSALTI was 41% (95% CI [36.4-
94.7%], p=0.030) at 4 weeks. This improvement was also sustained up to three months 
(Figure 8).  
 
Figure 8: Geometric mean (95%CI) change in cough per hour frequency in PSALTI 
and control groups, baseline data includes all data, 4 weeks and 3 month follow up 
includes per-protocol data. 
 
 
 
 
0
2
4
6
8
10
12
14
16
18
20
Baseline 4 weeks 3 months follow up
G
e
o
m
e
tr
ic
 M
e
an
 C
Fp
e
rh
o
u
r 
(l
o
g 
9
5
%
 C
I)
 
Placebo
PSALTI
 Page 141 of 288 
 
 
Urge to cough during capsaicin challenge  
 
No significant between group differences were observed for C2 (p=0.575) or C5 
(p=0.512), however a significant difference between groups was observed for participants’ 
reported urge to cough during the capsaicin cough challenge. Cu improved in the PSALTI 
group by mean 3.1 (95% CI [0.6 to 5.6]) µmol/L compared to control (p=0.016) at four 
weeks, indicating that participants in the PSALTI group were able to tolerate a higher 
capsaicin dose before reporting an urge to cough (Table 13).  
 
Other questionnaire data 
 
There were no significant between group differences for change (4 weeks - baseline) in 
depression, anxiety or SF-36 (Table 13). However there was a trend towards 
improvement in VAS severity in PSALTI group compared to control (p=0.084). There were 
significant within group differences for change (4 weeks – baseline) in both groups for 
VAS severity (control p=0.007; PSALTI p=0.000), (Table 14). Although for VPQ and 
HADS-anxiety significant within group changes (4 weeks – baseline) only occurred in the 
PSALTI group (p=0.044 and p=0.045 respectively), (Table 14).   
 
Sub-analyses 
Breathing pattern 
At baseline there were no significant differences between PSALTI and control groups for 
any breathing pattern characteristics (Table 15). In both groups participant’s respiratory 
rate was within normal limits and predominantly most participants’ main route for 
breathing was via their nose. However around half of the participants in both groups had 
an altered breathing pattern in regards to the primary region of movement; as for these 
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participants the primary region of movement observed was upper thoracic expansion 
rather than abdominal excursion. 
There were no significant differences in age, gender, cough duration or any of the other 
baseline characteristics between those participants who at baseline were observed to 
have a primarily upper thoracic expansion breathing pattern or an abdominal expansion 
breathing pattern.  
Table 15: Baseline breathing pattern characteristics of participants 
 
Characteristic 
 
  Control (n=41)    PSALTI (n=35) p value 
N  n   
Respiratory Rate 27 15 (4) 25 16 (5) 0.376 
Primary region of movement 
(% abdominal expansion) 
28 50% 25 48% 0.884 
Route of breathing 
(% nose) 
28 89% 25 92% 0.736 
 
At the end of treatment (4 weeks) there was a significant difference between PSALTI and 
control groups for primary region of movement (p=0.013). Seven of the eleven PSALTI 
participants whose breathing pattern was reassessed after the 4 weeks had changed their 
breathing pattern to primary abdominal expansion; therefore by week 4 all 11 PSALTI 
participants who were reassessed, were found to have a primary abdominal excursion 
breathing pattern. In contrast, in the control group only 4 of the 9 participants reassessed 
had altered their breathing pattern to primary abdominal excursion. Therefore by week 
four in the control group, 5 of the 9 participants had a primary abdominal excursion 
breathing pattern.  
Despite the changes in breathing pattern there were no significant within group changes in 
respiratory rate for PSALTI (Mean 1.7 (95% CI -1.6 to 5.1, n=11)) or control group (Mean 
0.5 (95%CI -1.9 to 2.9, n=11) or between group changes (4 weeks - baseline) in 
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respiratory rate (Mean -1.08 (95%CI -5.02 to 2.86, n=21). For route of breathing by the 
end of the 4th session (end of treatment) 100% of the participants were breathing via their 
nose.  
Table 16  shows the within group changes in the study outcome measures for those 
participants in the PSALTI treatment arm who by 4 weeks had changed their breathing 
pattern to primary abdominal excursion compared to participants whose breathing pattern 
at start of the trial was already primary abdominal excursion. For those with no change in 
breathing pattern there was no significant changes in any of the study outcome measures 
(4 weeks – baseline). However for participants who had altered their breathing pattern in 
the PSALTI arm their LCQ total score significantly improved (Mean (95%CI) 3.94 (1.69 to 
6.19), p=0.005), their cough VAS severity significantly decreased (Mean(95%CI -25.67 [-
51.03 to -0.30], p=0.048) and their cough frequency per hour decreased (Mean (95%CI -
0.34 [-0.68 to 0.00], p=0.051) which was borderline significant.  
When between group differences for change was assessed only cough VAS severity was 
significantly different between those participant in the PSALTI group who had altered their 
breathing pattern and those who had not (Table 17). Cough VAS severity score at 4 
weeks had decreased by Mean -30.19 (95%CI [-56.87 to -3.50]) points more in those 
participants who had altered their breathing pattern compared to those who did not.   
Caution does have to be taken with the data analyses in Table 16 and 17 as the above 
analysis is based only on 7 participants who changed their breathing pattern and 4 who 
did not. 
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Table 16: Within-group change in primary and secondary endpoints for those participants in the PSALTI arm who changed their primary 
region of movement of their breathing pattern and those who did not. 
 
 
 
 
 
 
 
 
 
 
Positive change in LCQ, SF36 PCS and SF36 MCS; Negative change VAS, HADS and VPQ indicates improvement in symptoms. 
† 
Interpret CFperhour as a ratio. 
 
LCQ, Leicester cough questionnaire; CFperhour, average log cough frequency per hour over a 24 hour period, VAS, visual analogue scale; SF-36, short-form 36 questionnaire; PCS, 
Physical component score; MCS, Mental component score; VPQ, vocal performance questionnaire HADS, hospital anxiety and depression scale. 
 Change from baseline to  four weeks in PSALTI arm 
Change in breathing pattern 
Mean Difference (95% CI) 
P No change in breathing 
pattern 
Mean Difference (95% 
CI) 
P 
LCQ Total    3.94 (1.69 to 6.19) 0.005* 1.82 (-4.01 to 7.64) 0.394 
CFperhour
†
 (Geometric 
Mean (log 95% CI) 
0.46 (-0.68 to 0.00) 0.051 
 
     0.27 (-1.66 to 0.51) 0.190 
 
VAS severity -25.67 (-51.03 to -0.30) 0.048* -1.50 (-30.83 to 27.83) 0.881 
SF36 PCS 1.43 (-6.01 to 8.87) 0.655 3.34 (-12.62 to 19.29) 0.554 
SF36 MCS -1.28 (-8.04 to 5.49) 0.661 2.76 (-17.07 to 22.59) 0.688 
VPQ 5.86 (-2.32 to 14.03) 0.130 12.33 (-17.61 to 42.28) 0.218 
HADS – Anxiety -1.50 (-6.23 to 3.23) 0.452 -1.50 (-7.85 to 4.85) 0.205 
HADS – Depression -1.33 (-3.88 to 1.21) 0.235 1.00 (-11.71 to 13.71) 0.500 
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Table 17: Between-group change in primary and secondary endpoints for those participants in the PSALTI arm who changed their primary 
region of movement of their breathing pattern those who did not. 
 
 
 
 
 
 
 
 
 
 
 
 
 *p<0.05 
Positive change in LCQ, SF36 PCS and SF36 MCS; Negative change in VAS, HADS and VPQ  indicates improvement in symptoms. 
† 
Interpret CFperhour as a ratio. 
 
LCQ, Leicester cough questionnaire; CFperhour, average log cough frequency per hour over a 24 hour period; VAS, visual analogue scale; SF-36, short-form 36 questionnaire; PCS, 
Physical component score; MCS, Mental component score; VPQ, vocal performance questionnaire HADS, hospital anxiety and depression scale.
 Between group difference 
Baseline to four weeks 
Mean Difference (95% CI) p value 
LCQ Total 2.10 (-2.89 to 7.09) 0.361 
CFperhour
†
 
(Geometric Mean (log 95% CI) 
         1.74 (-0.59 to 1.08) 0.510 
VAS severity     -30.19 (-56.87 to -3.50)   0.032* 
SF36 PCS    -1.90 (-15.33 to 11.52) 0.862 
SF36 MCS    -2.87 (-17.55 to 11.82) 0.345 
VPQ  -7.97 (-22.06 to 6.13) 0.223 
HADS – Anxiety 0.30 (-8.21 to 8.81) 0.931 
HADS – Depression -2.03 (-7.21 to 3.16) 0.362 
Cu -3.78 (-8.63 to 1.08) 0.102 
C5 (Geometric Mean (log 95% 
CI) 
    1.74 (-0.41 to 0.89) 0.401 
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Participants whose LCQ total score improved by week four vs those who did not  
Of the 26 participants who completed the 4 weeks of PSALTI, 23 participants improved 
their LCQ scores from baseline to 4 weeks (improvements ranged from 0.1 to 8.9 points, 
twenty participants’ improvements were >1.3 points which is the LCQ MID). Due to the 
small number of participants who did not improve their LCQ score, analysis of this data is 
limited.  
When participants in the PSALTI group are split as to who improved greater than the LCQ 
MID of 1.3 (n=-20) and those who did not (n=6) no significant differences were found in 
baseline variables (Table 18 and 19). 
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Table 18: Difference in baseline values for participants in PSALTI group who improved greater than LCQ MID (1.3) and those who did 
not continue 
 
 
 
  
 
 
Table 19: Difference in baseline values for participants in PSALTI group who improved greater than LCQ MID (1.3) and those who did 
not continue 
 
 
 
 
 
 
 
† 
Interpret CFperhour as a ratio. 
 Gender Age Cough duration FEV1 FEV1/FVC LCQ Total  
<1.3 change of LCQ  
(n=6) 
83% female 59  
(42 to 74) 
90 
(24 to 139.5) 
2.48  
(1.93 to 3.07) 
78 
(76.75 to 82.00) 
13.34  
(9.67 to 18.06) 
>1.3 change of LCQ 
(n=20) 
75% female 62  
(58 to 69) 
54 
 (28 to 144) 
2.40 
(1.76 to 2.83) 
75.85  
(72.00 to 78.75) 
9.93 
(7.67 to 11.86) 
p value 0.67 0.84 0.98 0.82 0.09 0.083 
 VAS severity SF36 PCS SF36 MCS C2 C5 Urge to 
cough 
VPQ HADS-A HADS-D CFperhour 
(Geometric mean 
(log 95%CI) 
<1.3 change 
of LCQ  (n=6) 
69           
(22.50 to 
82.75) 
48.72 (24.81 
to 58.17) 
51.12 (38.15 
to 57.10) 
3.9 
(1.95 to -) 
3.9  
(3.9 to -) 
0  
(0 to 0) 
20  
(10.5 to 
25.00) 
5  
(2.5 to 16) 
2 
(0.5 to 
12.00) 
  10.72 
(0.94 to 1.37) 
>1.3 change 
of LCQ 
(n=20) 
60.00 (49.25 
to 72.75) 
40.17 (35.03 
to 47.36) 
44.59 (39.04 
to 56.53) 
3.9          
(0.98 to 7.8) 
7.8  
(3.9 to 
15.60) 
0.49 
(0 to 1.71) 
19  
(13.5 to 
26.00) 
6.5  
(3.75 to 
9.25) 
5  
(2 to 6.25 
 23.44 
(1.20 to 1.50) 
p value  0.70 0.46 0.53 0.65 0.50 0.16 0.71 0.80 0.33 0.10 
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In the control group by 4 weeks, 18 of the 37 participants who completed the study 
improved their LCQ total score by equal to or greater than 1.3 points. When these 
participants were compared to those participants who did not improve or their 
improvements were less than 1.3 points no statistically significant differences were found 
for any of the baseline variables. 
Week by week comparison of change in participants in PSALTI group  
Week by week LCQ scores were recorded for the majority of PSALTI participants (n=26 
baseline, n=20 week 2, n=21 week 3, n=26 week 4). For LCQ the greatest mean change 
in score was between baseline assessment and beginning of week two (at the beginning 
of 2nd treatment session), (Figure 9).  
Figure 9: LCQ at each treatment visit for PSALTI treatment arm 
 
 
 
 
 
 
 
 
 
 
 
Data displayed as Mean(SD) 
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For week by week changes in VAS severity peak decrease was reached by week 3 
(beginning of 3rd treatment session) with the biggest decrease between week 2 and 
week3. VAS continued to decline between week 3 and week 4 however this change was 
less than between any other visit (Figure 10). 
Figure 10: VAS Severity score at each treatment visit for PSALTI treatment arm 
 
 
 
 
 
CHAPTER 6 
THESIS DISCUSSION 
 
 
Data displayed as Mean(SD) 
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Attrition and Retention  
When the 8 dropouts across both treatment arms (excluding the protocol violations and 1 
participant who had no baseline data) are compared to the participants who did not drop 
out (see Table 20 and 21).  Only FEV1 was significantly different (p=0.011). Those 
participants who dropped out had a significantly higher FEV1 (Median (IQR) 3.10 (2.89 to 
4.20) than those who completed (Median (IQR) 2.50(1.85 to 3.02).  
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Table 20: Difference in baseline values for participants who dropped out of study and those who completed treatment 
 
 
 
 
 
 
 
Table 21: Difference in baseline values for participants who dropped out of study and those who completed treatment continued 
 Gender Age Cough duration FEV1 FEV1/FVC LCQ Total  
Drop-outs  
(n=8) 
50% female 49             
(36 to 61) 
78.00                 
(60.50 to 102.00) 
3.10                   
(2.89 to 4.20) 
78.00             
(69.00 to 
79.00) 
9.35                
(7.21 to 10.83) 
Completers 
(n=63) 
71% female 58                
(50 to 67) 
48.00                   
(24.00 to 127.50) 
2.50                   
(1.85 to 3.02) 
76.00         
(72.00 to 
79.25) 
11.16              
(8.68 to 14.08) 
p value 0.217 0.061 0.186 0.011* 0.857 0.079 
 VAS 
severity 
SF36 PCS SF36 MCS C2 C5 Urge to 
cough 
VPQ HADS-A HADS-D CFperhour 
(Geometric mean 
(log 95%CI) 
Drop-outs 
(n=8) 
58.50 
(50.00 to 
76.25) 
47.27 
(44.29 to 
54.32) 
51.80 
(37.71 to 
59.20) 
19.53               
(3.05 to 
39.06) 
31.25               
(5.97 to 
85.94) 
0.00               
(0.00 to 
17.09) 
21                
(13 to 28) 
8                
(6 to 12) 
3                 
(1 to 7) 
19.50      
(0.56 to 1.62) 
Completers 
(n=63) 
 
65.50 
(45.25 to 
77.75) 
46.22 
(38.07 to 
52.63) 
47.73 
(38.40 to 
55.22) 
3.90                 
(1.95 to 
7.80) 
7.80                
(3.90 to 
15.60) 
0.00           
(0.00 to 
0.98) 
18               
(12 to 24) 
7                
(4 to 10) 
5                   
(2 to 7) 
19.05        
(0.99 to 1.49) 
p value 0.870 0.447 0.553 0.145 0.069 0.904 0.634 0.401 0.341 0.866 
† 
Interpret CFperhour as a ratio 
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5.5 Discussion 
 
This study is the first multi-centred RCT to evaluate the effects of a non-pharmacological 
intervention, in the form of Physiotherapy and Speech and Language Therapy intervention 
(PSALTI) using validated outcome measures. In this RCT, the PSALTI group showed a 
statistically significant improvement in cough related QoL compared to equal attention 
control group, the difference between groups was greater than MID (1.3) of LCQ. Cough 
frequency was reduced by more than half in the PSALTI group compared to control. This 
finding is likely to be clinically as well as statistically relevant since the minimum clinical 
important difference in cough frequency in acute cough is estimated at 54% (Lee et al., 
2013). Urge to cough during capsaicin cough challenge was also significantly improved in 
the PSALTI group compared with control.  
 
PSALTI was compared to an ‘equal attention’ control group to account for treatment time 
with a therapist. Clinically there are limited Physiotherapy and Speech and Language 
therapy services available for refractory chronic cough patients and in many areas usual 
care consists of no active treatment. As expected the control group showed significant 
benefits demonstrating a hawthorn effect occurrence, it could be hypothesised that if 
compared with usual care (often no active treatment) the differences between groups 
would have been bigger.  
 
Despite PSALTI showing a clear benefit in cough related QoL there were no significant 
differences between groups in anxiety, depression, patient perceived physical or mental 
health scores. This may reflect the lack of disease specific tools available for these 
outcomes. As disease specific tools are likely to show greater responsiveness to such 
interventions than generic tools, as shown by Wiebe et al (2003) who found in a large 
systematic review of generic  and specific quality-of-life instruments across Neurological, 
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Musculoskeletal, Cardiovascular and Pulmonary disorders that specific quality-of-life 
instruments were more responsive to change than generic quality-of-life instruments 
(Wiebe et al., 2003). There was however a statistically significant within group change in 
anxiety for the PSALTI group. This is in contrast to the findings of Ryan et al (2010) who 
reported no significant change in anxiety and depression scores post Speech Pathology 
management.  This difference between the studies is likely to be due to subtle differences 
in the treatments delivered. Although both our study and Ryan et al (2010) delivered 
similar treatments small differences are to be expected. For example both studies 
included counselling but participants in PSALTI were guided from a booklet specifically 
designed by a Clinical Psychologist to address stress and anxiety associated with chronic 
cough.  
 
Participants’ reported urge to cough in response to capsaicin was significantly different 
between groups in favour of greater tolerance in PSALTI group. Urge to cough sensation 
has been shown to precede the motor response of cough and increases with increasing 
dosages of Capsaicin (Davenport, 2008). However, no differences were observed in 
cough motor response to capsaicin in our study. PSALTI appears to have positively 
affected the perceived urge to cough sensation but failed to influence the cough motor 
response. This is in contrast to Ryan et al’s (2010) study who investigated the effect of 
Speech Pathology management for refractory chronic cough and found a significant 
reduction in cough sensitivity (C5) after three to four 30 minute sessions over eleven to 
sixteen weeks. In addition they showed a significant improvement in participants’ 
perceived urge to cough in response to capsaicin and significant improvements in 
patients’ cough reflex sensitivity (C5) after each individual treatment session. Differences 
in the results of the studies may reflect subtle differences in treatments included within the 
two studies. Although PSALTI was based on previous studies of Speech Pathology 
management the interpretation and delivery of the key components is likely to be different 
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between the two studies. Caution should also be taken when interpreting Ryan et al 
(2010) results as this was an uncontrolled trial with a small sample size (n=17).  
 
The sub-analyses of the RCT data provide some interesting further perspectives on the 
PSALTI treatment. This is the first study to explore the breathing pattern technique of 
patients with chronic cough and 50% of those included in the study were found to have 
breathing pattern dysfunction with an increased apical breathing pattern. Breathing pattern 
re-education exercises were included in the PSALTI treatment arm and breathing pattern 
was found to be significantly improved in the PSALTI arm at end of treatment.  
Interestingly it was only those who improved their breathing pattern technique in the 
PSALTI arm who had significant improvements in LCQ, cough severity and borderline 
significant improvements in cough frequency. Those in the PSALTI arm whose breathing 
pattern remained unchanged (and showed no evidence of dysfunction) at the end of the 
study showed no significant improvements in any of the outcome measures. This finding 
may be a relevant indicator in identifying those participants for whom PSALTI treatment is 
most effective. A limitation of our study though is that breathing pattern was only assessed 
on a limited number of participants and was assessed by observation by the leading 
Physiotherapist in the trial, who was unblinded to treatment allocation of the participants. 
Future studies are needed that investigate breathing pattern in people with refractory 
chronic cough using an objective outcome measure, this will be discussed further in 
Chapter 6.   
 
Week by week changes in LCQ and cough severity VAS were taken in this study and 
identify that the greatest change in LCQ was between baseline and the beginning of the 
treatment session in week 2 for the PSALTI group, which would have been after only the 
first treatment session. For cough severity the greatest change was between the 
treatments in week two and the treatment in week 3, therefore after 2 treatment sessions. 
Our data showed a plateau in LCQ score after week 3 (beginning of third treatment 
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session). So it may be suggested that possibly only three treatments of PSALTI may be 
required to improve cough related QoL. Potentially the treatments delivered in session 1 
and 2; education on chronic cough, cough suppression techniques and breathing 
exercises have a greater impact on cough related QoL then the subsequent treatments in 
session 3 and 4; which were delivering the stress and anxiety booklet for chronic cough 
and reinforcement of taught techniques.   
 
However caution needs to be taken with these sub-analyses as the mechanisms of action 
of the treatment were not explored in this study and the sub-analyses sample sizes are 
small. Therefore these sub-analyses should be considered hypothesis generating only.  
 
We were unable to establish from these limited sub-analyses why some participants 
showed improvements greater than the MID of LCQ and others did not. No significant 
differences were found in baseline characteristics between these participants. Again this 
is likely to be due to the fact that this study did not aim to explore the mechanistic effects 
of PSALTI and therefore was not sufficiently powered for the sub-analyses. This is an 
important aspect for consideration in future studies. 
 
One of the strengths of this study was the involvement of different centres and the use of 
standardised treatment protocols for the different sites. This improves the generalizability 
of the findings and facilitates implementation into clinical practice. The fact that our 
therapists were a multi- professional group (nurses, physiotherapists and speech and 
language therapists) reinforces the notion that content rather than profession specific 
delivery is of primary importance. Improvements for future multi-centre studies of PSALTI 
would be to, as well as providing crib sheets and initial training as we did in our study, 
monitor the professionals delivering the treatment in the study to ensure they keep to the 
crib sheets and standardised material. This could be done through regular follow up 
training and video analysis.  
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 Limitations of the study include the fact that mechanical failure led to five cough 
recordings that were less than 24 hours in total duration and were therefore excluded from 
analysis, recordings of 4 hours or more were included in the analysis (Lee et al., 2012). 
Participant adherence with therapy was not measured and we are therefore unable to 
determine whether lack of compliance was a confounding variable for this study. However 
one could argue that not monitoring adherence reflects real life clinical practice and 
therefore the analysis is more likely to reflect changes that would be observed if the 
treatment was part of clinical practice. Therapist focussed elements of the PSALTI 
treatment were applied differently according to clinical presentation, which may be 
considered both a limitation and a strength of the work, in that repeatability may be 
reduced however real clinical practice is better reflected. The main limitation of our study 
was that by week 4 our sample size did not meet the trial sample size calculation based 
on effect size. This may have affected the power of our analyses and undermined the 
robustness of the results. Despite this however the sample size in our study is still larger 
than the pharmacological trials that have been conducted for people with refractory 
chronic cough (Jeyakumar et al., 2006, Morice et al., 2007b, Abdulqawi et al., 2014, Ryan 
et al., 2012, Dicpinigaitis and Rauf, 1998b, Mintz and Lee, 2006). 
 
Future research and support for non-pharmacological therapies for chronic cough are 
needed to identify the most appropriate patients likely to gain the greatest benefit from the 
treatment. The optimum frequency and intensity of treatment is presently unknown as is 
the most cost-effective delivery. In addition the optimal combination of components of 
non-pharmacological interventions should be established as well as the mechanistic 
effects of the different components. Currently patients are only referred to non-
pharmacological interventions for chronic cough when they are diagnosed as refractory. 
However the potential of incorporating non-pharmacological interventions for chronic 
cough at an earlier stage and/or in combination with pharmacological treatments could be 
explored.  
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In conclusion this study provides a compelling argument for the benefit of Physiotherapy, 
Speech and Language Therapy interventions in the management of refractory chronic 
cough. Both subjective measures of QoL and objective measures of cough frequency and 
urge to cough improved compared to a control. Improving access to these therapies 
should become local and national priorities.  
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CHAPTER 6 
THESIS DISCUSSION 
AND CONCLUSIONS
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6. Thesis Discussion  
 
The studies in this thesis have demonstrated that: 
 There is a significant European burden and impairment of QoL associated with 
chronic cough 
 PSALTI, a non-pharmacological intervention for refractory chronic cough, has been 
shown to significantly greater improve cough related QoL, cough frequency and urge 
to cough compared to control intervention.  
 
This chapter will discuss the key findings of the studies included in this thesis as well as 
explore what needs to be done in future studies to build upon and further develop research 
into non-pharmacological interventions for refractory chronic cough. 
 
As identified in Chapter 1 there is a need to further explore non-pharmacological 
interventions for refractory chronic cough due to the current failings of pharmacological 
treatments. The first study of this thesis was a systematic review to explore the effectiveness 
of previous studies of non-pharmacological interventions for refractory chronic cough. This 
study identified that most non-pharmacological studies have been conducted by Speech and 
Language therapists and Physiotherapists and therefore have mostly been named after the 
professions delivering the treatment; ‘Speech Pathology management’ (Vertigan et al., 2006, 
Ryan et al., 2010, Ryan et al., 2009) and ‘cough-suppression Physiotherapy’ (Patel et al., 
2011). Though differences were found in the different non-pharmacological treatments that 
have been investigated there was a composite package of care that had generally been 
delivered consisting of education regarding cough and/or identification of  cough triggers; 
instruction in  cough suppression techniques, breathing exercises, and sometimes vocal 
hygiene and hydration techniques, interventions also include some form of counselling 
(Vertigan et al., 2006, Patel et al., 2011, Ryan et al., 2010, Ryan et al., 2009). The main 
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difference between the studies tended to be the terminology used for breathing exercises. 
However despite the different terminology, both relaxed throat breathing control techniques 
and breathing control/diaphragmatic  breathing were used in order to relax the throat, neck 
and shoulder muscles whilst increasing abdominal excursion and reducing upper chest 
movement (Mathers-Schmidt., 2001, Bruton et al., 2011). Studies generally delivered 2 to 4 
treatment sessions but the frequency of sessions varied from weekly to within 11 to 16 
weeks (Chamberlain et al., 2014a). 
 
Our review found that non-pharmacological interventions have been shown to improve cough 
related QoL and reduce cough reflex sensitivity. Some of the studies also showed a 
reduction in cough frequency and cough severity but these were not measured using 
validated objective outcome measures. There is a need therefore, for further studies 
investigating non-pharmacological interventions for refractory chronic cough. Studies require 
adequate sample sizes and appropriate control/placebo arm as well as the use of validated 
objective outcome measures (Chamberlain et al., 2014a). 
 
Therefore our study included in this thesis of a non-pharmacological intervention for 
refractory chronic cough was designed to be a RCT with the inclusion of validated objective 
outcome measures to assess cough related QoL, cough frequency, severity, cough reflex 
sensitivity, patient perception of voice and mood. The non-pharmacological intervention in 
our study included all the treatment components described above as part of the general 
composite package of care of non-pharmacological treatments. However it is important to 
mention there will probably have been subtle differences to previous studies as there will 
have been differences in interpretation and delivery of the treatment components. For 
example education on chronic cough has been listed as a treatment component but how one 
study teaches this to their participants is likely to be different to another; equally the largest 
area for different interpretation is the counselling aspect. The number and frequency of 
treatment sessions included in our study was based on the previous non-pharmacological 
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studies; four sessions once a week. In contrast to previous studies of non-pharmacological 
interventions, the researchers involved in our study wanted to reflect the fact that this 
treatment can be delivered by both Physiotherapists and Speech and Language Therapists. 
Therefore the treatment was titled ‘Physiotherapy, Speech and Language Therapy 
Intervention (PSALTI)’ and involved both professions. 
 
Our study of the efficacy of Physiotherapy, Speech and Language Therapy intervention 
(PSALTI) for patients with refractory chronic cough is the first multi-centred RCT of any non-
pharmacological intervention for refractory chronic cough. It also is the first study to include 
both Physiotherapists and Speech and Language Therapists as the treating clinicians, as 
participants in the study who were randomised to the PSALTI arm received the same 
treatment, but this was either delivered by a Physiotherapist or Speech and Language 
Therapist depending on which site they were treated at. This reflected the clinical set up and 
access to allied health care professionals within respiratory outpatients for chronic cough 
patients at each site involved.  
 
Our study found that PSALTI caused a significantly greater increase in cough related QoL, 
significantly greater decrease in cough frequency and a significantly improved urge to cough 
compared to control (general healthy lifestyle advice) intervention. This study has clearly 
shown that PSALTI is an effective treatment option for refractory chronic cough and when 
compared to the current pharmacological interventions one could argue it is a safer and more 
effective treatment option. 
 
As discussed and described in Chapter 1 table 5 (pg 57) five main medications have been 
investigated for their effects on refractory chronic cough, those being; slow release Morphine, 
Amitriptyline, Gabapentin, Baclofen and P2X3 receptor antagonist (AF-219). In comparison 
to our study of PSALTI for refractory chronic cough, the quality of some of these 
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pharmacological studies has been poor and many of the medications have caused adverse 
side effects.   
 
For the majority of the medication studies sample sizes have been small; slow release 
morphine (Morice et al., 2007b), Amitriptyline (Bastian et al., 2006, Jeyakumar et al., 2006), 
Baclofen (Dicpinigaitis and Rauf, 1998b) and P2X3 receptor antagonist (AF-219) (Abdulqawi 
et al., 2014) have all been investigated in studies with less than thirty participants. Baclofen 
has only been explored in 2 refractory chronic cough participants in Dicpinigaitis and Rauf 
(1998) study. Although PSALTI did not meet the sample size calculation based on effect 
size, the number of participants who completed treatment at four weeks (n=63) is greater 
than all the pharmacological studies’ sample sizes. In additional to many of the 
pharmacological studies having small sample sizes some have included limited objective 
cough outcome measures. Bastian et al (2006) study of Amitriptyline and Mintz and Lee 
(2006) study of Gabapentin for refractory chronic included no objective cough outcome 
measures. Cough reflex sensitivity has only been explored in the studies of Baclofen, 
Morphine and Gabapentin (Dicpinigaitis and Rauf, 1998b, Morice et al., 2007b, Ryan et al., 
2012). Cough frequency and cough severity have only been objectively measured in 
Abdulqawi et al (2014) P2X3 receptor antagonist (AF-219) trial and Ryan et al (2012) 
Gabapentin trial. However in the Ryan et al (2012) Gabapentin trial the cough monitor was 
used in a non-validated way. In comparison to our study of PSALTI we included objective 
cough outcome measures for cough related QoL, cough frequency, cough reflex sensitivity, 
cough severity and mood. 
 
Another limitation of the pharmacological treatments for refractory chronic cough is that the 
majority of the medications that have shown significant beneficial results for refractory 
chronic cough; morphine, amitriptyline, gabapentin and P2X3 receptor antagonist (AF-219) 
have been found to also have significant adverse side effects. Morphine was found to cause 
constipation and drowsiness (Morice et al., 2007b). Gabapentin caused blurred vision, 
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disorientation, confusion, dizziness, dry mouth, fatigue, headaches, memory loss, nausea 
and stomach pains (Ryan et al., 2012). P2X3 receptor antagonist (AF-219) caused 88% of 
participants to have Dysgeusia, other side effects included hypogeusia, nausea, 
oropharyngeal pain, headaches, salivary hypersecretion, cough, anosmia, constipation, 
GORD, glossodynia, depressed mood and blurred vision (Abdulqawi et al., 2014). A number 
of participants in each of the above trials subsequently withdrew from the studies due to 
these side effects.   
 
This thesis has established there is a clear role for non-pharmacological interventions for 
refractory chronic cough and there are potentially benefits of these treatments over the 
conventional pharmacological therapy. However our study of PSALTI in this thesis is only 
one of the beginning steps into exploring the role of non-pharmacological interventions for 
refractory chronic cough. More research is required to determine the optimum treatment 
components, treatment frequency and duration, as well as the mechanisms behind the 
beneficial effects of the treatment. 
 
With regards to exploring the mechanisms of action this was not an aim of our PSALTI study 
however the sub-analysis of the trial data highlighted some interesting findings regarding 
breathing pattern dysfunction, which is an aspect that may shed some light on a mechanism 
of action of the PSALTI treatment. Our PSALTI study is the first study to explore breathing 
pattern dysfunction in people with refractory chronic cough. Prior to treatment 50% of 
participants in the study whose breathing pattern was assessed were found to have 
breathing pattern dysfunction with an increased apical breathing pattern. Interestingly it was 
only those who improved their breathing pattern technique in the PSALTI arm who had 
significant improvements in cough related QoL, cough severity and borderline significant 
improvements in cough frequency. Those in the PSALTI arm whose breathing pattern 
remained unchanged (and showed no evidence of dysfunction) at the end of the study 
showed no significant improvements in any of the outcome measures. 
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As discussed in Chapter 5, in our study breathing pattern was only assessed on a limited 
number of participants and was assessed by observation by the leading Physiotherapist in 
the trial. Future studies are required that investigate breathing pattern in people with 
refractory chronic cough using an objective outcome measure.  If an abnormal breathing 
pattern is still observed when compared to healthy adults using an objective measurement 
tool, then future studies investigating non-pharmacological treatments for refractory chronic 
cough should include objective measurement of breathing pattern.  
 
As to which objective measure should be used Respiratory Inductive Plethysomography has 
been used in other respiratory diseases to measure breathing pattern including COPD and 
Asthma (Cancelliero-Gaiad et al., 2014, Tobin et al., 1983).  Respiratory Inductive 
Plethysomography devices consist of two elastic straps which contain a coil of wire 
(transducer) embedded in each; one strap is placed around the ribcage and the other around 
the abdomen, both are connected to an oscillator and computer. The self-inductance of the 
coils and the frequency of their oscillations are altered by changes in the cross-sectional area 
of the ribcage and the abdomen which reflects changes in volume of the ribcage and 
abdomen (Cancelliero-Gaiad et al., 2014). A number of different measurements can be taken 
from Respiratory Inductive Plethsomography including tidal volume, respiratory rate, 
inspiratory and expiratory time, minute ventilation, percent rib cage inspiratory contribution to 
tidal volume ratio and laboured breathing index (which is the ratio of the sum of the ribcage 
and abdomen inspiratory volumes divided by the corresponding tidal volume), (Warren et al., 
1997, Cancelliero-Gaiad et al., 2014). 
 
Another type of plethysmography, structured light plethysmography (SLP) which is a non-
contact method of monitoring lung function and chest wall movement, is a new device still 
undergoing early studies and development but may be an alternative to the Respiratory 
Inductive Plethysomography device described above (Alimohamed et al., 2011). This device 
projects a light grid onto a patient’s thoraco-abdominal surface, which is imaged by two 
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cameras. This therefore gives a 3D reconstruction of the patient’s thoraco-abdominal surface 
whilst the patient breathes (Alimohamed et al., 2011).  
For assessment of breathing pattern in refractory chronic cough these plethysmography 
devices need to be investigated in this patient group, to determine which is the most 
appropriate device for assessment of breathing pattern. The most appropriate device then 
needs to be used to objectively measure breathing pattern in people with refractory chronic 
cough and compare this to healthy adults.   If a difference is established this measurement 
should then be incorporated into future studies of non-pharmacological interventions for 
refractory chronic cough to see if changes in breathing pattern is a mechanism of action of 
the treatment. 
 
As well as breathing exercises, PSALTI and other non-pharmacological interventions have 
included as part of the treatment; vocal hygiene and hydration, education regarding chronic 
cough, cough suppression techniques as well as counselling or anxiety management 
regarding the cough. Therefore these other components of treatment need to be investigated 
in future studies to see if they are part of the mechanism of action of the treatment.  
 
With regards to vocal cord hydration, phonation threshold pressure (PTP) is a measurement 
which measures the minimum amount of pressure required for the vocal folds to vibrate 
(Vertigan et al., 2006). It measures the ease of phonation, as the ease of phonation is 
affected by the biomechanics of the vocal cords (the tissue thickness, elasticity and viscosity) 
PTP has been used to give an indication of the hydration status of the vocal cords 
(Sivasankar and Leydon, 2010). Greater hydration of the vocal cords lowers the vocal cords 
viscosity and therefore reduces PTP. The opposite has also been shown, that dehydration 
causes an increase in PTP (Sivasankar and Leydon, 2010). Although studies by Vertigan et 
al (Vertigan et al., 2007b, Vertigan et al., 2006) have mentioned PTP as being an indication 
of vocal cord hydration, this outcome measure has not be used or studied in people with 
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refractory chronic cough; neither prior to treatment or after non-pharmacological treatment. 
As discussed above for using Plethysomography to measure breathing pattern, initially for 
measuring PTP the most effective method needs to be investigated to be used to measure 
PTP in people with refractory chronic cough. Comparisons could then be made with healthy 
aged matched participants. PTP may also prove to be of value in other non-pharmacological 
intervention studies for refractory chronic cough examining the effect of the treatment on 
vocal cord hydration. 
 
Treatment for anxiety and stress related to the chronic cough was included in the PSALTI 
study. In our study we used HADS as our outcome measure for refractory chronic cough. 
This outcome measure did not detect significant levels of anxiety and depression in our 
refractory chronic cough population. However this does not reflect opinions shared by the 
participants in the study with the treating clinicians. This raises the debate as to whether this 
is the most appropriate and specific measure for measuring anxiety and depression in people 
with refractory chronic cough. As discussed in chapter 5 disease specific tools have been 
found to have greater responsiveness than generic tools (Wiebe et al., 2003). Therefore 
maybe a more specific tool for refractory chronic cough needs to be developed to measure 
anxiety and depression. 
 
Education and counselling was included in PSALTI and has been in other non-
pharmacological studies of refractory chronic cough. How we measure the effectiveness of 
this is tricky however the aim of this aspect of the treatment is to increase a person’s 
understanding of their chronic cough, understand the non-pharmacological treatment they 
are undertaking and increase their ability to self-manage their chronic cough symptoms. 
Illness perception has been measured in other conditions such as diabetes and asthma 
using illness perception questionnaires (IPQ). IPQs measure an individual’s response to a 
perceived health threat, how a person perceives a health threat involves the individual’s 
perception of their illness, the behaviours they adopt to cope with the illness and their 
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perceived efficacy of their behaviours to cope with their illness (Broadbent et al., 2006). IPQs 
cover the five dimensions of cognitive representation of illness: identity, consequences, 
cause, timeline and cure or control.  Identity being the terms a person uses to describe the 
condition or symptoms; consequences being the expected effects of the condition; cause is 
the person’s perceived cause of the condition; timeline is how long the person expects to 
have the condition and cure or control is the person’s expectation of the likelihood of 
recovering from the condition (Broadbent et al., 2006). Changing a person’s perception of 
their illness has been shown to improve recovery in conditions such as myocardial infarction, 
asthma, diabetes and AIDS (Petrie et al., 2003).  
 
Illness perception has not been explored in refractory chronic cough, there may be some 
value in considering this outcome in this population and exploring illness perception pre and 
post treatment.  There are a number of IPQs that could be used: IPQ was the first 
questionnaire designed, this is 38 item questionnaire (Weinman et al., 1996); IPQ-revised 
was a revision of the original IPQ and is a 80 item questionnaire (Moss-Morris et al., 2002) 
and the Brief IPQ is a nine item questionnaire (Broadbent et al., 2006). Again as with 
Plethysmography and PTP the most appropriate measure for illness perception would need 
to be explored for people with refractory chronic cough. A benefit of all these IPQs is that the 
wording of the questions can be made specific to chronic cough as it has been done for other 
conditions. 
 
Lastly another measurement that is important to include in future studies of non-
pharmacological interventions of refractory chronic cough is urge to cough assessment. 
PSALTI as well as other non-pharmacological interventions aim to reduce the 
hypersensitivity of the cough reflex and teach participants cough suppression techniques to 
suppress their cough. Therefore assessment of urge to cough can provide a measure of 
whether participants’ perception of the urge to cough has changed. Unlike the above 
measures discussed this assessment was included in the PSALTI study and was included in 
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Ryan et al (2001) study of speech pathology management for refractory chronic cough. Both 
studies showed a significant improvement in urge to cough following treatment. 
 
Once initial studies have been completed that explore the best outcome measures to 
investigate breathing pattern, PTP, anxiety and depression as well as illness perception in 
people with refractory chronic cough and these have been explored in people with refractory 
chronic cough compared to healthy adults.  There should be a clearer understanding of 
which components of PSALTI and other non-pharmacological interventions are essential and 
may be involved in the mechanism of action. This could then allow the current treatments to 
be revised, removing elements that may not have beneficial results and re-emphasising 
those that do.  Finally a large scale multi-centred trial could then be performed of this revised 
treatment using the outcome measures identified to explore the mechanism of action, whilst 
also exploring the optimum frequency and duration of treatment. This could be completed by 
designing the study to have different groups receiving treatment over different durations and 
with different frequencies of the treatment sessions. The study would have to be sufficiently 
powered though to allow this subgroup analysis and therefore only a few variations in 
frequency and duration of treatments would be able to be studied. Cost effectiveness 
analysis is another aspect that would need to be included as this needs to be explored prior 
to recommending non-pharmacological interventions becoming part of routine clinical 
practice.  
 
Additionally to exploring the mechanisms of action of PSALTI and other non-pharmacological 
treatments for refractory chronic cough, the timing of when patients should be referred to 
these treatments also needs to be reviewed. People with refractory chronic cough tend to 
only be referred to non-pharmacological interventions once they have completed extensive 
medical investigations and treatment trials for the main causes of chronic cough, and then 
after trialling medications to treat refractory chronic cough. In our study of PSALTI 
participants prior to the study had, had their cough for up to 45 years, with a third of our 
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participants having had their cough for over 8 years. Why should refractory chronic cough 
patients wait this length of time to trial non-pharmacological interventions? Why are these 
treatments not implemented earlier either as a sole treatment option or alongside medical 
treatment for refractory chronic cough. An argument could also be made that non-
pharmacological treatments could be delivered even before a person is diagnosed as 
refractory chronic cough and may even have benefits for a broader range of chronic cough 
patients. This is an area that needs further exploration and development.  
 
The need to further develop treatment options in chronic cough and refractory chronic cough 
specifically is not just a highlighted priority by researchers and clinicians but was also 
highlighted by respondents in our European chronic cough survey (Chamberlain et al., 
2015a). Respondents’ opinions on the effectiveness of their current treatment options and 
management was poor and the main aspect they wanted more information on was treatment 
options.    
6.1 Conclusions 
 
This thesis has provided a greater insight into the impact chronic cough has across Europe 
and gathered opinions of those with chronic cough on the current treatment and 
management of the condition. It has highlighted that people with refractory chronic cough 
want more information to be made available on chronic cough with the priorities being 
information on treatment and causes. This survey also highlighted that advances need to be 
made in the treatment and management of chronic cough due to current perceived poor 
efficacy of these by those with chronic cough. 
The main findings of this thesis are related to the non-pharmacological management of 
refractory chronic cough. This thesis has shown that Physiotherapy, Speech and Language 
Therapy Intervention (PSALTI) is an effective treatment option for people with refractory 
chronic cough. PSALTI was shown to significantly improve cough related QoL, reduce cough 
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frequency and improve participants’ perceived urge to cough greater than control in a multi-
centred RCT.  
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ABSTRACTS OF PRESENTATIONS PRESENTED  
AT CONFERENCES FROM WORK FROM THESIS 
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7. Conference Abstracts and Presentations arising from Thesis studies 
7.1 Evaluation of Vocal Performance questionnaire in people with chronic refractory 
cough abstract presented at European Respiratory Society Conference September 
2013 (Chamberlain et al., 2013a) 
 
Background: Perceptual voice analysis has shown a high prevalence of abnormal voice 
quality in people with chronic refractory cough (CRC). However little is known regarding 
patients’ perception of voice in this population.  
 
Aims: This study aims to explore vocal problems using the Vocal Performance 
Questionnaire (VPQ) and to evaluate its possible relationships with cough outcome 
measures. 
 
Methods: 27(10 male) people with CRC, defined as cough>8weeks and refractory to 
medical management, completed Leicester Cough Questionnaire (LCQ), capsaicin cough 
challenge (log C5), cough frequency (24 hour Leicester Cough Monitor); and severity 
(VAS) outcome measures. The VPQ; a 12 item tool assesses impact of voice disorders 
with a score >12 indicating dysphonia. It has not previously been used in CRC. Mann-U 
Whitney and Spearman’s statistical tests were performed. 
 
Results: Of 27 CRC participants, mean age 58 (SD:13); 17 reported a change in voice 
since onset of cough, 22 reported talking as a trigger for cough and 19 laughing. When 
VPQ scores for those participants who reported voice changes were compared to those 
who did not, there was a significant difference; median (IQR), 22(13) for those who 
reported voice changes, and 12(6) (p=0.02) for those who did not. A significant correlation 
was found between VPQ and cough frequency per hour (r=0.42, p=0.039), but not 
between VPQ and LCQ (rs=-0.16, p=0.444); capsaicin cough challenge (rs=-0.30, 
p=0.146); and VAS (rs=0.06, p=0.786).  
 
Conclusions: This study shows that VPQ may be a useful tool to assess voice 
impairment in CRC and that an increased cough frequency was associated with a higher 
VPQ score; therefore an increased patient perceived dysphonia. 
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7.2 The Impact of chronic cough: A European perspective abstract presented as a 
poster at European Respiratory Society Conference September 2013 (Chamberlain 
et al., 2013c) 
 
Background and Aims: In collaboration, the European Lung Foundation (ELF) and 
European Respiratory Society Chronic cough Taskforce launched a European-wide 
patient survey to explore the management and impact of chronic cough in Europe. 
Methods: An Internet based survey was launched in January 2012 on the ELF website 
and was available in 12 languages by October 2012. The survey was promoted via 
Google through a Google Ad account, and was promoted by the ELF.  Survey responses 
were collected between 05/01/2012 and 06/01/2013 and are reported as an interim 
analysis, with Chi-Square analysis to explore relationships between variables.  
Results: 1868 subjects responded; 1234 responses were excluded due to incomplete 
demographic data, non-European responses, age <18 years, or cough duration <2 
months.  
634 (66% females) responses from 28 European countries were analysed. Mean age was 
50 (SD:15) years, median cough duration ≥ 10 years, and 84% were non-smokers. Only 
56% reported they had been given a diagnosis, despite 93% having seen a doctor 
regarding their cough.  Asthma was the most common diagnosis at 13%. 97% reported 
their quality of life was impaired and 95% reported a limitation in the activities they liked to 
do due to their cough; females compared to males reported a significantly greater 
limitation (p=0.004). 95% reported their cough worried or disturbed their family or friends 
and 93% felt fed-up or depressed at least sometimes, the latter was significantly greater in 
women (p=0.004). 
Conclusions: This European survey highlights many patients with chronic cough are 
undiagnosed, or unaware of their diagnosis, and the impact of chronic cough on daily life 
and mood is considerable. 
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7.3 Breathing pattern characteristics in refractory chronic cough patients abstract 
as a Platform presentation at Physiotherapy UK Conference October 2013  
 
Introduction: Cough suppression treatment (CST) programmes have been shown to be 
effective in reducing cough symptoms for chronic cough (CC) sufferers refractory to 
medical management. Breathing pattern retraining exercises are included as a component 
in CST. However little is known regarding the baseline breathing pattern characteristics of 
CC sufferers. 
Relevance: Initially CST programmes were developed by speech and language therapists 
and therefore the effects of breathing exercises have focused on the larynx. However 
clinically both physiotherapists and Speech and Language therapists are now involved in 
treating CC sufferers. A greater understanding of CC sufferers’ breathing patterns would 
help to increase understanding of the possible effects and mechanisms of breathing 
patterns on cough. 
Participants: n=30 (11males) refractory CC sufferers were recruited. Median cough 
duration 42 months (IQR 117), mean age 58(SD:12). 
Methods: Breathing pattern was assessed in sitting, over 1 minute by one trained 
respiratory physiotherapist. Normal RR was defined as 12-16. Route and region of most 
movement during breathing was also recorded and documented as mostly upper chest 
movement (UCM) or abdominal movement (ABM). 
Analysis: Mann-U Whitney and Spearman’s test were used. 
Results: We found that 50% of the participants had increased UCM on examination, 33% 
had an increased RR, and 13% had a reduced RR. RR significantly correlated with 
breathing pattern (rs=0.44, p=0.02) and when UCM breathers were compared to ABM 
breathers a significant difference in respiratory rate was found (p=0.02).90% of the 
participants were nose breathers. 
Conclusion: These preliminary data show that a high proportion of CC sufferers had 
increased UCM, and a third had an increased RR. 
 
Implications: These data provide some evidence to support the role of breathing pattern 
retraining techniques in people with CC. However more research is needed in this area to 
investigate further the effects of different breathing patterns on cough and whether CST is 
effective in changing breathing patterns. 
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7.4 Efficacy of a Physiotherapy, Speech and Language Therapy Intervention 
(PSALTI) on cough health related quality of life (HRQoL) for patients with refractory 
chronic cough (RCT) abstract presented as a Poster Discussion at the BTS 
Conference December 2014 (Chamberlain et al., 2014b) 
Introduction: Refractory chronic cough has a significant negative impact on HRQoL. 
There are currently limited effective antitussive therapies. Few studies have explored the 
effectiveness of nonpharmacological interventions for refractory chronic cough. This study 
investigated the efficacy of PSALTI on HRQoL for people with refractory chronic cough in 
a multi-centred RCT. 
Methods: Participants were recruited across five NHS hospitals trusts. 76 participants 
were randomised to PSALTI or placebo (equal attention) intervention.  PSALTI consisted 
of education, laryngeal hygiene and hydration advice, cough control techniques and 
psycho-educational counselling. Placebo consisted of general education on exercise, diet, 
stress and relaxation. Both groups attended 4 weekly sessions of 1:1 therapy. HRQoL 
was measured at baseline, four weeks (end of treatment) and 3 month follow up by 
Leicester cough questionnaire (LCQ). Cough reflex sensitivity was assessed at baseline 
and four weeks by capsaicin cough challenge (C2, C5, concentration that caused first 
urge to cough (Cu)) and was analysed by geometric means (GM). Outcomes between 
groups were analysed using ANCOVA. 
Results: The PSALTI (n=35) and Placebo groups (n=41) were well matched (p>0.05) for 
age [mean (SD)] 58(15) vs. 56(11) years; gender 71% vs 63% females; cough duration 
[median (IQR)] 60(30 to 126) vs 48(24 to 126) months and baseline LCQ [mean (SD)] 
10.4(3.6) vs 11.9(3.5). At four weeks HRQoL improved in both groups, mean LCQ 
increase in PSALTI was 3.4 (95%CI 2.26 to 4.55) vs placebo 1.7 (95%CI 0.78 to 2.54); 
difference in LCQ change between groups was 1.5 (95%CI 0.27 to 7.31, p=0.02) points 
more on average in the PSALTI group. This effect is greater than the MCID for LCQ and 
was sustained at 3 months (mean difference change between groups after 4 weeks to 3 
months was -0.28 (95%CI -1.83 to 1.38). There was a significant increase in Cu in the 
PSALTI group compared to placebo (GM(SD) change 2µm(5.07) vs 0.612µm(3.26), 
p=0.02). There was no significant difference in cough reflex sensitivity between the groups 
(C2, p=0.46; C5, p=0.74). 
Conclusions: PSALTI significantly improved HRQoL compared with equal attention 
placebo intervention and this improvement was sustained at three months. PSALTI also 
significantly increased Cu compared to placebo. 
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7.5 World Congress Physical Therapy Conference Abstract presented as a platform 
presentation in May 2015 (Chamberlain et al., 2015b) 
 
Background: Chronic cough (cough present for >8 weeks) has an estimated prevalence of 
approximately 12% in the general population and causes significant physical and psycho-
social morbidity. In up to 42% of cases, despite extensive investigations and treatments 
trials, the cause of cough remains unexplained, often called refractory chronic cough. 
Physiotherapy and speech and language therapy are emerging nonpharmacological 
treatments for refractory chronic cough. The efficacy of these treatments have not been 
evaluated with objective cough outcome measures in a randomised control trial (RCT).  
Purpose: This study aimed to assess the effect of Physiotherapy, speech and language 
therapy intervention (PSALTI) on quality of life (QoL), severity, frequency and reflex 
sensitivity of cough for patients suffering with refractory chronic cough. 
Methods: A multi-centre, single blinded RCT was conducted across five hospitals. Eligible 
patients were adults diagnosed with refractory chronic cough. Participants were 
randomised to PSALTI or placebo intervention.  PSALTI consisted of education, laryngeal 
hygiene and hydration advice, cough control techniques and psycho-educational 
counselling. Placebo consisted of general education on exercise, diet, stress and 
relaxation. Both groups attended 4 weekly sessions of 1:1 therapy. Outcome measures 
included were: Leicester cough questionnaire (LCQ- cough related QoL questionnaire, 
primary outcome); Capsaicin cough challenge to assess cough reflex sensitivity 
(concentration that caused 5 or more coughs (C5), concentration that caused first urge to 
cough (Cu)); Leicester cough monitor (LCM) to assess cough frequency (ambulatory 
cough-monitoring device worn for 24 hours); Visual analogue scale (VAS) to assess  
cough severity (0-100mm); Short-form 36 (SF-36) to assess general QoL and hospital 
anxiety and depression scale (HADS) to assess mood and anxiety. With the exception of 
Capsaicin cough challenge all measures were completed at baseline, 4 weeks (end of 
treatment) and 3 months. Differences in baseline characteristics were analysed using 
Mann-Whitney or independent t-test. Between group analysis was assessed using 
analysis of covariance (ANCOVA). 
Results: 76 participants were randomised post baseline assessment for the trial. Both 
PSALTI (n=35) and placebo (n=41) arms were well matched for baseline characteristics. 
At 4 weeks mean LCQ scores had improved in both arms but the PSALTI arm improved 
more than placebo (Mean difference (MD) 1.53, 95%, CI 0.21 to 2.85, p=0.02). The 
difference between arms appeared to be sustained up to 3 months. The PSALTI arm had 
a greater decrease in cough frequency than placebo (MD 41%, 95% CI 5% to 64%, 
p=0.03) and greater increase in their tolerance to capsaicin before reporting an urge to 
cough (MD 3.1, 95% CI 0.6 to 5.6, p=0.02). No significant differences between groups 
were found for SF-36, HADS, VAS or C5. 
Conclusions: PSALTI significantly improved cough related QoL, decreased cough 
frequency and improved patients’ tolerance to capsaicin before reporting an urge to cough 
compared with placebo intervention. 
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Implications: This study is the first to provide evidence for the efficacy of this new 
Physiotherapy treatment for RCC within a multi-centred RCT with validated outcomes. It 
will hopefully promote the need for Physiotherapy in this new and exciting area. 
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Appendices 
Appendix 1: Chronic Cough Survey 
 
1. How long have you had your cough? 
(<3 weeks, 3-8 weeks, 2-6 months, 6-12 months, 1-2 years, 2-5 years, 5-10 
years, 10+ years) 
 
2. What was the reason(s) for first visiting your doctor for your cough?* 
 
3. How many times have you seen your doctor regarding your cough? 
(0, 1, 2, 3, 4, 5+ times) 
 
4. When did you last see you doctor regarding your cough? 
(1 week ago, 1 month, 1-2 months, 2-6 months, 6-12 months, 1-2 years, 2-5 
years, 5+ years) 
 
5. Does your cough stop you from doing the things you would like to do? 
(Frequently, sometimes, never) 
 
6. Do you feel fed-up or depressed because of your cough? 
(Yes, sometimes, never) 
 
7. Does your cough disturb or worry your partner, family or friends? 
(Yes, sometimes, never) 
 
8. Does your cough affect your quality of life? 
(Severely, moderately, a little, not at all) 
 
Question 9.Has a diagnosis for your cough been given? 
(Yes/No) 
10. If you received a diagnosis for your cough, what was it? 
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11. Do you feel your doctor/specialist has dealt with your cough thoroughly? 
(Yes/no) 
 
12. Have you ever attended a specialist Cough Clinic? 
(Yes/no) 
 
13. Would you consider attending a specialist Cough Clinic if available to you? 
(Yes/no) 
 
14. Do you currently smoke? 
(Yes/no) 
 
15. Have the treatment(s) for your cough worked? 
 (Yes, a little, no) 
 
16. Please tell us what, if anything, has worked?* 
 
17. Have you found over the counter pharmacy (non-prescription) cough 
suppressant medications effective? 
 (Yes, a little, no) 
18 Would you like more information on chronic cough to be available? 
 (Yes/no) 
19. If yes, what further information would you like?* 
20. What other support do you think would be beneficial?* 
21. Would you like to receive further information about the ELF/ERS chronic cough 
taskforce and patient involvement? 
(Yes, no) 
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Demographics  
Age 
Country of Residence 
Gender 
Ethnicity 
(White Caucasian, Black Caribbean, Black African, East Asian, South Asian, 
Mixed, Other) 
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Appendix 2: Reasons for why respondents initially consulted their doctor about 
their cough  
 
        Themes                                       Categories 
 
 
 
 
1.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Persistent cough 
Frequency of cough 
Severity of cough 
Worsening cough 
Daytime cough 
Night time cough 
Characteristics of 
cough 
(n=422) 
Pharyngitis 
General complaints of 
not feeling well 
Fever 
Sinusitis 
Laryngitis 
      Viral Infection  
(n=140) 
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Sputum 
Breathlessness 
Problems with sleep 
Pain and discomfort 
Lethargy 
Vomiting 
Physical symptoms 
associated with 
cough 
(n=380) Irritation 
Choking symptoms  
Incontinence 
Reflux symptoms 
Haemoptysis 
Chest tightness and 
wheeze 
Changes in voice 
Frustration 
Cough taking over life 
Anxiety 
 Psychological 
symptoms associated 
with cough 
(n=88) 
Worry 
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Social anxiety 
Affecting family and 
friends 
Affecting life 
Affecting enjoyment 
of life 
Affecting work 
Social symptoms 
associated with 
cough 
(n=76) 
Asthma 
Bronchitis 
COPD 
SARS 
Primary Cilary 
Dyskinesia 
Interstitial Lung 
Disease 
To consult doctor 
regarding an existing 
respiratory or other 
health condition 
(n=80) 
Cystic Fibrosis 
Bronchiectasis  
Non-respiratory pre-
existing health 
problems 
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Diagnosis 
To get rid of cough 
Treatment of cough 
For 
diagnosis/assessment 
/treatment of cough 
(n=32) 
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Appendix 3: Quotations from participants: why they first consulted their doctor 
 
Characteristics of the cough 
“Because it was continuous” (Italian responder) 
“An increase in the number of coughing fits each day: between 10 and15” (day and night) 
(French responder) 
Physical symptoms associated with cough  
“I was coughing so much my chest hurt” (Spanish survey responder) 
“Breathlessness and wheezing” (Polish survey responder) 
“I couldn’t hold conversation without coughing” (English survey responder) 
Viral infection symptoms  
“Chest infection” (English survey participant) 
Psychological symptoms associated with cough  
“Because my cough was beginning to take over my life” (French survey responder) 
“Because of the distress it was causing myself and other close persons” (English survey 
responder) 
To consult a doctor about existing respiratory or other health condition  
“”Pulmonary fibrosis, COPD” (Polish survey responder) 
“Have cystic fibrosis” (English survey responder) 
Social symptoms associated with the cough  
 Page 200 of 288 
 
“The coughing interfered with my interactions with other people” (Lithuanian survey 
responder) 
“My cough was degrading my quality of life” (Bulgarian Survey responder) 
For diagnosis/assessment and treatment of the cough  
“Clarify causes” (German responder) 
“To try to get a cure” (German responder) 
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Appendix 4: Information and support requested by participants (Themes and 
quotations) 
 
Treatment 
“How to treat it” (English responder) 
“An effective cure” (Italian responder) 
Causes  
“Explanation of the cause” (German responder)  
“Explain the causes of the cough because I am lost” (Polish responder) 
Self-help and alternative therapies 
“I don’t know, something we could do about it on our own” (Spanish responder) 
“How to manage the coughing, things to avoid etc” (English responder) 
“Herbal alternatives when medication simply does not work” (English responder) 
General information in a variety of formats  
“Provide information on-line, with daily updates if possible” (Spanish responder) 
“All info that might help me get rid of this inconvenience” (Swedish responder) 
“Links to internet sites so that I can obtain information on my problem” (Greek responder) 
“Brochure for patients” (Russian Responder) 
Better understanding, awareness and support from doctors  
“To be taken seriously by the doctors” (German responder) 
“Information for Doctors on how to treat as they don’t seem to be very aware” (English 
responder) 
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Assessment 
“What specific test to get done” (Italian responder) 
“Differential diagnosis” (English responder) 
Information on access to specialist cough clinics 
“Details of specialist cough clinics” (Italian responder) 
“Referrals to specialist to be made when symptoms have persisted for an extended 
period” (English responder) 
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Appendix 5: Modified FEES protocol 
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Appendix 6: PSALTI RCT Consent Form 
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Appendix 7: Capsaicin Cough Challenge Assessment Forms 
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Appendix 8: Urge to cough Assessment Form 
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Appendix 9: Leicester Cough Monitor Assessment Form 
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Appendix 10: Leicester Cough Questionnaire Assessment Form 
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Appendix 11: Short Form 36 Assessment Form 
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Appendix 12: Visual Analogue Scale (VAS) Severity – Week 1  
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Appendix 13: Visual Analogue Scale (VAS) Severity – Week 2 onwards  
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Appendix 14: Hospital Anxiety and Depression Scale (HADS) Assessment form 
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Appendix 15: Vocal Performance Questionnaire (VPQ) Assessment form 
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Appendix 16: Control Intervention – Exercise Session Information 
 
Exercise Session  
What is Exercise/ Physical Activity 
 Includes all forms of activity such as everyday walking or cycling, work related activity active recreation (such as working out in a 
gym), dancing, gardening or playing active games, as well as organised and competitive sport. 
 
What happens when you exercise? 
 When you exercise, your muscles demand more oxygen to create the energy they need to perform the activity you are doing. 
 To increase the oxygen supplied to your muscles, your heart rate and the strength of each heartbeat increases to increase the 
amount of blood that is pumped with each heartbeat. 
 Your breathing rate increases to increase the amount of oxygen breathed in and thus supplied to your muscles. 
 This all causes your body temperature to increase making you feel hot, your blood vessels expand to help release this heat which 
causes you to sweat and appear red as the blood vessels appear closer to the skin surface.   
 Overtime with increased exercise your muscles become more efficient, this then reduces the muscles’ demand for oxygen and 
energy, therefore reducing your breathlessness when exercising. 
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Benefits of Physical activity 
 
 There are many benefits of physical activity. 
 
 For adults, doing 30 minutes of at least moderate intensity physical activity on at least 5 days a week helps to prevent and 
manage over 20 chronic conditions, including coronary heart disease, stroke, type 2 diabetes, cancer, obesity, mental health 
problems and musculoskeletal conditions. 
 
 For adults based on physical activity of 30 minutes of at least moderate physical activity on at least 5 days a week are: 
 
 20 to 35% lower risk of cardiovascular disease, coronary heart disease and stroke. 
 30 to 40% lower risk of metabolic syndrome and type 2 diabetes  
 Reduced risk of hip fracture by 36% to 68%. 
 30% lower risk of colon cancer and approximately 20% lower risk of breast cancer. 
 20 to 30% reduction in risks for dementia and depression. 
 Exercise can also improve self-perception, self-esteem, mood and sleep quality, and reduce levels of anxiety and 
fatigue. 
 Can help to reduce weight.  
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Recommended Guidelines for Exercise 
 
1. Adults should aim to be active daily. Over a week, activity should add up to at least 150 minutes (2½ hours) of moderate 
intensity activity in bouts of 10 minutes or more – one way to approach this is to do 30 minutes on at least 5 days a week.  
 
- Moderate Intensity Exercise - Is at a level when your breathing rate and heart becomes faster and you start to feel a bit warmer 
and sweaty. 
- Overall volume of physical activity is more important than the specific type of activity intensity or frequency of sessions. 
 
- Should aim to be active everyday and therefore spread the 150 hours over the week.  
 
-  Accumulated short sessions of physical activity (≥10 minutes in duration) can provide similar health benefits to the same 
volume of exercise performed in longer continuous sessions. 
 
- Higher volumes of activity (i.e. greater than 150 minutes per week) are associated with additional health benefits. There is 
insufficient evidence to determine whether there are health benefits from undertaking volumes of activity greater than 300 
minutes per week 
 
 
2. Alternatively, comparable benefits can be achieved through 75 minutes of vigorous intensity activity spread across the week 
or a combination of moderate and vigorous intensity activity.  
 
- Vigorous Intensity Exercise - Is at a level that you breathing becomes very hard, so you are short of breath, have a rapid heart 
rate and will not be able to have a full conversation comfortably. 
 
 
3. Adults should also undertake physical activity to improve muscle strength on at least two days a week.  
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- The optimum dose of muscle strengthening activity is to perform 8-12 repetitions of muscle strengthening activities involving all 
major muscle groups on two or more days per week. 
 
 
4. All adults should minimise the amount of time spent being sedentary (sitting) for extended periods.  
 
 
 
 
Safety when exercising 
If you feel any of the symptoms below then stop exercising: 
 Chest pain 
 Unexplained breathlessness 
 Dizzyness or lightheadness 
 Feeling sick 
 
 
 
Source: Department of Health (2011) Start Active, Stay Active. UK, Department of Health. 
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Exercise Level of Different Activities                                                                                      Different Types of Physical Activity/Exercise 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Department of Health (2011) Start Active, Stay Active. UK, Department of Health. 
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           Available at https://www.gov.uk/government/publications/uk-physical-activity-guidelines 
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      Available at https://www.gov.uk/government/publications/uk-physical-activity-guidelines
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Appendix 17: Control Intervention – Diet Diary example from participant in Control 
group 
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Appendix 18: Control Intervention – Diet Session Information 
The below information is from NHS choices website available at 
http://www.nhs.uk/Livewell/Goodfood/Pages/eight-tips-healthy-eating.aspx 
Your health, your choices 
Eight tips for healthy eating 
 
Eating a healthy, balanced diet is an important part of maintaining good health, and 
can help you feel your best. It can be simple, too. Just follow these eight tips to get 
started.  
The two keys to a healthy diet are: 
 Eat the right number of calories for how active you are, so that you balance the 
energy you consume with the energy you use. If you eat or drink too much, you’ll 
put on weight. If you eat too little you’ll lose weight. The average man needs 
around 2,500 calories a day. The average woman needs 2,000 calories. Most adults 
are eating more calories than they need, and should eat fewer calories.  
 Eat a wide range of foods to ensure that you’re getting a balanced diet and that your 
body is receiving all the nutrients it needs.  
Get started  
The eatwell plate 
 To help you get the right balance of the five main food groups, take a look at the 
eatwell plate. 
 To maintain a healthy diet, the eatwell plate shows you how much of what you eat 
should come from each food group  
These practical tips cover the basics of healthy eating, and can help you make healthier 
choices: 
1. Base your meals on starchy foods 
Starchy foods include potatoes, cereals, pasta, rice and bread. Choose wholegrain 
varieties when you can: they contain more fibre, and can make you feel full for 
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longer. Starchy foods should make up around one third of the foods you eat. 
Most of us should eat more starchy foods: try to include at least one starchy food 
with each main meal. Some people think starchy foods are fattening, but gram for 
gram they contain fewer than half the calories of fat. Learn more in Starchy foods.  
 
2. Eat lots of fruit and veg 
It’s recommended that we eat at least five portions of different types of fruit and 
veg a day. It’s easier than it sounds. A glass of 100% unsweetened fruit juice can 
count as one portion, and vegetables cooked into dishes also count. Why not chop a 
banana over your breakfast cereal, or swap your usual mid-morning snack for some 
dried fruit? Learn more in 5 A DAY.  
 
3. Eat more fish 
Fish is a good source of protein and contains many vitamins and minerals. Aim for 
at least two portions a week, including at least one portion of oily fish. Oily fish is 
high in omega-3 fats, which may help to prevent heart disease. You can choose 
from fresh, frozen and canned; but remember that canned and smoked fish can be 
high in salt. Oily fish include salmon, mackerel, trout, herring, fresh tuna, sardines 
and pilchards. Non-oily fish include haddock, plaice, coley, cod, tinned tuna, skate 
and hake. Anyone who regularly eats a lot of fish should try to choose as wide a 
variety as possible.  
 
4. Cut down on saturated fat and sugar 
We all need some fat in our diet. But it’s important to pay attention to the amount 
and type of fat we’re eating. There are two main types of fat: saturated and 
unsaturated. Too much saturated fat can increase the amount of cholesterol in the 
blood, which increases your risk of developing heart disease. Saturated fat is found 
in many foods, such as hard cheese, cakes, biscuits, sausages, cream, butter, lard 
and pies. Try to cut down, and choose foods that contain unsaturated rather than 
saturated fats, such as vegetable oils, oily fish and avocados. For a healthier choice, 
use a just a small amount of vegetable oil or reduced fat spread instead of butter, 
lard or ghee. When you're having meat, choose lean cuts and cut off any visible 
fat. Learn more, and get tips on cutting down, in Eat less saturated fat.  
  
Most people in the UK eat and drink too much sugar. Sugary foods and drinks, 
including alcoholic drinks, are often high in calories, and could contribute to weight 
gain. They can also cause tooth decay, especially if eaten between meals. Cut down 
on sugary fizzy drinks, alcoholic drinks, cakes, biscuits and pastries, which contain 
added sugars: this is the kind of sugar we should be cutting down on rather than 
sugars that are found naturally in foods such as fruit and milk. Food labels can help: 
use them to check how much sugar foods contain. More than 15g of sugar per 100g 
means that the food is high in sugar.  
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5. Eat less salt 
Even if you don’t add salt to your food, you may still be eating too much. About 
three-quarters of the salt we eat is already in the food we buy, such as breakfast 
cereals, soups, breads and sauces. Eating too much salt can raise your blood 
pressure. People with high blood pressure are more likely to develop heart disease 
or have a stroke. Use food labels to help you cut down. More than 1.5g of salt per 
100g means the food is high in salt. Adults and children over 11 should eat no more 
than 6g of salt a day. Younger children should have even less.  
 
6. Get active and be a healthy weight 
Eating a healthy, balanced diet plays an important part in maintaining a healthy 
weight, which is an important part of overall good health. Being overweight or 
obese can led to health conditions such as type 2 diabetes, certain cancers, heart 
disease and stroke. Being underweight could also affect your health. Check whether 
you’re a healthy weight by using our Healthy weight calculator. Most adults need to 
lose weight, and need to eat fewer calories in order to do this. If you're trying to 
lose weight, aim to eat less and be more active. Eating a healthy, balanced diet will 
help: aim to cut down on foods that are high in fat and sugar, and eat plenty of fruit 
and vegetables. Don't forget that alcohol is also high in calories, so cutting down 
can help you to control your weight. You can find information and advice to help in 
Lose weight. If you’re underweight, see Underweight adults. If you're worried 
about your weight, ask your GP or a dietitian for advice. 
 
Physical activity can help you to maintain weight loss or be a healthy weight. Being 
active doesn’t have to mean hours at the gym: you can find ways to fit more activity 
into your daily life. For example, try getting off the bus one stop early on the way 
home from work, and walking. Being physically active may help reduce the risk of 
heart disease, stroke and type 2 diabetes. For more ideas, see Get active your way. 
After getting active, remember not to reward yourself with a treat that is high in 
calories. If you feel hungry after activity choose foods or drinks that are lower in 
calories but still filling.  
 
7. Don't get thirsty 
We need to drink about 1.2 litres of fluid every day to stop us getting 
dehydrated. This is in addition to the fluid we get from the food we eat. All non-
alcoholic drinks count, but water, milk and fruit juices are the most healthy. Try to 
avoid sugary soft and fizzy drinks that are high in added sugars and can be high in 
calories and bad for teeth. When the weather is warm, or when we get active, we 
may need more. Learn more in Drinks.   
 
8. Don’t skip breakfast 
Some people skip breakfast because they think it will help them lose weight. In 
fact, research shows that eating breakfast can help people control their weight. A 
healthy breakfast is an important part of a balanced diet, and provides some of the 
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vitamins and minerals we need for good health. Wholemeal cereal, with fruit 
sliced over the top is a tasty and nutritious breakfast.  
 From: http://www.nhs.uk/Livewell/Goodfood/Pages/eight-tips-healthy-eating.aspx  
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Available at: http://www.nhs.uk/Livewell/Goodfood/Pages/eatwell-plate.aspx 
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Available at: 
http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/publichealth/healthimprovement/fiveaday/dh_4069867 
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Available at: 
http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/publichealth/healthimprovement/fiveaday/dh_4069867 
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A quick guide to labels 
 
 
 
 
 
 
 
 
 
 
 
 A lot A little 
Sugar 
 
15g or more per 100g 5g or less per 100g 
 
Salt 
 
Sodium 
 
1.5g or more per 100g 
 
0.6g sodium or more per 100g 
0.3g or less per 100g 
 
0.1g sodium or less per 100g 
Fat 
 
20g or more per 100g 3g or less per 100g 
Saturated fat 
 
5g or more per 100g 1.5g or less per 100g 
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Appendix 19: Control Intervention – Stress Management session Information 
 
 
 
Stress and Relaxation 
 
 
 
 
 
 
Managing your stress levels and knowing how 
to relax is important for your health, 
particularly as stress can make your breathing 
feel worse. 
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1. What is stress? 
 
Stress is a normal response to the demands put on us in 
life. 
We all need a little bit of stress to keep us going but the 
problem comes when the stresses become overwhelming. 
 
2. How do you know when you are stressed? What 
changes about you when you are stressed? 
 
Physical Response Emotional Response 
(how you think or feel) 
Increase heart rate   Racing thoughts 
Blood pressure rises   Difficulty concentrating 
Breathing gets faster   Harder to make 
decisions 
Muscles become tense and sore Loss of confidence 
Sweating      Increased cravings for  
Nausea/diarrhoea     alcohol/cigs/food 
Clenching of jaw/fists   Fear and panic 
Palpitations     Feeling low 
Headaches     Difficulty sleeping 
Blurred vision     Negative thoughts 
Frequent urination     
Change in appetite 
Dry mouth 
Pins and needles 
 
Physical symptoms due to ‘fight or flight’ response 
(Describe) 
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The chemical adrenalin is released and this causes our 
↑HR, ↑BP and ↑ RR.  We don’t really run away or begin to 
fight and the chemical builds up in our bodies and gives us 
our symptoms as listed above.  
Your behaviour may change as well – e.g you may avoid 
situations, start snapping at people etc 
 
3. What causes your stress?  
 
(Patients ideas) 
e.g’s public transport, hospital visit, your 
breathing problems, family, financial, traffic jams 
 
4. Your breathing is closely related to how you are 
feeling.  If you feel stressed or anxious, you may 
then feel more breathless, but being breathless 
can also make you feel anxious.  Go through the 
negative cycle of anxiety and breathlessness 
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5. We all have different abilities to deal with 
stress: The stress jug 
 
       This is all about how we contain our stress. 
Ideally draw jug on flipchart 
Shortness of 
Breath
Anxiety
Shallow 
breathing
Muscle 
Tension
More Shortness 
of Breath 
Tiredness 
Less energy for 
doing the activities 
you want to do
Increased Anxiety and 
Frustration
Jessica Callaghan
Senior Occupational Therapist
Stress Management Leaflet
Surrey PCT
NEGATIVE CYCLE 
RELATED 
TO BREATHING
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Everyone’s jug is a different size – some of us have a 
larger capacity for stress than others 
This is due to our genetic makeup – just the way we 
are – plus how much support we have, your upbringing 
and life experience 
Put into the jug all the things that cause us stress 
with the everyday things that aren’t going to go away 
at the bottom (e.g breathing problems) 
Eventually this jug gets fuller and fuller and you get 
to the point when a very small thing can cause the jug 
to overflow and you see a behavioural change. 
e.g you burst into tears because you can’t find a 
parking space, or because someone snaps at you 
 
It is important that we try to empty the jug of stress 
regularly to stop it overflowing. Sustained high stress 
levels can be detrimental to our health.  It is important 
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that we recognise when we are stressed and find ways to 
reduce our stress levels 
 
6. Ways to deal with stress 
 
What do you do to ‘empty the jug’?? 
(get examples from group.. listen to music, go for a walk, 
talk to someone, watch tv, hot bath, glass of wine etc.) 
 
 Lifestyle 
You need to schedule in time for ‘me’, for things you enjoy 
and even time to relax. Also helpful to be aware of your 
diet, exercise and even sleep as they are significant little 
things that can affect your ability to cope. 
 
 Hobbies or interests 
Do things you enjoy  
 
 Distraction 
Things that distract you from worrying thoughts or from 
the physical symptoms of stress. Happy memories, 
counting or reciting, focussing on an object, reading or 
listening to the radio, word or number games, getting out 
and talking to somebody. 
 
 Using a Diary 
Writing down how you’re feeling can help you to feel you 
have off loaded some of your stress. Can also increase 
your self-awareness. 
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 Positive thinking 
Calming words or positive self talk.  Be kind to yourself.   
 
 Be realistic 
Don’t have too high expectations of yourself.   
 
 
 Acceptance 
Look at the situation – think about it – change what you 
can – accept what can’t be changed 
 
 Relaxation 
To release your tense muscles and slow down your heart. 
 
Relaxation 
 
Prevent the build up of stress through the use of short, 
frequent periods of physical and mental relaxation 
 
As physical tension is eased, your mind starts to empty 
and feel relaxed too.  Learning to relax can be difficult.  
Just as you have to practise a new skill, you must also 
practise relaxation. 
 
Relaxation will help to: 
 
 Calm you 
 Regulate your breathing 
 Lower your blood pressure/heart rate 
 Help you sleep 
 Help you feel able to cope with life a bit better 
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Appendix 20: Control Intervention – Relaxation session Information 
 
Your health, your choices 
Relaxation tips for stress 
 
Relaxation can help to relieve the symptoms of stress. It can help you calm down and 
take a step back from a stressful situation.  
Although the cause of the anxiety won’t disappear, you will probably feel more able to 
deal with it once you've released the tension in your body and cleared your thoughts.  
All relaxation techniques combine breathing more deeply with relaxing the muscles.  
Don't worry if you find it difficult to relax at first. It's a skill that needs to be learned and it 
will come with practice. 
Relaxed breathing  
Practise deep breathing at a regular time and in a quiet place where you won’t be disturbed. 
Loosen or remove any tight clothes, such as shoes or jackets. Be completely comfortable.  
Sit in a comfy chair which supports your head or lie on the floor or bed. Place your arms 
on the chair arms, or flat on the floor or bed, a little bit away from the side of your body 
with the palms up. If you’re lying down, stretch out your legs, keeping them hip-width 
apart or slightly wider. If you’re sitting in a chair, don’t cross your legs. 
Good relaxation always starts with focusing on your breathing. The way to do it is to 
breathe in and out slowly and in a regular rhythm as this will help you to calm down. 
 Fill up the whole of your lungs with air, without forcing. Imagine you're filling up a 
bottle, so that your lungs fill from the bottom.  
 Breathe in through your nose and out through your mouth.  
 Breathe in slowly and regularly counting from one to five (don’t worry if you can’t 
reach five at first).  
 Then let the breath escape slowly, counting from one to five.  
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 Keep doing this until you feel calm. Breathe without pausing or holding your 
breath.  
Practise this relaxed breathing for three to five minutes, two to three times a day (or 
whenever you feel stressed).  
Deep muscle relaxation  
This technique takes around 20 minutes. It stretches different muscles in turn and then 
relaxes them, to release tension from the body and relax your mind. 
Find a warm, quiet place with no distractions. Get completely comfortable, either sitting or 
lying down. Close your eyes and begin by focusing on your breathing; breathing slowly 
and deeply, as described above. 
If you have pain in certain muscles, or if there are muscles that you find it difficult to focus 
on, spend more time on relaxing other parts.  
You may want to play some soothing music to help relaxation. As with all relaxation 
techniques, deep muscle relaxation will require a bit of practice before you start feeling its 
benefits. 
For each exercise, hold the stretch for a few seconds, then relax. Repeat it a couple of 
times. It’s useful to keep to the same order as you work through the muscle groups: 
 Face: push the eyebrows together, as though frowning, then release.  
 Neck: gently tilt the head forwards, pushing chin down towards chest, then slowly 
lift again.  
 Shoulders: pull them up towards the ears (shrug), then relax them down towards 
the feet.  
 Chest: breathe slowly and deeply into the diaphragm (below your bottom rib) so 
that you're using the whole of the lungs. Then breath slowly out, allowing the belly 
to deflate as all the air is exhaled.  
 Arms: stretch the arms away from the body, reach, then relax.  
 Legs: push the toes away from the body, then pull them towards body, then relax.  
 Wrists and hands: stretch the wrist by pulling the hand up towards you, 
and stretch out the fingers and thumbs, then relax.  
Spend some time lying quietly after your relaxation with your eyes closed. When you feel 
ready, stretch and get up slowly. 
From : http://www.nhs.uk/Livewell/Stressmanagement/Pages/Relaxation.aspx 
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Appendix 21: PSALTI Participant Treatment session Therapist Instructors for 
Session 1  
 
Session 1 (1 hour)  
 Remember adminster outcome measures first. 
 
 Complete assessment 
 
 Issue with cough handout 
 
 Start education +++++ about negative effects of coughing. 
 
o Cough reflex is voluntary and involuntary. Explain cough receptors. 
 
o There are negative effects from repeated coughing - exacerbation of 
irritation and perpetuation of coughing. Talk about eczema example, 
scratching the throat causing irritation. 
 
o Encourage participants to internalise control over their cough, to view 
cough as a response to irritating stimuli rather than a phenomenon outside 
their control. Talk about the need for them to suppress their cough even 
when there is a sensation to cough to reduce repeated irritation.  
 
 Discuss eliminating triggers. 
 
 Set realistic goals and emphasise to participants that treatment is demanding, 
there is no easy cure and that results may not be observed immediately. 
 
  Start the minimisation techniques: water, sweets, increasing hydration, gum, 
nasal pattern etc……. 
o They keep water bottle with them and when they feel the tickle they sip 
water. 
o When talking having sweets etc ready so they know they producing saliva 
and swallow. 
o Possibly talking about food re: what eating etc.. if related to cough/ night 
time coughing with GOR. 
 
 Slightly productive patients discuss trying to suppress non-productive 
coughs – so if patient is normally only slightly productive first thing in the 
morning, get them to try to suppress their coughs in the afternoon. 
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Appendix 22: PSALTI Participant Handout 
 
 
 
 
 
 
 
 
This booklet is aimed at giving you easy-to-read information about chronic cough. It aims 
to tell you what the condition is, some of the symptoms you may experience and what 
treatment with physiotherapy comprises. 
 
 
Produced by: Respiratory Physiotherapy Department. 
 
 
 
 
CHRONIC 
COUGH 
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What is Cough? 
 
A cough is one of our strongest reflexes and is a defence mechanism that aims to clear the lungs 
of secretions or any foreign bodies that enter it.   
 
Who develops a Cough? 
 
Chronic cough is a cough that lasts longer than eight weeks. It is present in 3% of the general 
population and if a cause for this is not found it is called Refractory cough.  
 
The cause of most cases of chronic cough in patients with normal spirometry (breathing 
tests) who are non-smokers and have a normal chest x-ray is asthma, gastro-
oesophageal reflux (acid coming back up your throat from your stomach) and rhinitis 
(inflammation of the nasal passages) or a combination of these. 
 
Chronic cough can be associated with distressing symptoms such as joint and muscle pain, chest 
pains, fainting, incontinence, disturbed sleep, and social embarrassment.  
 
What causes Chronic Cough? 
 
There are cough receptors in the upper airways that when stimulated cause the cough 
reflex.  Most cases of chronic cough are associated with increased sensitivity of these 
receptors, especially if the cough is dry. 
 
Some people however have no underlying diagnosis or cause.  Coughing can be caused 
by dry irritable airways, increasing the sensitivity of the cough receptors.  The habit of 
coughing and throat clearing continues to worsen the cycle.  
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How is it diagnosed? 
 
A variety of tests can be performed to rule out the different causes of cough and to assess 
the irritability of your airways: 
 
 Lung Function Tests 
 Chest X-ray  
 Metacholine challenge/Capsaicin challenge 
o Inhale an irritant and then perform breathing tests to check for hyperactivity 
of airways or hypersensitivity of the cough reflex 
 Cough recording 
o Wear a monitor that records the number of times you cough over a 24hour 
period 
 Trial of corticosteroid medications 
o Preventer inhalers and/or tablets used in asthma 
 Gastrointestinal (stomach and bowel) investigations 
o Trial of anti-reflux medications 
o 24hour pH monitor 
 Ear Nose and Throat (ENT) examination  
 CT scan 
 Bronchoscopy 
o Tube with a camera is passed into your lungs to have a close-up look. 
 
How is it treated? 
 
If a diagnosis or cause for the cough is found, appropriate medication will be given to help 
decrease the irritating cause and improve your cough.  Some people remain symptomatic 
despite optimal medical therapy. 
 
  PSALTI will aim to show you how to: 
 
 Reduce your sensitivity of your cough reflex 
 Increase your control of your cough 
 Retrain your breathing pattern  
 Clear secretions if you have any 
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Methods for Reducing Cough 
 
1. Nose breath as much as you can, try to build it up slowly so you are eventually 
using your nose all the time (except when talking!) 
 
2. Retraining breathing pattern with the help of your physiotherapist. 
 
3. Ensuring your airways are clear of secretions if you have any. 
 
4. Take frequent sips of water to ensure that your throat is moist and less irritable.  
Have a bottle of water with you at all times to keep you upper airways moist and 
clear. 
 
5. Sucking a sweet, this also helps ensure that your throat is kept moist.  This is 
particularly helpful prior to talking on the phone or talking for long periods. 
 
6. If you feel a cough coming on swallow hard, relax your shoulders and concentrate 
on breathing slowly and gently out.   
 
What are my triggers? 
 
It is important to know what your triggers are so that you can pre-empt a cough. This will 
help you to regain control over your cough. 
 
Some Common triggers: Your triggers: 
 Changes in temperature   
 Sprays   
 Stress or Anxiety   
 Smoky atmosphere   
 Exertion   
 Changing position   
 Talking   
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Normal breathing 
 
‘Normal breathing’ means moving air in and out of the chest with minimum effort and 
using the airways and chest muscles to their best advantage. This should be a relaxed, 
silent process including nose breathing. 
 
Your nose is designed to warm, moisten and filter the air around us so that it is the right 
temperature, humidity and volume when it reaches your lungs. 
 
If you breathe in and out through your mouth there is little opportunity for any of the above 
to occur making the air move faster, be drier and colder and be more irritable to your 
airways and cough reflex. 
Diaphragm: 
The main breathing muscle is the diaphragm.  It is a strong flat muscle that is attached to 
the lower edges of the ribs.  It separates the chest from the gut.  It is shaped like the dome 
of an umbrella when it is relaxed. 
 
 
 
 
 
 
 
As you breathe in, your diaphragm flattens and moves down to give your more space for 
your lungs to expand and this causes your stomach to push outwards.  When you breathe 
out your stomach relaxes back to where it started and the diaphragm moves back up. 
 
In normal breathing:  
The diaphragm does 70-80% of the work, 
20-30% by the lower chest muscles (intercostals), 
All breaths should go in and out of the nose quietly, 
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A healthy breathing rate is 10-12 breaths/minute. 
Breathing Retraining 
 
First, let’s check your breathing: 
 
 
 
 
 Rest one hand on your upper chest and one on your abdomen (just below your 
ribs) 
 
 Breathe in and out through your nose 
 
 Your breathing should be completely quiet. If you can hear yourself breathing you 
are ‘over breathing’ 
 
 Be aware of the movement under your hands as you breathe – notice which hand 
is moving most. 
 
 As you breathe in you should feel the hand on your abdomen rise up to the ceiling as air 
enters your lungs. 
 
 As you breathe out you should feel this hand fall as air exits your lungs  
 
It can be tempting to take big breaths when you are doing this but try not to. 
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Appendix 23: PSALTI Participant Treatment session Therapist Instructors for 
Session 2  
 
Session 2: (45 min) 
 Remember administer outcome measures first. 
  
 Questions from them and answers. 
 
 Check if they have noticed anything else with coughing? Any other triggers that 
they have now realised. 
 
 Reiterate cough control, strategies – drinking water, chewing gum, sucking sweets. 
 
 Reiterate avoidance of triggers, reduce caffeine intake and increase hydration, 
decrease intake of acidity foods. 
 
 Teach them the swallow technique. 
 
 Teach them breathing control. You need to educate the diaphragm, how it 
works. What is normal breathing. Continue re-inforcing nose breathing etc….. 
 
 Nose breathing ++++ talk about how important the nose is for the body etc…. 
 
 Discussing how these techniques can be used as distraction techniques. They 
need to stop coughing fits (the coughs that turns into an attack. So they will be 
good at stopping the little ones but they need to nip the big ones, if appropriate) 
 
 Positive re-inforcement. Talk about how long it has been, talking about bad 
behaviours and how they have control over this. 
 
 Airway clearance if needed (ACBT – sheet) 
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Appendix 24: PSALTI Airway clearance technique  
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Appendix 25: PSALTI Participant Treatment session Therapist Instructors for 
Session 3 
 
Session 3: (45 min) 
 
 Remember adminster outcome measures first. 
 
 Review from last week. 
 
 Possibly more breathing control techniques (may be that you need to include 
exercise and breathing control as they cough when they get to the top of the stairs, 
or progress to more functional movements if they were only able to do in lying 
when first taught technique). 
 
 May need to start introducing lifestyle techniques? Looking at stress and anxiety 
and how this can feed into cough and maybe they can start thinking about regular 
exercise etc… This is the ones when you know that it could be work related 
etc….use stress and anxiety with cough handbook 
 
 Or you may need to briefly go through relax techniques etc….. as this may be 
integral to breathing control. 
 
 Maybe thinking about re-introducing triggers, smells etc….. they need to see 
how they handle these situations. 
 
 If really struggling with nose breathing may need to look into nasal sprays, 
steam inhalations or trying nasal douching… 
 
 This session of session 2: May be that they feel it is not working it may be that you 
go through all the triggers and minimisation stuff again. Reinforce need for them to 
control their cough. 
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Appendix 26: Stress and Anxiety Booklet for PSALTI Participants  
 
Stress and Anxiety 
 
 
 
Stress and anxiety can make the urge to cough more troublesome. 
This booklet will help you learn ways of overcoming them. 
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Anxiety is very common, particularly at stressful times in our lives. 
For some people, stress and anxiety can be intense and seem 
overwhelming, but they can be overcome. This booklet will go 
through some of the ways this can be done.  
 
You might find it useful to look at this booklet with a health care 
professional and discuss which of the suggestions might work best 
for you. 
 
Our minds and bodies affect each other in many ways 
 
 For example, when we are ill, we often feel low in mood. 
 You might have noticed “butterflies” in your stomach when you 
are nervous or excited. 
 You may also have seen a child no longer troubled by the pain 
from a grazed knee once they have been given an ice cream or a 
hug. 
 
Understanding anxiety 
 
The first step to overcoming anxiety is to understand it. Everyone 
experiences anxiety at some time or other. It is a normal reaction to 
feelings of danger and stress. When you are feeling anxious, you 
might think that it will get worse and worse, but anxiety does go 
away on its own, unless it is kept going by anxious thinking. 
 
Anxiety can affect the body in many ways. The physical sensations 
you experience are not harmful, but they can be unpleasant and 
frightening, particularly if you do not know what is causing them. It 
is useful to be able to recognise these sensations so you can learn 
to work through them. You might want to tick the ones on this list 
which apply to you. 
 
Common physical sensations of anxiety 
 
 Pain or tightness in your chest 
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 Fast, shallow breathing 
 Fast or pounding heart beat 
 Feeling dizzy or faint 
 Tense or aching muscles 
 Headaches 
 Sweating 
 Stomach churning 
 Needing to go to the toilet 
 Trembling 
 Pins and needles or numbness 
 
It is worth remembering that these sensations can be caused by 
anxiety and that, even when they are caused by medical problems, 
they can be made worse by anxiety. You will probably feel more 
anxious at times when you are feeling unwell or run down. 
 
Stress hormones, such as adrenalin, can often be the cause of these 
feelings of anxiety. These hormones are vital as they allow us to 
react quickly in emergencies, for example, if we need to move 
quickly to avoid an accident but they are troublesome when you 
don’t need them.  
 
The good news is that you can learn ways of counteracting these 
changes. 
 
How can anxiety make coughing worse?  
 
 When we are anxious, we think less clearly. This makes it harder 
to spot the triggers which make us cough, and to do something 
about these triggers. 
 Thinking less clearly also makes it harder to remember to use 
the cough suppression techniques. 
 The more anxious we are, the more we tend to focus on 
wanting to cough. This, in turn, can make us cough more. 
 Anxiety makes us breathe faster and less deeply. This may make 
us more likely to want to cough. 
 
 
What can help? 
 
Using your techniques for cough suppression 
 
 These techniques tend to work best if they are used in a calm, 
relaxed way. 
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Noticing your thoughts 
 
 How you think about a situation can affect how you feel and 
what action you take. 
 Some thoughts are unhelpful. For example, if you think “I can’t 
cope with having a coughing fit in public”, you may stay indoors 
more often. You might miss out on socialising with friends and 
family, doing things you enjoy or taking part in exercise. This would 
leave you less confident, and less fit and active. 
 It would be more helpful to think “I feel a bit self-conscious 
when I cough a lot while I’m out and about, but I can keep calm 
and cope with it, using the techniques that work for me, that I have 
been taught and practiced”. 
 Another unhelpful thought might be “I need to cough to ease 
this lump or tickle in my throat” or “I need to cough to clear my 
throat”. In fact, coughing might just make you focus more on your 
throat and so feel more uncomfortable and increase the urge to 
cough. 
 
 
 Trying not to think something tends not to work very well. As 
an example of this, try not to think of a polar bear right now. Many 
people find that the polar bear tends to come back into our minds if 
we try not to think about it. 
 It’s better to notice the thought, and to remind yourself that it is 
just a thought, and not necessarily true. 
 
Distraction and dealing with worry 
 
 Distraction can help. Depending on the circumstances, you 
might distract yourself by getting up and doing something else or 
talking to someone about a different subject. 
 It can also help to occupy your mind, for example, by thinking 
of a girls’ name or a country beginning with every letter of the 
alphabet, or making a list of your top-ten films of all time. 
 If you worry a lot, it can help to sit down with a pen and paper 
for about twenty minutes a day to focus on your worries and try to 
resolve them. For the rest of the day, gently put them aside until 
that time. At the end of the twenty minutes, put your pen and 
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paper away. If any worries seem unresolved, you can come back to 
them afresh the following day. 
 The more you practice this, the easier it will get to put them 
aside until the allotted time.  
 When a particular worry is playing on your mind, it can be 
helpful to ask yourself “Can I do anything about this situation?” and 
“Can I do anything about it right now?”. If the answer to either 
question is no, it would be more useful to distract yourself, rather 
than carrying on worrying. 
 
Balanced awareness 
 
 Being aware of your body can help you to make wise 
choices…but over-awareness can make it hard to focus on other 
things. 
 This can mean you miss out on fully enjoying the good things in 
life. 
 Over-awareness can also mean unnecessary worry and distress, 
which can make you focus more on your cough. 
 It can help to put your feet flat on the ground and just notice 
how the ground feels underneath your feet. 
 You could also try focusing on what you can see and hear in the 
world around you. 
 
Learning to relax 
 
Learning how to relax your mind and body can reduce the adrenalin 
response we talked about above. This is a breathing exercise to 
help you relax. 
 Breathe out first, then just let your body breathe in. 
 Breathe as deeply down into your belly as you can, and do this 
as gently as you can. 
 Breathe out first, then just let your body breathe in gently 
through your nose, counting "One… two… three". Breathe as deeply 
down into your belly as you can, and do this as gently as you can. 
Pause a second, then breathe out through your mouth, counting 
"One… two… three… four". The counting protects you from fast, 
panicky breathing. Make sure you breathe out for one beat longer 
than you breathe in. This will help you empty your lungs between 
breaths. 
 As you do this, you can keep track of your anxiety. Before you 
start, rate how anxious you are feeling on a scale of one to ten, 
where ten is the worse you've ever felt. Then, after a couple of 
minutes, rate it again. You will probably notice that it has come 
down to a more manageable level. 
 
Being physically active also helps to relax your mind and body. 
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Reducing your stress levels 
 
 Take time to do the things which you enjoy doing, and help you 
to relax your mind and body. 
 Think about how you can make looking after yourself a priority. 
 Eat a well-balanced diet, allow yourself enough time for sleep, 
exercise 
 Learn not to take too much on, and to say 'no' to the things you 
don’t have time for. 
 
Your family and friends 
 
 Your family and friends may be unsure what to do for the best 
when you are coughing. 
 It’s good to plan ahead for this, and to explain what the person 
can do to help. 
 
Getting the information you need  
 
 
 
 If there is anything you are at all unsure about, do ask your 
doctor (or other health professional). 
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 Doctors are busy, but your appointment is your time to get the 
information you need. 
 Before the appointment, it can help to write down questions you 
would like to ask. 
 In the appointment, it can be useful to make notes of the 
important things the doctor says, or to take someone with you to 
help you remember what was said. 
 You might be worried that the doctor will give you bad news, 
but the more information you have, the better you can take care of 
yourself. 
 
Written by Dr Jane Hutton, Consultant 
Clinical Psychologist, King’s College 
Hospital, February 2012 
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What makes you feel stressed or anxious? 
 
 
Make a list here of all the things you can think of which cause you stress… 
 
 
 
 
…then pick out one you can do something about and circle it 
Now make another list here, of everything you could possibly do about it… 
 
 
 
 
…and pick out the one you would like to try first and circle it 
Write down here how you will put this option into practice, and how you will be able to 
tell if it’s working…  
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Appendix 27: PSALTI Participant Treatment session Therapist Instructors for 
Session 4 
 
Session 4: (45 min) 
 
 Review of last week. 
 
 Discuss how it went with triggers? What went well or wrong. 
 
 This is looking at their coping strategies. You need to give them an example:  
 
You are sitting on a crowded bus/ in the theatre and you start to feel the tickle (whatever 
their feeling is). And you are starting to feel warm and your heart starts racing. You are 
really trying to keep this cough at bay and you are getting anxious about it. 
 
Discussing how they would handle this situation: not getting anxious staying calm, sipping 
water or getting out that sweet. Using the swallow technique or breathing control 
techniques etc…… From this Gauge their coping strategies. 
 
 All outcome measures at the end of the session!!! 
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Appendix 28: Standard Operating Procedure for Capsaicin Solution preparation 
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Appendix 29: Standard Operating Procedure for Capsaicin Cough challenge testing  
 
 
 
 
 
 
 
Capsaicin Cough Challenge  
Standard Operating Procedure #2 
May 2002 by S. Birring 
Reviewed in April 2012 by S. Chamberlain 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Page 277 of 288 
 
CAPSAICIN COUGH SENSITIVITY TEST PROTOCOL 
 
EQUIPMENT 
- Digidoser filters 
 - 3 litre calibration syringe 
 - Koko digidoser with connector valve for tubing from air cylinder 
            - Digidoser connection tube to nebuliser pot. 
 - Digidoser laptop connector cable 
 - Laptop with Koko Digidoser programme on. 
- Nebulisers pots x2  
- Mouthpiece for nebuliser pots 
- Nose-clips 
- Thermometer Hyborometer 
- Air Cylinder with head valve 
- Air Cylinder key 
- Capsaicin solutions prepared as per Capsaicin Preparation Standard Operating     
Procedure  
- 3ml/5ml pipettes 
-Cough Monitor 
- Gloves 
- Weighing scales 
- Stadiometer 
 
DIGIDOSER POWER SUPPLY 
Connect digidoser to laptop via USB lead, ensure laptop is plugged into to power supply so battery 
does not run out during testing. 
 
AIR TUBING 
One end into base of digidoser via connector valve (twist+click) 
Other end to air cylinder regulator 
 
AIR VALVE 
1. Open main air valve with key, turn anticlockwise until loose, and dial moves up. 
 
CALIBRATION 
1. Open Koko software on laptop 
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2. Select calibrate icon – 9th icon from the left in the tool bar 
3. Enter the room details – temperature, humidity, barometric pressure (in mmHg, if 
thermometer hyborometer used measures in inHg need to multiple measurement by 25.4). 
5. Attach new filter to digidoser  
6. Make sure calibration syringe is set to 3L (dial on base where syringe is) 
7. Attach calibration syringe to other end of filter 
8. Single L click green circle 
9. Pull syringe out and Click OK 
10. Follow instructions on screen (computer will ask you to pull syringe in/out 3 times- smooth 
action) 
11. Click OK when done 
12. Close calibration screen 
13.       Detach syringe 
 
ENTER DETAILS OF NEW PATIENT 
1. Prior to starting measure patients height and weight 
2. Click 5th icon from left (perform challenge test) 
3. Click 1st icon from left OR if it asks do you want to continue his test series / do you want to 
select new patient – click on latter option – new patient 
4. Click entering new patient then next. 
5. Enter patient’s first name initial as first name, first initial of surname as surname, 
participant’s number in study as study I.D, date of birth, sex, height and weight. 
6. Click OK when done 
7. Click OK again, maximise screen 
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SPIROMETRY 
Must do this to proceed to capsaicin cough challenge! 
 
1. Select Setup in the toolbar, then challenge protocol, then edit challenge protocol. You need 
to select which nebuliser you are going to use after the spirometry by selecting either: 
Capsaicin 1.232ml/min or capsaicin 1.205ml/min. This is etched into the bottom and top of 
the nebulisers. You need to ensure that both the top and bottom parts of the nebuliser 
match. DO NOT CONNECT NEBULISER YET. 
2. Place new filter on end of digidoser. 
3. Give patient noseclip to place on their nose. 
4. Give instructions to the participant first:  
- You will asked to put the mouth piece into your mouth, and take four 
normal breaths first 
- Then I will ask you to take a deep breath IN and then a deep/fast breath 
OUT, blowing out all the air you can 
-  Then I will ask you to take the mouth piece out of your mouth 
5. Press SPACEBAR when you are ready to start 
6. Follow instructions that will display at the bottom of the screen. Initially it will ask you to 
maintain zero flow. Then the bottom display with the instructions will turn black, at that 
point give the digidoser to the participant and tell them to place the filter in their mouth, 
ask them to take four normal breaths. Then the display will say perform maximal 
inspiration at any time, instruct the participant to do so. Then it will ask for a maximal 
exhalation and again instruct participant to do so. 
7. Take digidoser back when patient has had a breath in & out 
8. Click YES 
9. Write down actual and predicted spirometry reading on results sheet 
 
ASSEMBLE NEBULISER 
1. Connect short plastic tubing from base of nebuliser to digidoser  
2. Add 3ml normal saline (or capsaicin solution later) to base using a pipette 
3. Screw on top of the nebuliser (ensuring it matchs the same flow volume as the bottom 
nebuliser, check ml/min value on it) 
4. Attach nebuliser to filter, and a mouthpiece to the nebuliser. 
5. Make sure nebuliser well is level and fluid doesn’t tip back into digidoser!  
 
 
 
  
Page 280 of 288 
 
START COUGH TESTING! 
1. Verbally instruct patient  
- When I ask you to, put the mouthpiece into your mouth 
- When I ask you to, take a sustained 2-3 second breath in 
- Do not try to stop or suppress your cough, allow yourself to cough if you need to. 
2. Click 2nd icon from left, to go to next stage, then click OK 
3. To start click on 3rd button from left 
4. When bottom half of screen is BLACK tell patient to put mouth piece in mouth (never 
when screen is red) and carry out above instructions (PRESS space bar during initial breath 
out). At the point of administering the dose press record on the cough monitor at the same 
time. 
5. Count coughs for 15 seconds after administering, if needed listen back to cough monitor to 
check number of coughs and write it down on results sheet 
 
6. NEXT DOSE – take off nebuliser well from filter, unscrew base, dispose of solution in 
nebuliser pot, put 3ml of next dose in 
7. Start again with clicking 2nd icon from left, go to next stage, then 3rd icon from left 
administer dosage, always press OK. 
8. Finish cough testing when they cough 5 or more times 
 
9. TO START ON PREVIOUSLY TESTED PATIENT – select options, type patient’s ID 
number, click show all matches, single click on the name, click test series: new (bottom of 
screen), click OK, click yes to save (previous data), now do spirometry stage above 
 
SHUTTING DOWN - DISCONNECT AIR 
1. Close valve on air cylinder (clockwise) 
2. Disconnect Digidoser 
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Appendix 30: Ethical Approval Letter 
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Appendix 31: Substantial Amendment Approval Letter – November 2011 
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Appendix 32: Substantial Amendment Approval Letter – May 2012 
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Appendix 33: Sample Size calculation for PSALTI RCT  
 
Power calculations for the primary outcome (LCQ score) were performed based on 
estimates from a previous study (Birring and Pavord, 2009), reporting a mean LCQ score 
in patients with chronic cough of 14.03 (SD: 3.87) (Birring and Pavord, 2009). Group 
sample sizes of 33 in each group achieve 80% power with a significance level of 5% to 
detect a clinically relevant LCQ change of 2.7 (seen in the pilot study completed prior to 
this thesis). Allowing for a 25% drop out we aimed to recruit 88 patients in total.  
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Appendix 34: Shapiro-Wilk Normality Testing p values for Baseline variables 
(PSALTI RCT) 
 
 
For variables which were non-normally distributed for one treatment arm; both variables were 
reported as non-parametric data. 
* Though SF-36 MCS was normally distributed for both treatment arms, as SF-36 PCS was non-
normally distributed it was decided to report both as non-parametric data, as this is two halves of 
the same questionnaire. 
 
Characteristic Control (p value) PSALTI (p value) 
Age 0.284 0.006 
Cough Duration 0.000 0.000 
FEV1 0.121 0.641 
FEV1/FVC 0.534 0.983 
LCQ 0.504 0.387 
Cough Severity VAS 0.041 0.179 
SF-36 PCS 0.052 0.796 
SF-36 MCS* 0.048 0.047 
HADS – anxiety 0.257 0.098 
HADS – depression 0.024 0.001 
VPQ 0.012 0.154 
CFper hour 0.633 0.703 
C2 0.000 0.001 
C5 0.000 0.000 
Cu 0.000 0.000 
